



US012385068B2

(12) **United States Patent**
Bublot et al.

(10) **Patent No.:** US 12,385,068 B2(45) **Date of Patent:** Aug. 12, 2025

(54) **RECOMBINANT HVT VECTORS
EXPRESSING MULTIPLE ANTIGENS OF
AVIAN PATHOGENS AND USES THEREOF**

(71) Applicant: **BOEHRINGER INGELHEIM
VETMEDICA GMBH**, Duluth, GA
(US)

(72) Inventors: **Michel Bublot**, Chaponost (FR);
Teshome Mebatson, Watkinsville, GA
(US); **Joyce Pritchard**, Gainesville, GA
(US); **Perry Linz**, Jefferson, GA (US);
Aemro Kassa, Watkinsville, GA (US)

(73) Assignee: **BOEHRINGER INGELHEIM
ANIMAL HEALTH USA INC.**,
Duluth, GA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **17/812,732**

(22) Filed: **Jul. 15, 2022**

(65) **Prior Publication Data**

US 2023/0175017 A1 Jun. 8, 2023

Related U.S. Application Data

(63) Continuation of application No. 17/035,109, filed on Sep. 28, 2020, now Pat. No. 11,421,249, which is a continuation of application No. 16/393,743, filed on Apr. 24, 2019, now Pat. No. 10,822,620, which is a continuation of application No. 15/840,764, filed on Dec. 13, 2017, now Pat. No. 10,323,257.

(60) Provisional application No. 62/433,842, filed on Dec. 14, 2016.

(51) **Int. Cl.**

C12N 15/869 (2006.01)
A61K 39/12 (2006.01)
A61K 39/155 (2006.01)
A61K 39/245 (2006.01)
A61K 39/295 (2006.01)
C07K 14/03 (2006.01)
C07K 14/08 (2006.01)
C12N 7/00 (2006.01)

(52) **U.S. Cl.**

CPC **C12N 15/869** (2013.01); **A61K 39/12** (2013.01); **A61K 39/155** (2013.01); **A61K 39/245** (2013.01); **A61K 39/295** (2013.01);
C07K 14/03 (2013.01); **C07K 14/08** (2013.01);
C12N 7/00 (2013.01); **C12N 2710/16311** (2013.01); **C12N 2710/16334** (2013.01); **C12N 2710/16363** (2013.01); **C12N 2720/10034** (2013.01); **C12N 2760/16163** (2013.01); **C12N 2760/18134** (2013.01); **C12N 2760/18163** (2013.01); **C12N 2830/20** (2013.01); **C12N 2830/50** (2013.01);
C12N 2840/203 (2013.01)

(58) **Field of Classification Search**
CPC .. A61K 39/12; A61K 39/295; A61K 2039/53;
C12N 2710/16334; C12N 2710/20034;
C12N 2760/18134

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,306,400 B1	10/2001	Bublot et al.
2014/0147457 A1	5/2014	Bublot et al.
2016/0375122 A1 *	12/2016	Mebatsion
		A61K 39/12 424/186.1
2017/0043006 A1 *	2/2017	Reddy
		C12N 7/00

FOREIGN PATENT DOCUMENTS

CN	103072306 A	5/2013
CN	103074306 A	5/2013
CN	106701693 A	5/2017
JP	H11503009 A	3/1999
JP	2001513630 A	9/2001
JP	2006055171 A	3/2006
JP	2015500631 A	1/2015
JP	2015500806 A	1/2015
WO	1996005291 A1	2/1996
WO	1996029396 A1	9/1996
WO	1998037216 A1	8/1998
WO	WO-0105988 A1 *	1/2001
WO	2013057235 A1	A61K 39/12 4/2013
WO	2013057236 A1	4/2013
WO	2013082317 A2	6/2013
WO	2013082327 A1	6/2013
WO	2018112051 A1	6/2018

OTHER PUBLICATIONS

Hall RN, Meers J, Fowler EV, Mahony TJ. Identification of non-essential loci within the Meleagrid herpesvirus 1 genome. *Virol J*. Aug. 27, 2015;12:130. (Year: 2015).*

Zai X, Shi B, Shao H, Qian K, Ye J, Yao Y, Nair V, Qin A. Identification of a Novel Insertion Site HVT-005/006 for the Generation of Recombinant Turkey Herpesvirus Vector. *Front Microbiol*. May 25, 2022; 13:886873. (Year: 2022).*

Zhang F, Chen W, Ma C, Zhang Z, Zhao P, Du Y, Zhang Y, Duan L, Fang J, et al. Transcriptional activity comparison of different sites in recombinant Marek's disease virus for the expression of the H9N2 avian influenza virus hemagglutinin gene. *J Virol Methods*. Oct. 2014;207:138-45. Epub Jul. 14, 2014. (Year: 2014).*

(Continued)

Primary Examiner — Rachel B Gill

(57) **ABSTRACT**

The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

20 Claims, 34 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**OTHER PUBLICATIONS**

- López de Juan Abad BA, Cortes AL, Correa M, Gimeno IM. Evaluation of Factors That Influence Dose Variability of Marek's Disease Vaccines. *Avian Dis.* Dec. 2019;63(4):591-598. (Year: 2019).*
- Atasoy, MO, 2021. Herpesvirus of Turkeys as a vaccine vector in viral diseases: Pros and cons. *Hosts and Viruses*, 8(3): 13-20. (Year: 2021).*
- Linda Gergen et al., "A double recombinant 1-20 herpesvirus of turkeys for the protection of chicken against Newcastle, infectious laryngotracheitis and Marek's diseases", *Avian Pathology*, vol. 48, No. 1, Jan. 1, 2019, pp.45-56.
- Gimeno Isabel M., Cortes Aneg L., Guy James S., et al. "Replication of recombinant herpesvirus of turkey expressing genes of infectious

laryngotracheitis virus in specific pathogen free and broiler chickens following…". *Avian pathology* 40.4 (Aug. 2011): 395-403. Johnson (2010); *Avian Dis.* 54(4):1251-1258.

Zhao (2014); *J. Virol.* 88(15):8397-8406.

Jin Hee Kim, et al., "High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice", *PLoS One*, 2011, vol. 6, Part 4, e18556.

Kingham et al., The genome of herpesvirus of turkeys: comparative analysis with Marek's disease viruses, *Journal of General Virology*, 2001, 82(5):1123-1135.

First page of GenBank acc. Nr. NC_002641: genome of HVT strain FC-126 (first seen 2001).

First page of GenBank accession No. NC_003985: genome of porcine Teschovirus-1 (first seen 2002).

Ngoi et al., *Current Gene Therapy*, vol. 4, 2004, pp. 15-31.

Liu et al., *Viruses*, vol. 2, 2016, p. 301.

English Abstract of CN103074306A.

* cited by examiner

Figure 1

SEQ ID NO:	type	Gene Description
1	DNA	Polynucleotide encoding IBDV VP2
2	protein	IBDV VP2
3	DNA	Polynucleotide encoding NDV-F of NDV strain VII ^d , codon-optimized in pFSV40VP2 (vHVT309) and pFIRESP2 (vHVT310)
4	DNA	Polynucleotide encoding NDV-F of NDV strain VII ^d , wild-type in pFP2AVP2 (vHVT311), pFwtSV40VP2 (vHVT313), pVP2IRESFwt (vHVT316) and pFwtIRESgD (vHVT322)
5	protein	NDV-F protein (vHVT309, vHVT310, vHVT311, vHVT313, vHVT316, vHVT322)
6	DNA	mCMV IE promoter for IBDV VP2
7	DNA	SV40 Promoter for NDV F and ILTV gD
8	DNA	SV40 Poly A
9	DNA	Synthetic Poly A
10	DNA	IRES in pFIRESP2, pVP2IRESgD and pVP2IRESFwt
11	DNA	Polynucleotide encoding P2A in pFP2AVP2
12	DNA	Plasmid pFSV40VP2 for vHVT309
13	DNA	Plasmid pFIRESP2 for vHVT310
14	DNA	Plasmid pFP2AVP2 for vHVT311
15	DNA	Plasmid pVP2IRESgD for vHVT317
16	DNA	Polynucleotide encoding ILTV gD, wild-type in pVP2IRESgD (vHVT317), HVT US2SVgDwtsyn (vHVT407), pHVTIG1gDCaFopt (vHVT308), pFwtIRESgD (vHVT322), and pHVTUS2SVgDwtsyn (vHVT406)
17	protein	ILTV gD
18	DNA	Plasmid pFwtSV40VP2 for vHVT313
19	DNA	Plasmid pVP2IRESFwt for vHVT316
20	DNA	Plasmid HVT US2SVgDwtsyn for vHVT407
21	DNA	Polynucleotide encoding NDV-F of genotype V, codon-optimized in pHVTIG1gDCaFopt (vHVT308)
22	protein	NDV-F of genotype V (vHVT308)
23	DNA	HHV3gB promoter (reverse direction)
24	DNA	HHV3gB promoter
25	DNA	Plasmid pHVTIG1gDCaFopt for vHVT308
26	DNA	Plasmid pFwtIRESgD for vHVT322
27	DNA	pHVTUS2SVgDwtsyn for vHVT406

Figure 2

Genome Structure of HVT and Insertion Sites

Genomic Structure of HVT, ORFs of the *BamHI* fragment,
and Insertion/Replacement Locations
(GenBank accession number for HVT FC126 sequence: AF291866.1)




Figure 3

pFSV40VP2 plasmid map




Figure 4

Schematic representation of primer binding sites for vHVT309





Figure 5

vHVT309 Identity PCR



- Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT309

Figure 6

pFIRESV P2 plasmid map




Figure 7

Schematic representation of primer binding sites for vHVT310





Figure 8

vHVT310 identity PCR



- Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT310

Figure 9

pFP2AVP2 plasmid map




Figure 10

Schematic representation of primer binding sites for vHVT311





Figure 11

vHVT311 identity PCR



- Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT311

Figure 12

pVP2IRESgD plasmid map




Figure 13

Schematic representation of primer binding sites for vHVT317





Figure 14

vHVT317 identity PCR



MB080+
MB081

mCMVF+
SV40tailR

MB080+
ILTgDwt.F

MB080+
VP2.F

-
- Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT317

Figure 15

pFwtSV40VP2 plasmid map





Figure 16

Schematic representation of primer binding sites for vHVT313




Fragment of vHVT313 with primers - sequence verified

7658 bp (molecule 164411 bp)

Figure 17

vHVT313 identity PCR



Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT313

Figure 18

pVP2IRESFwt plasmid map




Figure 19

Schematic representation of primer binding sites for vHVT316





Figure 20

vHVT316 identity PCR



MB080+	mCMVF+	MB080+	MB080+
MB081	SV40tailR	312P6	VP2.F

Lane 1: no template
Lane 2: Vaxxitek
Lane 3: vHVT316

Figure 21A

Sequence alignments of NDV F polynucleotides

SEQ ID NO:21	1	50
SEQ ID NO:3	(1)	
SEQ ID NO:4	(1)	
	ATGAGCTC AAAATTCTTA	
	51	100
SEQ ID NO:21	(51)	
SEQ ID NO:3	(51)	
SEQ ID NO:4	(51)	
	GAGATCTT GAGCTT TCA	
	101	150
SEQ ID NO:21	(101)	
SEQ ID NO:3	(101)	
SEQ ID NO:4	(101)	
	TACGGCTT TCACTT TACGAA TTACAA AGAACATA	
	151	200
SEQ ID NO:21	(151)	
SEQ ID NO:3	(151)	
SEQ ID NO:4	(151)	
	AAATCTCA CTTTGAAAGGAAATGATTA	
	201	250
SEQ ID NO:21	(201)	
SEQ ID NO:3	(201)	
SEQ ID NO:4	(201)	
	GATTTATG GATTTGGCGGGTCCAA	
	251	300
SEQ ID NO:21	(251)	
SEQ ID NO:3	(251)	
SEQ ID NO:4	(251)	
	TTAAATGAACTTAACTTTCCTTCTCTT	
	301	350
SEQ ID NO:21	(301)	
SEQ ID NO:3	(301)	
SEQ ID NO:4	(301)	
	AGATGCGG TAAAGGCGG	
	351	400
SEQ ID NO:21	(351)	
SEQ ID NO:3	(351)	
SEQ ID NO:4	(351)	
	GGGGGCTTATCTT GGCCTT	
	401	450
SEQ ID NO:21	(401)	
SEQ ID NO:3	(401)	
SEQ ID NO:4	(401)	
	AGCTAAACCAATTGGCTTAACTAA	
	451	500
SEQ ID NO:21	(451)	
SEQ ID NO:3	(451)	
SEQ ID NO:4	(451)	
	CCCGTTAAGGCGGTTGCA	
	501	550
SEQ ID NO:21	(501)	
SEQ ID NO:3	(501)	
SEQ ID NO:4	(501)	
	AGCTTAAACCAATTGGCTTAACTAA	
	551	600
SEQ ID NO:21	(551)	
SEQ ID NO:3	(551)	
SEQ ID NO:4	(551)	
	AGCTTGGCTTAACTAACTTGGCGGC	

Figure 21B

601
SEQ ID NO:21 (601)
SEQ ID NO:3 (601)
SEQ ID NO:4 (601)
650
SEQ ID NO:21 (651)
SEQ ID NO:3 (651)
SEQ ID NO:4 (651)
700
SEQ ID NO:21 (701)
SEQ ID NO:3 (701)
SEQ ID NO:4 (701)
750
SEQ ID NO:21 (751)
SEQ ID NO:3 (751)
SEQ ID NO:4 (751)
800
SEQ ID NO:21 (801)
SEQ ID NO:3 (801)
SEQ ID NO:4 (801)
850
SEQ ID NO:21 (851)
SEQ ID NO:3 (851)
SEQ ID NO:4 (851)
900
SEQ ID NO:21 (901)
SEQ ID NO:3 (901)
SEQ ID NO:4 (901)
950
SEQ ID NO:21 (951)
SEQ ID NO:3 (951)
SEQ ID NO:4 (951)
1000
SEQ ID NO:21 (1001)
SEQ ID NO:3 (1001)
SEQ ID NO:4 (1001)
1050
SEQ ID NO:21 (1051)
SEQ ID NO:3 (1051)
SEQ ID NO:4 (1051)
1100
SEQ ID NO:21 (1101)
SEQ ID NO:3 (1101)
SEQ ID NO:4 (1101)
1150
SEQ ID NO:21 (1151)
SEQ ID NO:3 (1151)
SEQ ID NO:4 (1151)
1200
SEQ ID NO:21 (1201)
SEQ ID NO:3 (1201)
SEQ ID NO:4 (1201)

Figure 21C

	1251	1300
SEQ ID NO:21 (1251)	CGA CTT TGG	TGG
SEQ ID NO:3 (1251)	CCT GGT TCC	CCC
SEQ ID NO:4 (1251)	ATG AGT TAT CGTC ATG CTAA CAT AA	GGG AAT T
	1301	1350
SEQ ID NO:21 (1301)	TTG CTT CGG ATG TAC CTT GAA TCA GAG	GCT
SEQ ID NO:3 (1301)	TGG TTT CGG ATG TAC CTT GAA TCA GAG	GCT
SEQ ID NO:4 (1301)	ATGG CCA TGG GAA TTG CTT GAA TCA GAG	TCA ATA
	1351	1400
SEQ ID NO:21 (1351)	CGT GAT TCT TTT GGT TGT GAA GGT	GCT
SEQ ID NO:3 (1351)	CGT GAT TCT TTT GGT TGT GAA GGT	GCT
SEQ ID NO:4 (1351)	CTA ATT CCT AAC TCT GTT AAG GAA TCT TGT GAA TCA AA	TAC T
	1401	1450
SEQ ID NO:21 (1401)	CGT GAT TCT TTT GGT TGT GAA GGT	GCT
SEQ ID NO:3 (1401)	CGT GAT TCT TTT GGT TGT GAA GGT	GCT
SEQ ID NO:4 (1401)	TGC AAT CCT TTG CAA TGT TTT GGT TGT GAA GGT	TGC AAT
	1451	1500
SEQ ID NO:21 (1451)	CGT GAT TCT TTT GGT TGT GAA GGT	GAG GGC
SEQ ID NO:3 (1451)	CGT GAT TCT TTT GGT TGT GAA GGT	GAG GGC
SEQ ID NO:4 (1451)	TAA TGT TAA TAC GCA TAT GCA TAA TGT TAA TGT TAA	TGC AAT
	1501	1550
SEQ ID NO:21 (1501)	CGT GAT TCT TTT GGT TGT GAA GGT	TGA T
SEQ ID NO:3 (1501)	CGT GAT TCT TTT GGT TGT GAA GGT	TGA T
SEQ ID NO:4 (1501)	TCA TGT TAA TGT TAA TGT TAA TGT TAA TGT TAA	TGA T
	1551	1600
SEQ ID NO:21 (1551)	CGT GAT TCT TTT GGT TGT GAA GGT	TCA A
SEQ ID NO:3 (1551)	CGT GAT TCT TTT GGT TGT GAA GGT	TCA A
SEQ ID NO:4 (1551)	TCA TGT TAA TGT TAA TGT TAA TGT TAA TGT TAA	TCA A
	1601	1650
SEQ ID NO:21 (1601)	CGT GAT TCT TTT GGT TGT GAA GGT	TCA A
SEQ ID NO:3 (1601)	CGT GAT TCT TTT GGT TGT GAA GGT	TCA A
SEQ ID NO:4 (1601)	TCA TGT TAA TGT TAA TGT TAA TGT TAA TGT TAA	TCA A
	1651	
SEQ ID NO:21 (1651)	AGT GAA	
SEQ ID NO:3 (1651)	AGT GAA	
SEQ ID NO:4 (1651)	AGT GAA	

Sequence identity between SEQ ID NO:3 and SEQ ID NO:4 is 72.2%.
 Sequence identity between SEQ ID NO:21 and SEQ ID NO:3 is 92.1%
 Sequence identity between SEQ ID NO:21 and SEQ ID NO:4 is 69.4%

Figure 21D

Sequence alignments of NDV F proteins

	1	50
SEQ ID NO:22	(1) MGRGRRWISVT	
SEQ ID NO:5	(1) MGRGRRWISVT	
	51	100
SEQ ID NO:22	(51) MGRGRRWISVT	
SEQ ID NO:5	(51) MGRGRRWISVT	
	101	150
SEQ ID NO:22	(101) MGRGRRWISVT	
SEQ ID NO:5	(101) MGRGRRWISVT	
	151	200
SEQ ID NO:22	(151) MGRGRRWISVT	
SEQ ID NO:5	(151) MGRGRRWISVT	
	201	250
SEQ ID NO:22	(201) MGRGRRWISVT	
SEQ ID NO:5	(201) MGRGRRWISVT	
	251	300
SEQ ID NO:22	(251) MGRGRRWISVT	
SEQ ID NO:5	(251) MGRGRRWISVT	
	301	350
SEQ ID NO:22	(301) MGRGRRWISVT	
SEQ ID NO:5	(301) MGRGRRWISVT	
	351	400
SEQ ID NO:22	(351) MGRGRRWISVT	
SEQ ID NO:5	(351) MGRGRRWISVT	
	401	450
SEQ ID NO:22	(401) MGRGRRWISVT	
SEQ ID NO:5	(401) MGRGRRWISVT	
	451	500
SEQ ID NO:22	(451) MGRGRRWISVT	
SEQ ID NO:5	(451) MGRGRRWISVT	
	501	550
SEQ ID NO:22	(501) MGRGRRWISVT	
SEQ ID NO:5	(501) MGRGRRWISVT	
	551	
SEQ ID NO:22	(551) MRT	
SEQ ID NO:5	(551) MRA	

SEQ ID NO:5 and SEQ ID NO:22 is 91.9% identical.

Figure 22

HVT US2SVgDwtsyn plasmid map




Figure 23

pHVTIG1gDCaFopt map




Figure 24

Schematic representation of primer binding sites for vHVT308





Figure 25

vHVT308 Identity PCR



Lane 1: no template

Lane 2: HVT FC126

Lane 3: vHVT308 pre-MSV

Lane 4: vHVT308 pre-MSV+13 passages

Figure 26

pFwtIRESgD plasmid




Figure 27

Schematic representation of primer binding sites for vHVT322





Figure 28

vHVT322 Identity PCR



Lane 1: no template

Lane 2: vHVT13

Lane 3: vHVT322 pre-MSV

Lane 4: vHVT322 pre-MSV+13

Figure 29

pHVTUS2SVgDwtsyn plasmid map




Figure 30

Schematic representation of primer binding sites for vHVT406






Figure 31

vHVT406 Identity PCR



Lane 1: no template

Lane 2: FC126

Lane 3: donor plasmid pHVTUS2SVgDwtsyn

Lane 4: vHVT406 pre-MSV

Lane 5: vHVT406 pre-MSV+13

1

**RECOMBINANT HVT VECTORS
EXPRESSING MULTIPLE ANTIGENS OF
AVIAN PATHOGENS AND USES THEREOF**

**CROSS-REFERENCE TO RELATED
APPLICATIONS**

This application is a continuation of U.S. patent application Ser. No. 16/393,743, filed Apr. 24, 2019, now U.S. Pat. No. 10,822,620, which is a continuation of U.S. patent application Ser. No. 15/840,764, filed Dec. 13, 2017, now U.S. Pat. No. 10,323,257, which claims the benefit of U.S. Application No. 62/433,842, filed Dec. 14, 2016, the entire contents of which are hereby incorporated by reference herein.

SEQUENCE LISTING

This application contains a sequence listing which has been submitted electronically in XML format. The sequence listing accompanying this application is hereby incorporated by reference in its entirety. Said XML copy, created on Feb. 8, 2023, is named MER16-307-US-5_SL.xml and is 94,243 bytes in size.

FIELD OF THE INVENTION

The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use as safe immunization vehicles to protect against a variety of pathogens. It also relates to multivalent composition or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making and using the recombinant viral vectors.

BACKGROUND OF THE INVENTION

Poultry vaccination is widely used to protect poultry flocks against devastating diseases including Newcastle disease (ND), infectious bursal disease (IBD), Marek's disease (MD), infectious bronchitis (IB), infectious laryngotracheitis (ILT) and avian influenza (AI). ND is caused by the avian paramyxovirus 1 (APMV-1) also designated ND virus (NDV) belonging to the Paramyxoviridae family. MD is caused by Gallid herpesvirus 2 (Herpesviridae family) also designated as MD virus serotype 1 (MDV1). IB is caused by IB virus (IBV) belonging to the Coronaviridae family, ILT is caused by Gallid herpesvirus 1 (Herpesviridae family) also designated ILT virus (ILTV) and AI is caused by AI virus (AIV) belonging to the Orthomyxoviridae family.

A number of recombinant avian viral vectors have been proposed with a view to vaccinating birds against these avian pathogens. The viral vectors used comprise avipox viruses, especially fowlpox (EP-A-0,517,292), Marek's virus, such as serotypes 1, 2 and 3 (HVT) (WO87/04463; WO2013/082317), or alternatively the ITLV, NDV and avian adenovirus. When some of these recombinant avian viral vectors were used for vaccination, they display variable levels of protection.

Several recombinant herpesvirus of turkeys (HVT, also designated Meleagrid herpesvirus 1 or MDV serotype 3) vectors expressing antigens from various pathogens (U.S. Pat. Nos. 5,980,906, 5,853,733, 6,183,753, 5,187,087) including IBDV, NDV, ILTV and AIV have been developed and licensed. Of particular interest is a HVT vector-expressing IBDV VP2 protective gene that has shown clear advan-

2

tages over classical IBD vaccines (Bublot et al J. Comp. Path. 2007, Vol. 137, S81-S84; U.S. Pat. No. 5,980,906). Other HVT vectors of interest are those expressing either NDV (Morgan et al 1992, Avian dis. 36, 858-70; U.S. Pat. Nos. 6,866,852; 5,650,153), ILTV (Johnson et al, 2010 Avian Dis 54, 1251-1259; U.S. Pat. Nos. 6,299,882; 5,853,733, EP 1801204), or NDV and IBDV (U.S. Pat. No. 9,114,108; WO2016102647, WO2013/057235, WO2015032910, WO2013144355) protective gene(s). US2016/0158347 reported the use of the oligodeoxynucleotide TLR21 agonist to increase the immune response against the antigen that expressed by HVT vector.

One of the practical problems of using several HVT-based recombinant vaccines together is their interference. Lower protection is induced at least against one of the disease when two HVT recombinants expressing different antigens are mixed (Rudolf Heine 2011; Issues of the Poultry Recombinant Viral Vector Vaccines which May Cause an Effect on the Economic Benefits of those Vaccines; paper presented at the XVII World Veterinary Poultry Association (WVPA) Congress in Cancun, Mexico, Aug. 14-18, 2011; Slacum G, Hein R. and Lynch P., 2009, The compatibility of HVT recombinants with other Marek's disease vaccines, 58th Western Poultry Disease Conference, Sacramento, CA, USA, March 23rd-25th, p 84).

Considering the potential effect of animal pathogens, such as NDV and IBDV on veterinary public health and the economy, efficient methods of preventing infection and protecting animals are needed. There is a need for a solution of combined effective vector vaccines and a suitable method for making the vaccine that could alleviate the problem of interference observed between two HVT-based vector vaccines.

SUMMARY OF THE INVENTION

The present invention showed surprising result when polyvalent compositions or vaccines comprising recombinant HVT vector were effective to protect animals against a variety of avian pathogens without interference. Surprising results were also observed when various combinations of promoters/linkers, codon-optimized gene, polyA tails and insertion sites conferred different levels of efficacy and stability to the expression of one or more heterologous genes in vivo and in vitro. The present invention provides stable HVT vectors which are able to efficiently express multiple genes and overcomes the well-known problem that HVT vectors with multiple inserts are less stable.

The present invention relates to a recombinant HVT vector comprising one, two or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.

The present invention provides a composition or vaccine comprising one or more recombinant HVT vectors comprising one, two or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.

The present invention relates to a method of vaccinating an animal, or inducing an immunogenic or protective response in an animal, comprising at least one administration of the composition or vector of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description, given by way of example, and which is not intended to limit the invention to specific embodiments described, may be understood in

conjunction with the accompanying figures, incorporated herein by reference, in which:

FIG. 1 is a table showing the SEQ ID NO assigned to each DNA and protein sequence.

FIG. 2 depicts the genome structure of HVT and its insertion sites.

FIG. 3 depicts pFSV40VP2 plasmid map.

FIG. 4 depicts schematic representation of primer binding sites for vHVT309.

FIG. 5 depicts PCR identity result of vHVT309.

FIG. 6 depicts pFIRESVP2 plasmid map.

FIG. 7 depicts schematic representation of primer binding sites for vHVT310.

FIG. 8 depicts PCR identity result of vHVT310.

FIG. 9 depicts pFP2AVP2 plasmid map.

FIG. 10 depicts schematic representation of primer binding sites for vHVT311.

FIG. 11 depicts PCR identity result of vHVT311.

FIG. 12 depicts pVP2IRESgD plasmid map.

FIG. 13 depicts schematic representation of primer binding sites for vHVT317.

FIG. 14 depicts PCR identity result of vHVT317.

FIG. 15 depicts pFwtSV40VP2 plasmid map.

FIG. 16 depicts schematic representation of primer binding sites for vHVT313.

FIG. 17 depicts PCR identity result of vHVT313.

FIG. 18 depicts pVP2IRESFwt plasmid map.

FIG. 19 depicts schematic representation of primer binding sites for vHVT316.

FIG. 20 depicts PCR identity result of vHVT316.

FIG. 21A-21D depict DNA and protein sequence alignments.

FIG. 22 depicts HVT US2SVgDwtsyn plasmid map.

FIG. 23 depicts pHVTIG1gDCaFopt plasmid map.

FIG. 24 depicts schematic representation of primer binding sites for vHVT308.

FIG. 25 depicts PCR identity result of vHVT308.

FIG. 26 depicts pFwtIRESgD plasmid map.

FIG. 27 depicts schematic representation of primer binding sites for vHVT322.

FIG. 28 depicts PCR identity result of vHVT322.

FIG. 29 depicts pHVTUS2SVgDwtsyn plasmid map.

FIG. 30 depicts schematic representation of primer binding sites for vHVT406.

FIG. 31 depicts PCR identity result of vHVT406.

DETAILED DESCRIPTION OF THE INVENTION

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims. This invention includes all modifications and equivalents of the subject matter recited in the aspects or claims presented herein to the maximum extent permitted by applicable law.

It is noted that in this disclosure and particularly in the claims, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting

"essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicate otherwise. The word "or" means any one member of a particular list and also includes any combination of members of that list.

It will also be understood that, although the terms first, second, etc. may be used herein to describe various elements, these elements should not be limited by these terms.

These terms are only used to distinguish one element from another. For example, a first gesture could be termed a second gesture, and, similarly, a second gesture could be termed a first gesture, without departing from the scope of the present invention. All methods or processes described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.

The term "animal" is used herein to include all mammals, birds and fish. The animal as used herein may be selected from the group consisting of equine (e.g., horse), canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g., lions, tigers, domestic cats, wild cats, other big cats, and other felines including cheetahs and lynx), bovine (e.g., cattle), swine (e.g., pig), ovine (e.g., sheep, goats, lambs, bison), avian (e.g., chicken, duck, goose, turkey, quail, pheasant, parrot, finches, hawk, crow, ostrich, emu and cassowary), primate (e.g., prosimian, tarsier, monkey, gibbon, ape), humans, and fish. The term "animal" also includes an individual animal in all stages of development, including embryonic and fetal stages.

The term "about" as used herein, means approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 10%. In one aspect, the term "about" means plus or minus 20% of the numerical value of the number with which it is being used. Therefore, about 50% means in the range of 45%-55%. Numerical ranges recited herein by endpoints include all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be understood that all numbers and fractions thereof are presumed to be modified by the term "about."

The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of consecutive amino acid residues.

The term "nucleic acid", "nucleotide", and "polynucleotide" are used interchangeably and refer to RNA, DNA, cDNA, or cRNA and derivatives thereof, such as those containing modified backbones. It should be appreciated that the invention provides polynucleotides comprising sequences complementary to those described herein. The "polynucleotide" contemplated in the present invention includes both the forward strand (5' to 3') and reverse complementary strand (3' to 5'). Polynucleotides according to the invention can be prepared in different ways (e.g. by chemical synthesis, by gene cloning etc.) and can take various forms (e.g. linear or branched, single or double stranded, or a hybrid thereof, primers, probes etc.).

The term "genomic DNA" or "genome" is used interchangeably and refers to the heritable genetic information of a host organism. The genomic DNA comprises the DNA of the nucleus (also referred to as chromosomal DNA) but also the DNA of the plastids (e.g., chloroplasts) and other cellular organelles (e.g., mitochondria). The genomic DNA or genome contemplated in the present invention also refers to the RNA of a virus. The RNA may be a positive strand or a negative strand RNA. The term "genomic DNA" contemplated in the present invention includes the genomic DNA containing sequences complementary to those described herein. The term "genomic DNA" also refers to messenger RNA (mRNA), complementary DNA (cDNA), and complementary RNA (cRNA).

The term "gene" is used broadly to refer to any segment of polynucleotide associated with a biological function. Thus, genes or polynucleotides include introns and exons as in genomic sequence, or just the coding sequences as in cDNAs, such as an open reading frame (ORF), starting from the start codon (methionine codon) and ending with a termination signal (stop codon). Genes and polynucleotides can also include regions that regulate their expression, such as transcription initiation, translation and transcription termination. Thus, also included are promoters and ribosome binding regions (in general these regulatory elements lie approximately between 60 and 250 nucleotides upstream of the start codon of the coding sequence or gene; Doree S M et al.; Pandher K et al.; Chung J Y et al.), transcription terminators (in general the terminator is located within approximately 50 nucleotides downstream of the stop codon of the coding sequence or gene; Ward C K et al.). Gene or polynucleotide also refers to a nucleic acid fragment that expresses mRNA or functional RNA, or encodes a specific protein, and which includes regulatory sequences.

The term "heterologous DNA" as used herein refers to the DNA derived from a different organism, such as a different cell type or a different species from the recipient. The term also refers a DNA or fragment thereof on the same genome of the host DNA wherein the heterologous DNA is inserted into a region of the genome which is different from its original location.

As used herein, the term "antigen" or "immunogen" means a substance that induces a specific immune response in a host animal. The antigen may comprise a whole organism, killed, attenuated or live; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a polypeptide, an epitope, a hapten, or any combination thereof. Alternately, the immunogen or antigen may comprise a toxin or antitoxin.

The term "immunogenic protein or peptide" as used herein includes polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein. Preferably the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the invention comprises or consists essentially of or consists of at least one epitope or antigenic determinant. An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By "immunogenic fragment" is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping

techniques, well known in the art. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance.

10 The term "immunogenic protein or peptide" further contemplates deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein. The term "conservative variation" denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change or is another biologically similar residue. In this regard, particularly preferred substitutions will generally be conservative in 15 nature, i.e., those substitutions that take place within a family of amino acids. For example, amino acids are generally divided into four families: (1) acidic—aspartate and glutamate; (2) basic—lysine, arginine, histidine; (3) non-polar—alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar—glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another hydrophobic residue, or the substitution of one polar residue for another polar residue, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like; or a 20 similar conservative replacement of an amino acid with a structurally related amino acid that will not have a major effect on the biological activity. Proteins having substantially the same amino acid sequence as the reference molecule but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide. All of the polypeptides produced by these modifications are included herein. The term "conservative variation" also includes the use of a substituted amino acid in 25 place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

The term "epitope" refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.

An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Usually, an "immunological response" includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally dis-

played by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.

The terms "recombinant" and "genetically modified" are used interchangeably and refer to any modification, alteration or engineering of a polynucleotide or protein in its native form or structure, or any modification, alteration or engineering of a polynucleotide or protein in its native environment or surrounding. The modification, alteration or engineering of a polynucleotide or protein may include, but is not limited to, deletion of one or more nucleotides or amino acids, deletion of an entire gene, codon-optimization of a gene, conservative substitution of amino acids, insertion of one or more heterologous polynucleotides.

The terms "polyvalent vaccine or composition", "combination or combo vaccine or composition" and "multivalent vaccine or composition" are used interchangeably to refer to a composition or vaccine containing more than one composition or vaccines. The polyvalent vaccine or composition may contain two, three, four or more compositions or vaccines. The polyvalent vaccine or composition may comprise recombinant viral vectors, active or attenuated or killed wild-type viruses, or a mixture of recombinant viral vectors and wild-type viruses in active or attenuated or killed forms.

One embodiment of the invention provides a recombinant HVT viral vector comprising one, two or more heterologous polynucleotides coding for and expressing at least one antigen or polypeptide of an avian pathogen. The HVT strains used for the recombinant viral vector may be any HVT strains, including, but not limited to, the HVT strain FC126 (Igarashi T. et al., J. Gen. Virol. 70, 1789-1804, 1989).

The genes coding for antigen or polypeptide may be those coding for Newcastle Disease Virus fusion protein (NDV-F), Newcastle Disease Virus hemagglutinin neuraminidase (NDV-HN), Marek's Disease Virus glycoprotein C (gC), Marek's Disease Virus glycoprotein B (gB), Marek's Disease Virus glycoprotein E (gE), Marek's Disease Virus glycoprotein I (gI), Marek's Disease Virus glycoprotein H (gH) or Marek's Disease Virus glycoprotein L (gL), Infectious Bursal Disease Virus (IBDV) VP2, IBDV VPX, IBDV VP3, IBDV VP4, ILTV glycoprotein B, ILTV glycoprotein I, ILTV UL32, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, influenza hemagglutinin (HA), influenza neuraminidase (NA), protective genes derived from *Mycoplasma gallisepticum* (MG), or *Mycoplasma synoviae* (MS), or combinations thereof. The antigen or polypeptide may be any antigen from the poultry pathogen selected from the group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia virus, avian astrovirus, avian parvovirus, avian retrovirus, avian picornavirus, coccidiosis (*Eimeria* sp.), *Campylobacter* sp., *Salmonella* sp., *Pasteurella* sp., *Avibacterium* sp., *Mycoplasma gallisepticum*, *Mycoplasma synoviae*, *Clostridium* sp., and *Escherichia coli*.

Moreover, homologs of aforementioned antigen or polynucleotides are intended to be within the scope of the present invention. As used herein, the term "homologs" includes orthologs, analogs and paralogs. The term "analog" refers to two polynucleotides or polypeptides that have the same or similar function, but that have evolved separately in unrelated organisms. The term "orthologs" refers to two polynucleotides or polypeptides from different species, but that have evolved from a common ancestral gene by speciation. Normally, orthologs encode polypeptides having the same or similar functions. The term "paralogs" refers to two poly-

nucleotides or polypeptides that are related by duplication within a genome. Paralogs usually have different functions, but these functions may be related. Analogs, orthologs, and paralogs of a wild-type polypeptide can differ from the wild-type polypeptide by post-translational modifications, by amino acid sequence differences, or by both. In particular, homologs of the invention will generally exhibit at least 80-85%, 85-90%, 90-95%, or 95%, 96%, 97%, 98%, 99% sequence identity, with all or part of the polynucleotide or polypeptide sequences of antigens described above, and will exhibit a similar function.

In one embodiment, the present invention provides a recombinant HVT viral vector comprising one, two or more heterologous polynucleotides coding for and expressing the NDV-F antigen or polypeptide, the IBDV VP2 antigen or polypeptide, the ILTV gD antigen or polypeptide, or a combination thereof. In one aspect of the embodiment, the NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5 or 22, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In another aspect of the embodiment, the heterologous polynucleotide encodes an NDV-F antigen or polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5. In yet another aspect of the embodiment, the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:3, 4 or 21.

In another aspect of the embodiment, the IBDV VP2 antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In another aspect of the embodiment, the heterologous polynucleotide encodes an IBDV VP2 antigen or polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2. In yet another aspect of the embodiment, the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1.

In another aspect of the embodiment, the ILTV gD antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:17, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In another aspect of the embodiment, the heterologous polynucleotide encodes an ILTV gD antigen or polypeptide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:17. In yet another aspect of the embodiment, the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:16.

Variants include allelic variants. The term "allelic variant" refers to a polynucleotide or a polypeptide containing polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (e.g., a virus species or variety). Such natural allelic variations can typically result in 1-5% variance in a polynucleotide or a polypeptide. Allelic variants can be identified by sequencing the nucleic acid sequence of interest in a number of different species, which can be readily carried out by using hybridization probes to identify the same gene genetic locus in those species. Any and all such nucleic acid variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity of gene of interest, are intended to be within the scope of the invention.

The term "identity" with respect to sequences can refer to, for example, the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur and Lipman). The sequence identity or sequence similarity of two amino acid sequences, or the sequence identity between two nucleotide sequences can be determined using Vector NTI software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA). When RNA sequences are said to be similar, or have a degree of sequence identity or homology with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Thus, RNA sequences are within the scope of the invention and can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.

The polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code, e.g., optimized codon usage for a specific host. As used herein, "optimized" refers to a polynucleotide that is genetically engineered to increase its expression in a given species. To provide optimized polynucleotides coding for NDV-F, IBDV VP2 or ILTV gD polypeptides, the DNA sequence of these genes can be modified to 1) comprise codons preferred by highly expressed genes in a particular species; 2) comprise an A+T or G+C content in nucleotide base composition to that substantially found in said species; 3) form an initiation sequence of said species; or 4) eliminate sequences that cause destabilization, inappropriate polyadenylation, degradation and termination of RNA, or that form secondary structure hairpins or RNA splice sites. Increased expression of NDV F, IBDV VP2 or ILTV gD protein in said species can be achieved by utilizing the distribution frequency of codon usage in eukaryotes and prokaryotes, or in a particular species. The term "frequency of preferred codon usage" refers to the preference exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the NDV-F, IBDV VP2 or ILTV gD polypeptide encoded by the nucleotide sequence is functionally unchanged.

Successful expression of the heterologous polynucleotides by the recombinant/modified infectious virus requires two conditions. First, the heterologous polynucleotides must be inserted or introduced into a region of the genome of the virus in order that the modified virus remains viable. The second condition for expression of inserted heterologous polynucleotides is the presence of a regulatory sequences

allowing expression of the gene in the viral background (for instance: promoter, enhancer, donor and acceptor splicing sites and intron, Kozak translation initiation consensus sequence, polyadenylation signals, untranslated sequence elements).

The insertion site may be any non-essential region of the HVT genome, including, but not limited to, the region between the STOP codon of ORF UL55 and the junction of UL with the adjacent repeat region (intergenic region 1, the IG1 locus, U.S. Pat. No. 5,980,906), the IG2 (intergenic region 2) locus, the IG3 (intergenic region 3) locus, the UL43 locus, the US10 locus, the US2 locus, the SORF3/US2 locus (see FIG. 2)

In general, it is advantageous to employ a strong promoter functional in eukaryotic cells. The promoters include, but are not limited to, an immediate early (IE) human cytomegalovirus (CMV) (hCMV) promoter, mouse CMV (mCMV) IE promoter, guinea pig CMV (gpcMV) IE promoter, an SV40 promoter, Pseudorabies Virus promoters such as that of glycoprotein X promoter, Herpes Simplex Virus-1 such as the alpha 4 promoter, Marek's Disease Viruses (including MDV-1, MDV-2 and HVT) promoters such as those driving glycoproteins gC, gB, gE, or gI expression, HHV3gB promoter (Human Herpesvirus Type 3 glycoprotein B promoter), Infectious Laryngotracheitis Virus promoters such as those of glycoprotein gB, gE, gI, gD, gC genes, or other herpesvirus promoters.

One embodiment of the invention provides a recombinant HVT vector comprising a first heterologous polynucleotide coding for and expressing the IBDV VP2 antigen or polypeptide and a second polynucleotide coding for and expressing the NDV-F antigen or polypeptide. In one aspect of the embodiment, the NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5. In another aspect of the embodiment, the IBDV VP2 antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2. In another aspect, the polynucleotide encoding the NDV-F polypeptide is operably linked to the SV40 promoter having the sequence as set forth in SEQ ID NO:7 and the expression of NDV-F antigen or polypeptide is regulated by the SV40 promoter. In yet another aspect, the expression of NDV-F antigen or polypeptide is regulated by the SV40 polyA signal having the sequence as set forth in SEQ ID NO:8, or the synthetic polyA signal having the sequence as set forth in SEQ ID NO:9. In another aspect, the expression of IBDV VP2 antigen or polypeptide is regulated by the mCMV-IE promoter having the sequence as set forth in SEQ ID NO:6 and the SV40 polyA signal having the sequence as set forth in SEQ ID NO:8, or the synthetic polyA signal having the sequence as set forth in SEQ ID NO:9.

Another embodiment of the invention provides a recombinant HVT vector comprising a first heterologous polynucleotide coding for and expressing the IBDV VP2 antigen or polypeptide and a second polynucleotide coding for and expressing the NDV-F antigen or polypeptide, and further comprising a sequence which regulates the expression of the second polynucleotide. The regulatory sequences or linkers may be an internal ribosome entry site (IRES), an RNA sequence derived from Encephalomyocarditis virus (EMCV), or a sequence encoding a self-cleaving porcine teschovirus-1 2A or foot and mouth disease virus (FMDV) peptide (P2A).

11

In one aspect of the embodiment, the recombinant HVT vector comprises a first polynucleotide encoding the IBDV VP2 antigen and a second polynucleotide encoding the NDV-F antigen, and further comprises the IRES having the sequence as set forth in SEQ ID NO:10. In another aspect of the embodiment, the recombinant HVT comprises a first polynucleotide encoding the IBDV VP2 antigen and a second polynucleotide encoding the NDV-F antigen, and further comprises the P2A encoding polynucleotide having the sequence as set forth in SEQ ID NO:11.

One embodiment of the invention provides a recombinant HVT vector comprising a first heterologous polynucleotide coding for and expressing the NDV F antigen or polypeptide and a second polynucleotide coding for and expressing the ILTV gD antigen or polypeptide, and further comprising a sequence which regulates the expression of the second polynucleotide. The regulatory sequences or linkers may be an internal ribosome entry site (IRES), an RNA sequence derived from Encephalomyocarditis virus (EMCV), or a sequence encoding a self-cleaving porcine teschovirus-1 2A or foot and mouth disease virus (FMDV) peptide (P2A). In one aspect of the embodiment, the ILTV gD antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:17. In another aspect of the embodiment, the NDV F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5 or 22. In yet another aspect of the embodiment, the recombinant HVT vector comprises a first polynucleotide encoding the NDV F antigen and a second polynucleotide encoding the ILTV gD antigen, and further comprises the IRES having the sequence as set forth in SEQ ID NO:10.

Another embodiment of the invention provides a recombinant HVT vector comprising a first heterologous polynucleotide coding for and expressing the NDV F antigen or polypeptide and a second polynucleotide coding for and expressing the ILTV gD antigen or polypeptide. In one aspect of the embodiment, the ILTV gD antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:17. In another aspect of the embodiment, the NDV F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5 or 22. In one aspect, the polynucleotide encoding the NDV F polypeptide is operably linked to the SV40 promoter and the expression of NDV F antigen or polypeptide is regulated by the SV40 promoter. In another aspect, the polynucleotide encoding the ILTV gD polypeptide is operably linked to the HHV3gB promoter and the expression of ILTV gD antigen or polypeptide is regulated by the HHV3gB promoter. In yet another aspect, the HHV3gB promoter is in the reverse direction. In yet another aspect, the expressions of the NDV F antigen and ILTV gD antigen are regulated by SV40 promoter and reverse HHV3gB promoter, and are in opposite directions.

Another embodiment of the invention provides a recombinant HVT vector comprising a first heterologous polynucleotide coding for and expressing the IBDV VP2 antigen or polypeptide and a second polynucleotide coding for and expressing the ILTV gD antigen or polypeptide. In one aspect of the embodiment, the ILTV gD antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having

12

the sequence as set forth in SEQ ID NO:17. In another aspect of the embodiment, the IBDV VP2 antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2. In yet another aspect of the embodiment, the recombinant HVT vector comprises a first polynucleotide encoding the IBDV VP2 antigen and a second polynucleotide encoding the ILTV gD antigen, and further comprises the IRES having the sequence as set forth in SEQ ID NO:10.

Another embodiment of the invention provides a recombinant HVT vector comprising a heterologous polynucleotide coding for and expressing the ILTV gD antigen or polypeptide. In one aspect of the embodiment, the ILTV gD antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:17. In another aspect of the embodiment, the polynucleotide encoding the ILTV gD polypeptide is operably linked to the SV40 promoter and the expression of ILTV gD antigen or polypeptide is regulated by the SV40 promoter.

In one embodiment, the polynucleotides encoding the IBDV VP2 antigen, and/or NDV-F antigen, and/or ILTV gD antigen may be inserted in one or more locus regions selected from the group consisting of IG1, IG2, US10, US2, SORF3-US2 and gD of HVT genome. In another embodiment, the polynucleotides encoding the IBDV VP2 antigen, and/or NDV-F antigen, and/or ILTV gD antigen are inserted in the same locus, such as IG1 of HVT genome.

In one embodiment, the present invention relates to a pharmaceutical composition or vaccine comprising one or more recombinant HVT vectors of the present invention and a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. The HVT vector may comprise two heterologous polynucleotides, and wherein the first polynucleotide comprises a polynucleotide encoding a polypeptide selected from the group consisting of an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen and a Newcastle Disease Virus F (NDV-F) antigen, and wherein the second polynucleotide comprises a polynucleotide encoding a polypeptide selected from the group consisting of an Infectious Bursal Disease Virus (IBDV) VP2 antigen, an Infectious Laryngotracheitis Virus (ILTV) glycoprotein D (gD) antigen and a Newcastle Disease Virus F (NDV-F) antigen.

In another embodiment, the present invention provides a composition or vaccine comprising an HVT viral vector comprising: i) a first heterologous polynucleotide coding for and expressing an IBDV VP2 antigen or an NDV-F antigen; ii) a second polynucleotide coding for and expressing an NDV-F antigen or an IBDV VP2 antigen; and iii) optionally a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In yet another embodiment, the present invention provides a composition or vaccine comprising an HVT viral vector comprising: i) a first heterologous polynucleotide coding for and expressing an IBDV VP2 antigen or an ILTV gD antigen; ii) a second polynucleotide coding for and expressing an ILTV gD antigen or an IBDV VP2; and iii) optionally a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In yet another embodiment, the present invention provides a composition or vaccine comprising an HVT viral vector comprising: i) a first heterologous polynucleotide coding for and expressing an NDV-F antigen or an ILTV gD antigen; ii) a second polynucleotide coding for and expressing an ILTV gD antigen or an NDV-F antigen; and iii) optionally a

13

pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In yet another embodiment, the present invention provides a composition or vaccine comprising an HVT viral vector comprising a heterologous polynucleotide coding for and expressing an ILTV gD antigen, and optionally a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. In yet another embodiment, the present invention provides a composition or vaccine comprising an HVT comprising a polynucleotide having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1, 3, 4, 12, 13, 14, 15, 16, 18, 19, 20, 21, 25, 26 or 27. In one embodiment, it is shown that insertion of two or more heterologous polynucleotides in one locus confers better protection and efficacy than insertion in multiple loci. In another embodiment, it is shown that expressing more than one heterologous polynucleotide from a single mRNA through an IRES or P2A provides better protection and efficacy against avian diseases. In yet another embodiment, the experimental data provided by the present invention disclose that constructs comprising IRES elements provided better protection than constructs comprising P2A elements.

The pharmaceutically or veterinarily acceptable carriers or adjuvant or vehicles or excipients are well known to the one skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipient can be Marek's disease vaccine diluent used for MD vaccines. Other pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipients that can be used for methods of this invention include, but are not limited to, 0.9% NaCl (e.g., saline) solution or a phosphate buffer, poly-(L-glutamate), the Lactated Ringer's Injection diluent (sodium chloride, sodium lactate, potassium chloride and calcium chloride), or polyvinylpyrrolidone. The pharmaceutically or veterinarily acceptable carrier or vehicle or adjuvant or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector *in vitro*), or facilitating transfection or infection and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.

Optionally other compounds may be added as pharmaceutically or veterinarily acceptable carriers or adjuvants or vehicles or excipients, including, but not limited to, alum; CpG oligonucleotides (ODN), in particular ODN 2006, 2007, 2059, or 2135 (Pontarollo R. A. et al., *Vet. Immunol. Immunopath.*, 2002, 84: 43-59; Wernette C. M. et al., *Vet. Immunol. Immunopath.*, 2002, 84: 223-236; Mutwiri G. et al., *Vet. Immunol. Immunopath.*, 2003, 91: 89-103); polyA-polyU, dimethyldioctadecylammonium bromide (DDA) ("Vaccine Design The Subunit and Adjuvant Approach", edited by Michael F. Powell and Mark J. Newman, *Pharmaceutical Biotechnology*, 6: p. 03, p. 157); N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine (such as AVRIDINE®) (*Ibid*, p. 148); carbomer, chitosan (see U.S. Pat. No. 5,980,912).

The pharmaceutical compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants. Suitable adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one or more

14

non-methylated CpG units (Klinman et al., 1996; WO98/16247), (3) an oil in water emulsion, such as the SPT emulsion described on p 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M. Newman, Plenum Press 1995, and the emulsion MF59 described on p 183 of the same work, (4) cation lipids containing a quaternary ammonium salt, e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference into the instant application, or (9) any combinations or mixtures thereof.

In one embodiment, the adjuvant may include TS6 TS7, TS8 and TS9 (U.S. Pat. No. 7,371,395), LR2, LR3 and LR4 (U.S. Pat. No. 7,691,368), TSAP (US20110129494), TRIGENT™ (Newport Labs), synthetic dsRNAs (e.g. poly-IC, poly-ICLC [HILTONOL®]), and MONTANIDE™ adjuvants (W/O, W/O/W, O/W, IMS and Gel; all produced by SEPPIC).

In another embodiment, the invention provides for the administration of a therapeutically effective amount of a vaccine or composition for the delivery of recombinant HVT vectors in a target cell. Determination of the therapeutically effective amount is routine experimentation for one of ordinary skill in the art.

Another aspect of the invention relates to a method for inducing an immunological response in an animal against one or more antigens or a protective response in an animal against one or more avian pathogens, which method comprises inoculating the animal at least once with the vaccine or pharmaceutical composition of the present invention. Yet another aspect of the invention relates to a method for inducing an immunological response in an animal to one or more antigens or a protective response in an animal against one or more avian pathogens in a prime-boost administration regimen, which is comprised of at least one primary administration and at least one booster administration using at least one common polypeptide, antigen, epitope or immunogen. The immunological composition or vaccine used in primary administration may be same, may be different in nature from those used as a booster.

The avian pathogens may be Newcastle Disease Virus (NDV), Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus), Marek's Disease Virus (MDV), Infectious Laryngotracheitis Virus (ILTV), avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian astrovirus and chick anemia virus coccidioides (*Eimeria* sp.), *Campylobacter* sp., *Salmonella* sp., *Mycoplasma gallisepticum*, *Mycoplasma synoviae*, *Pasteurella* sp., *Avibacterium* sp., *E. coli* or *Clostridium* sp.

Usually, one administration of the vaccine in avian is performed either at one day-of-age by the subcutaneous or intramuscular route or in ovo in 17-19 day-old embryo. A second administration can be done within 0-30 days after the first administration.

A variety of administration routes in day-old chicks may be used such as subcutaneously or intramuscularly, intradermally, transdermally. The in ovo vaccination can be performed in the amniotic sac and/or the embryo. Commercially available in ovo and SC administration devices can be used for vaccination.

The composition or vaccine may contain a dose from about 10² to about 10²⁰, about 10³ to about 10¹⁸, about 10⁴ to about 10¹⁶, about 10⁵ to about 10¹² VLPs (virus like particles) produced *in vitro* or *in vivo* from a viral vector, a plasmid, or baculovirus. The viral vector may be titrated

15

based on any virus titration methods including, but not limited to, FFA (Focus Forming Assay) or FFU (Focus Forming Unit), TCID₅₀ (50% Tissue Culture Infective Dose), PFU (Plaque Forming Units), and FAID₅₀ (50% Fluorescent Antibody Infectious Dose), and the VLPs produced in vitro can be titrated by hemagglutination assay, ELISA, and electron microscopy. Other methods may also be applicable depending on the type of VLP.

The composition or vaccine may contain from about 10^{2.0} to about 10^{7.0} TCID₅₀ or PFU/dose, from about 10^{2.0} to about 10^{7.0} TCID₅₀ or PFU/dose, and from about 10^{2.0} to about 10^{6.5} TCID₅₀ or PFU/dose.

The dose volumes can be between about 0.01 and about 10 ml, between about 0.01 and about 5 ml.

The invention will now be further described by way of the following non-limiting examples.

EXAMPLES

Construction of DNA inserts, plasmids and recombinant viral vectors was carried out using the standard molecular biology techniques described by J. Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, 4th edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York., 2014).

Example 1 Construction of Recombinant HVT Vectors Expressing Two Genes

Example 1.1 Construction of Recombinant vHVT309 Expressing IBDV-VP2 and NDV-F

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), Simian virus 40 poly A tail (SV40 poly A), Simian virus 40 promoter (SV40 promoter), a gene encoding a Newcastle disease virus fusion protein (NDV-F) and synthetic poly A tail (syn poly A tail) is integrated in the intergenic site 1 (IG1).

The parental virus used in the construct is vHVT13 (an HVT vector expressing the IBDV VP2 gene, active ingredient of Merial's VAXXITEK® (HVT+IBD) Vaccine, also known as vHVT17 in U.S. Pat. No. 5,980,906). The vHVT13 vector contains an expression cassette composed of mCMV IE promoter (SEQ ID NO:6), IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), and SV40 poly A tail (SEQ ID NO:8) inserted into the IG1 insertion site. A Newcastle disease virus Fusion Protein (NDV-F) corresponding to genotype VIId sequence was chemically synthesized and codon optimized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (AY337464). Mouse CMV IE promoter was used for IBD-VP2, and SV40 promoter was used for NDV-F. The insertion locus is intergenic site 1 (IG1) in HVT (FIG. 2). Donor plasmid pFSV40VP2 (an insertion plasmid containing the VP2/SV40 poly A and flanking arm of IG1+SV40 promoter+NDV-F+synthetic poly A) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Donor Plasmid Construction

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), SV40 poly A tail (SEQ ID NO:8), SV40 promoter (SEQ ID NO:7), NDV-F gene (SEQ ID NO:3 encoding SEQ ID NO:5), and synthetic

16

poly A tail (SEQ ID NO:9) was synthesized by GeneScript (FIG. 3). The plasmid, pFSV40VP2 was transformed using Top10 Oneshot kit (cat #C404002, Invitrogen) and a large scale culture was grown and plasmid extraction was done using Qiagens Maxi Prep kit. Transient expression of the maxi prep was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and chicken polyclonal sera against NDV.

Recombinant Generation

A standard homologous recombination procedure was followed by co-electroporation of secondary CEF cells using pFSV40VP2 plasmid and viral DNA isolated from vHVT13 Vaccine. Co-electroporation was performed using 1×10⁷ 2° CEF in 300 µl Opti-MEM and shocked at 150 volts with 950 capacitance in a 2 mm electroporation cuvette. The transfected cells were seeded into 96-well plate and incubated for 4 days. The cells grown in the 96-well plate were then duplicated into two 96-well plates and incubated for 3 more days. One set of 96-well plates was used for IFA using chicken polyclonal sera against NDV-F to identify positive wells containing recombinants and another set of 96-well plates was used for recovering the infected cells from the positive wells.

The recombinant viral purification methods were performed first by 96-well plate duplication and IFA selection for the wells containing the most IFA positive plaques with the least amount of IFA negative plaques. Wells matching those criteria were then harvested and adjusted to 1 ml in DMEM+2% FBS. From the 1 ml stock, 5-20 µl were removed and mixed with 1×10⁷ CEFs in 10 ml DMEM+2% FBS and aliquoted onto a new 96-well plate to have single virus plaques per well. The 96-well plates were duplicated after 5 days of incubation and wells that contained plaques were tested for the presence of double recombinant and absence of vHVT13 parental virus by IFA and PCR. Again the wells that appeared to have more recombinant virus, by comparing the PCR banding results, were harvested and adjusted to 1 ml and aliquoted onto new 96-well plates. After two rounds of purification of virus infected cells, recombinant virus expressing NDV-F protein was isolated and the purity of the recombinant virus was tested by IFA and PCR to confirm the absence of parental virus.

Analysis of Recombinant by PCR

DNA was extracted from a stock virus by phenol/chloroform extraction, ethanol precipitation, and resuspended in 20 mM HEPES. PCR primers (Table 1) were designed to specifically identify the IBDV-VP2 and NDV-F VIId gene, the promoters, the poly As, as well as, the purity of the recombinant virus from Vaxxitek parental virus. The locations of the primer binding sites are shown in FIG. 4. PCR was performed using 200 µg of DNA template along with the specified primer pairs indicated in Table 1. PCR cycling conditions are as follows: 94° C.-2 min; 30 cycles of 94° C.-30 sec, 60° C.-45 sec, 68° C.-3 min (5 min for MB080+MB081 primer set); 68° C.-5 min (7 min for MB080+MB081 primer set).

TABLE 1

Expected PCR bands using specific primer sets		
Primer set	Vaxxitek	vHVT309
MB080 + MB081	3350	5577
MB010 + NDVFVIIldopt.F	—	737
MB080 + VP2.F	405	2632
SV40tailR + mCMVF	3021	3021
syntailR + SV40promoterF	—	2184

Expression Analysis

For immunofluorescence testing, the recombinant material was diluted 1:100 in media. Approximately 50 µl of the diluted virus was added to 20 ml of DMEM+2% FBS with 2×10^7 CEFs and then aliquoted onto two 96 well plates (100 µl/well). The plates were incubated for 4 days at 37° C.+5% CO₂ until viral plaques were visible. The plates were fixed with 95% ice-cold acetone for three minutes, allowed to air dry for ten minutes and washed three times with water. Dual immunofluorescent staining was performed for plate #1 using chicken anti-sera against Newcastle Disease virus (NDV Pab) (lot #C0117A, Charles Rivers Laboratories) at 1:500 and HVT L78 monoclonal antibody (HVT Mab) (Lee et al. 1983, J. Immunol. 130 (2) 1003-6; Merial batch) at 1:3000 and the plate was incubated at 37° C. for 1 hour. Dual Immunofluorescent was performed for plate #2 using chicken anti-sera against Infectious Bursal Disease virus (IBDV Pab) at 1:500 (lot #G0117, Charles Rivers Laboratories) and HVT L78 monoclonal antibody (HVT Mab) (Merial) at 1:3000 and the plate was incubated at 37° C. for 1 hour. After one hour incubation, the plates were washed three times with PBS. To both plate #1 and #2 FITC labeled anti-chicken IgG (cat #F8888, Sigma) at 1:500 and TRITC labeled Alex Fluor donkey anti-mouse (cat #A10037, Invitrogen) at 1:300 was added. Again the plates were incubated at 37° C. for 1 hour. After one hour incubation the cells were rinsed three times with PBS and visualized with a fluorescent microscope using fluorescein isothiocyanate (FITC) filter and tetramethyl rhodamine iso-thiocyanate (TRITC) filter.

Results

The nucleotide and amino acid sequences of the donor plasmid pFSV40VP2 are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Genomic DNA of vHVT13 virus was co-electroporated with pFSV40VP2 donor plasmid to generate recombinant using homologous recombination technique. Recombinant virus was separated from parental Vaxxitek virus by immunofluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant virus expressing the NDV-F protein, designated vHVT309, was scaled up from tissue culture flasks to 5×850 cm² roller bottles. After about 72 hrs post infection the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen, each aliquot contained 10% FBS and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 1.5×10^5 pfu/ml was obtained for vHVT309.

Dual immunofluorescent staining was performed using chicken anti-sera (Pab) at 1:500 and HVT L78 monoclonal antibody (Mab) at 1:3000 followed by a FITC labeled anti-chicken IgG at 1:500 and TRITC labeled Alex Fluor donkey anti-mouse at 1:300. Plate #1 compares the expression of Newcastle Disease virus with HVT and plate #2 compares the expression of Infectious Bursal Disease virus with HVT. All examined HVT TRITC positive plaques of vHVT309 were found to express NDV-F and IBDV-VP2 proteins.

PCR Analysis of vHVT309

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoters, the NDV-F and IBDV-VP2 genes, and the poly A tails. The PCR results demonstrate that recombinant virus vHVT309 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 1 and FIG. 5).

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT309 is a recombinant virus containing an IBDV-VP2 gene under the control of mCMV promoter and a NDV-F gene under the control of an SV40 promoter. The newly generated vHVT309 is free of any detectable parental vHVT13 virus.

Example 1.2 Construction of Recombinant vHVT310 Expressing IBDV-VP2 and NDV-F

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), internal ribosome entry site (IRES), a gene encoding a Newcastle Disease virus fusion protein (NDV-F), and Simian virus 40 poly A tail (SV40 poly A) is integrated in the intergenic site 1 (IG1) (FIG. 2).

The parental virus used in the construct is vHVT13. A Newcastle disease virus Fusion Protein (NDV-F) corresponding to genotype VIIId sequence was chemically synthesized and codon optimized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (AY337464). Mouse CMV IE promoter was used for IBD-VP2 (in the parental Vaxxitek virus). IRES, an RNA sequence derived from Encephalomyocarditis virus (EMCV), that allows the initiation of translation within an mRNA immediately downstream from where the IRES is located, was inserted at the end of the VP2 gene to initiate translation of a downstream NDV-F gene. This was the first time that IRES was used in an HVT vector.

The insertion locus is intergenic site 1 (IG1) in HVT (FIG. 2). Donor plasmid pFIRESVP2 (an insertion plasmid containing the VP2 gene+IRES+NDV-F and SV40 poly A/flanking arm of IG1) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Donor Plasmid Construction:

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), IRES (SEQ ID NO:10), NDV-F gene (SEQ ID NO:3 encoding SEQ ID NO:5), and SV40 poly A tail (SEQ ID NO:8) was synthesized by GeneScript (FIG. 6). The plasmid, pFIRESVP2 was transformed using Top10 Oneshot kit (cat #C404002, Invitrogen) and a large scale culture was grown and plasmid extraction was done using Qiagens Maxi Prep kit.

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT310.

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify vHVT310.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT310.

Results

The nucleotide and amino acid sequence of the donor plasmid pFIRESVP2 are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Genomic DNA of Vaxxitek virus was co-electroporated with pFIRESVP2 donor plasmid to generate recombinant virus using homologous recombination technique. Recombinant virus was separated from parental vHVT13 virus by

immunofluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant virus expressing the NDV-F protein, designated vHVT310, was scaled up from tissue culture flasks to 5×850 cm² roller bottles. After about 72 hrs post infection the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen, each aliquot contained 10% FBS and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 2.0×10⁶ pfu/ml was obtained for vHVT310.

Dual Immunofluorescent staining was performed using chicken anti-sera (Pab) at 1:500 and HVT L78 monoclonal antibody (Mab) at 1:3000 followed by a FITC labeled anti-chicken IgG at 1:500 and TRITC labeled Alex Fluor donkey anti-mouse at 1:300. Plate #1 compares the expression of Newcastle Disease virus with HVT and plate #2 compares the expression of Infectious Bursal Disease virus with HVT. All examined HVT TRITC positive plaques of vHVT310 were found to express NDV-F and IBDV-VP2 proteins.

PCR Analysis of vHVT310

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the NDV-F and IBDV-VP2 genes, and the polyA tail. The PCR results demonstrate that recombinant virus vHVT310 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 2 and FIG. 7-8).

TABLE 2

Expected PCR bands using specific primer sets		
Primer set	Vaxxitek	vHVT310
MB080 + MB081	3350	5586
MB080 + NDVFVlldopt.F	—	798
MB080 + VP2.F	405	2641
SV40tailR + mCMVF	3021	5257

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT310 is a recombinant virus containing an IBDV-VP2 and NDV-F gene under the control of mCMV promoter, where the translation of NDV-F gene is initiated by IRES from EMCV. The newly generated recombinant vHVT310 is free of any detectable parental vHVT13 virus.

Example 1.3 Construction of Recombinant vHVT311 Expressing IBDV-VP2 and NDV-F

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), self-cleaving porcine teschovirus-1 2A peptide (P2A), a gene encoding a Newcastle Disease virus fusion protein (NDV-F), and Simian virus 40 poly A tail (SV40 poly A) is integrated in the intergenic site 1 (IG1) (FIG. 2).

The parental virus used in the construct is vHVT13 (an HVT vector expressing the IBDV VP2 gene, Merial's VAXXITEK® (HVT+IBD) Vaccine). The polynucleotide corresponding to wild-type genotype VII^d Newcastle disease virus Fusion Protein (NDV-F) sequence was chemically synthesized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence

deposited in GenBank (AY337464). Mouse CMV IE promoter was used for IBD-VP2 (in the parental Vaxxitek virus). A self-cleaving porcine teschovirus-1 2A peptide (P2A) that allows co-translational ‘cleavage’ of the upstream and downstream genes, VP2 and F, respectively from a single promoter mCMV, was inserted at the end of the VP2 gene. This is the first time that P2A was used in HVT vectors.

The insertion locus is intergenic site 1 (IG1) in HVT (FIG. 10 2). Donor plasmid pFP2AVP2 (an insertion plasmid containing the VP2+P2A+NDV-F and SV40 poly A/flanking arm of IG1) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

15 Donor Plasmid Construction

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), P2A encoding DNA (SEQ ID NO:11), NDV-F gene (SEQ ID NO:4 encoding SEQ ID NO:5), and SV40 poly A tail (SEQ ID NO:8) 20 was synthesized by GeneScript (FIG. 9). The plasmid, pFP2AVP2 was transformed using Top10 Oneshot kit (cat #C404002, Invitrogen) and a large scale culture was grown and plasmid extraction was done using Qiagens Maxi Prep kit.

25 Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT311. Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 30 was performed to verify vHVT311.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT311.

Results

35 The nucleotide and amino acid sequences of the donor plasmid pFP2AVP2 are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Genomic DNA of Vaxxitek virus was co-electroporated 40 with pFP2AVP2 donor plasmid to generate recombinant virus using homologous recombination technique. Recombinant virus was separated from parental Vaxxitek virus by immunofluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant virus expressing the NDV-F protein, designated vHVT311, was scaled up from tissue culture flasks to 5×850 cm² roller bottles. After about 72 hrs post infection the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen, each aliquot contained 10% FBS 45 and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 2.5×10⁶ pfu/ml was obtained for vHVT311.

Dual Immunofluorescents was performed using chicken anti-sera (Pab) at 1:500 and a monoclonal antibody (Mab) at 55 1:3000 followed by a FITC labeled anti-chicken IgG at 1:500 and TRITC labeled Alex Fluor donkey anti-mouse at 1:300. Plate #1 compares the expression of Newcastle Disease virus with HVT and plate #2 compares the expression of Infectious Bursal Disease virus with Newcastle Disease virus. All examined HVT TRITC positive plaques of vHVT311 were found to express NDV-F and all NDV TRITC positive plaques were found to express IBDV-VP2 60 proteins.

PCR Analysis of vHVT311

65 Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the NDV-F and IBDV-VP2 genes, and the poly A

21

tail. The PCR results demonstrate that recombinant virus vHVT311 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 3 and FIG. 10-11).

TABLE 3

Expected PCR bands using specific primer sets		
Primer set	Vaxxitek	vHVT311
MB080 + MB081	3350	5101
MB080 + NDVFVlldwt.F	—	840
MB080 + VP2.F	405	2156
SV40tailR + mCMVF	3021	4772

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT311 is a recombinant virus containing an IBDV-VP2 and NDV-F gene under the control of mCMV promoter in which the 2A peptide-mediated cleavage result in co-expression of VP2 and F proteins. The newly generated recombinant vHVT311 is free of any detectable parental vHVT13 virus.

Example 1.4 Construction of Recombinant vHVT317 Expressing IBDV-VP2 and ILTV-gD

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), internal ribosome entry site (IRES), a gene encoding an Infectious Laryngotracheitis glycoprotein D protein (ILTV-gD), and Simian virus 40 poly A tail (SV40 poly A) is integrated in the intergenic site 1 (IG1) (FIG. 2).

The parental virus used in the construct is vHVT13. An Infectious Laryngotracheitis virus glycoprotein D (ILTV gD) sequence which was chemically synthesized (GenScript) was used in the construct. Mouse CMV IE promoter was used for IBD-VP2 (in the parental vHVT13 virus). An RNA sequence (IRES) derived from Encephalomyocarditis virus (EMCV), that allows the initiation of translation within an mRNA immediately downstream from where the IRES is located, was inserted at the end of the VP2 gene to initiate translation of a downstream ILTV-gD gene.

The insertion locus is intergenic site 1 (IG1) in HVT (FIG. 2). Donor plasmid pVP2IRESGD (an insertion plasmid containing the VP2 gene+IRES+ILTV-gD and SV40 poly A/flanking arm of IG1) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Donor Plasmid Construction

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), IRES (SEQ ID NO:10), ILTV-gD gene (SEQ ID NO:16 encoding SEQ ID NO:17), and SV40 poly A tail (SEQ ID NO:8) was synthesized by GenScript. The plasmid, pFIRESPV2 was transformed into dcm-/dam-competent cells (New England Biolabs, cat #C2925I) then digested with HindIII/Sall. The 5 kb fragment was gel extracted. A synthetic DNA in pUC57 containing a partial IRES, ILTV-gD wildtype, and SV40 poly A tail was synthesized by GenScript. The plasmid, Sal-Fse gD-IRES was digested with HindIII/Sall. The 1.9 kb fragment was gel extracted. The two fragments were ligated and transformed using Top10 Oneshot kit (cat #C404002, Invitrogen). Colonies were screen by HindIII/Sall for the

22

correct pattern. The final donor plasmid was sequenced verified and designated pVP2IRESGD (see FIG. 12). Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT317. Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify vHVT317.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT317. Results

The nucleotide and amino acid sequence of the donor plasmid pVP2IRESGD are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Dual Immunofluorescence was performed using chicken anti-sera (Polyclonal antibody) at 1:500 and a monoclonal antibody (Mab) at 1:3000 followed by a FITC labeled anti-chicken IgG at 1:500 and TRITC labeled Alex Fluor donkey anti-mouse at 1:300. All examined plaques of vHVT317 were found to express IBDV-VP2 proteins compared to HVT positive plaques and all and plaques were found to express ILTV-gD proteins when compared to IBDV positive plaques.

PCR Analysis of vHVT317

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the ILTV-gD and IBDV-VP2 genes, and the poly A tail. The PCR results demonstrate that recombinant virus vHVT317 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 4 and FIG. 13-14).

TABLE 4

Expected PCR bands using specific primer sets		
Primer set	Vaxxitek	vHVT317
MB080 + MB081	3350	5101
MB080 + ILTgDwt.F	—	825
MB080 + VP2.F	405	2272
SV40tailR + mCMVF	3021	4888

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT317 is a recombinant virus containing an IBDV-VP2 and ILTV-gD gene under the control of mCMV promoter, where the translation of ILTV-gD gene is initiated by IRES from EMCV. The newly generated recombinant vHVT317 is free of any detectable parental vHVT13 virus.

Example 1.5 Construction of Recombinant vHVT313 Expressing IBDV-VP2 and NDV-F

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), Simian virus 40 poly A tail (SV40 poly A), Simian virus 40 promoter (SV40 promoter), a gene encoding a wildtype Newcastle disease virus fusion protein (NDV-F) and synthetic poly A tail (syn poly A tail) is integrated in the intergenic site 1 (IG1) (FIG. 2).

The parental virus used in the construct is vHVT13. A Newcastle disease virus Fusion Protein (NDV-F) corresponding to genotype VIIId wildtype sequence chemically

synthesized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (AY337464). Mouse CMV IE promoter for IBD-VP2 (in the parental Vaxxitek virus) and SV40 promoter for NDV-F were used.

The insertion locus is intergenic site 1 (IG1) (FIG. 2). Donor plasmid pFwtSV40VP2 (an insertion plasmid containing the VP2/SV40 poly A and flanking arm of IG1+SV40 promoter+NDV-F+synthetic poly A) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Donor Plasmid Construction

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), SV40 poly A tail (SEQ ID NO:8), SV40 promoter (SEQ ID NO:7), NDV-F gene (SEQ ID NO:4 encoding SEQ ID NO:5), and synthetic poly A tail (SEQ ID NO:9) was synthesized by GeneScript.

The plasmid, pFSV40VP2 was then digested with SbfI/AvrII and the 5.6 kb fragment was gel extracted. A plasmid, pHM103NDVFwtSyn was also digested with SbfI/AvrII and the 1.9 kb fragment was gel extracted. The fragments were then ligated together and transformed using Top10 Oneshot kit (cat #C404002, Invitrogen). Colonies were screened with PstI for the correct pattern. Transient expression of the maxiprep was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and chicken polyclonal sera against NDV. The final donor plasmid was sequenced verified and designated pFwtSV40VP2 (see FIG. 15).

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT313.

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify vHVT313.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT313.

Results

The nucleotide and amino acid sequence of the donor plasmid pFwtSV40VP2 are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Dual Immunofluorescence was performed using chicken anti-sera (Pab) and an anti-HVT monoclonal antibody (Mab) followed by a FITC labeled anti-chicken IgG and TRITC labeled Alex Fluor donkey anti-mouse. All examined TRITC positive plaques of vHVT313 were found to express NDV-F and IBDV-VP2 proteins.

PCR Analysis of vHVT313

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoters, the NDV-F and IBDV-VP2 genes, and the poly A tails. The PCR results demonstrate that recombinant virus vHVT313 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 5 and FIG. 16-17).

TABLE 5

Primer set	Expected PCR bands using specific primer sets	
	Vaxxitek	vHVT313
MB080 + MB081	3350	5574
MB080 + 312P6	—	556
MB080 + VP2.F	405	2629
SV40tailR + mCMVF	3021	3021
SyntailR + SV40promoterF	—	2181

10

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT313 is a recombinant virus containing an IBDV-VP2 gene under the control of mCMV promoter and a NDV-F wildtype gene under the control of an SV40 promoter. The newly generated vHVT313 is free of any detectable parental Vaxxitek virus.

Example 1.6 Construction of Recombinant vHVT316 Expressing IBDV-VP2 and NDV-F

The objective of the study is to construct a recombinant HVT in which an expression cassette containing a mouse cytomegalovirus promoter (mCMV), a gene encoding an infectious bursal disease virus viral protein 2 (VP2), internal ribosome entry site (IRES), a gene encoding a wildtype Newcastle Disease virus fusion protein (NDV-F), and Simian virus 40 poly A tail (SV40 poly A) is integrated in the IG1 locus (FIG. 2).

The parental virus used in the construct is vHVT13. A Newcastle disease virus Fusion Protein (NDV-F) corresponding to genotype VIId wildtype sequence chemically synthesized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (AY337464). Mouse CMV IE promoter was used for IBD-VP2 (in the parental Vaxxitek virus). IRES was inserted at the end of the VP2 gene to initiate translation of a downstream NDV-F gene.

The insertion locus is IG1 (FIG. 2). Donor plasmid pVP2IRESFwt (an insertion plasmid containing the VP2 gene+IRES+NDV-F and SV40 poly A/flanking arm of IG1) was constructed as described below. Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Donor Plasmid Construction

Synthetic DNA in pUC57 containing the IBDV VP2 gene (SEQ ID NO:1 encoding SEQ ID NO:2), IRES(SEQ ID NO:10), NDV-F gene (SEQ ID NO:4 encoding SEQ ID NO:5), and SV40 poly A tail (SEQ ID NO:8), was synthesized by GenScript. The plasmid, pFIRESVP2 was transformed into dcm-/dam-competent cells (New England Biolabs, cat #C2925I) then digested with HindIII/SalI. The 5 kb fragment was gel extracted. A synthetic DNA in pUC57 containing a partial IRES, NDV-F wildtype, and SV40 poly A tail was synthesized by GenScript. The plasmid, Sal-Hind-Fwt+ was digested with HindIII/SalI. The 2.2 kb fragment was gel extracted. The two fragments were ligated and transformed using Top10 Oneshot kit (cat #C404002, Invitrogen). The final donor plasmid was sequenced verified and designated pVP2IRESFwt (see FIG. 18).

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT316.

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify vHVT316.

65

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT316.

Results

The nucleotide and amino acid sequence of the donor plasmid pVP2IRESFwt are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Dual Immunofluorescent staining was performed using chicken anti-sera (Pab) and a monoclonal antibody (Mab) followed by a FITC labeled anti-chicken IgG and TRITC labeled Alex Fluor donkey anti-mouse. All examined plaques of vHVT316 were found to express IBDV-VP2 proteins compared to HVT positive plaques and all and plaques were found to express IBDV-VP2 proteins when compared to NDV positive plaques.

PCR Analysis of vHVT316

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the NDV-F and IBDV-VP2 genes, and the poly A tail. The PCR results demonstrate that recombinant virus vHVT316 carries the intended expression cassette and the virus stock is free from detectable amounts of parental Vaxxitek virus (Table 6 and FIG. 19-20).

TABLE 6

Expected PCR bands using specific primer sets		
Primer set	Vaxxitek	vHVT316
MB080 + MB081	3350	5574
MB080 + 312P6	—	604
MB080 + VP2.F	405	2629
SV40tailR + mCMVF	3021	5245

35

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT316 is a recombinant virus containing an IBDV-VP2 and NDV-F gene under the control of mCMV promoter, where the translation of NDV-F gene is initiated by IRES from EMCV. The newly generated recombinant vHVT316 is free of any detectable parental Vaxxitek virus.

Example 1.7 Construction of Recombinant vHVT407 Expressing IBDV-VP2 and ILTV-gD

The objective of the study is to construct a recombinant HVT in which an expression cassette containing an SV40 promoter, ILTV glycoprotein D, and synthetic poly A into the SORF3-US2 site of vHVT13.

The parental virus used in the construct is vHVT13. An Infectious Laryngotracheitis virus glycoprotein D (ILTV gD) sequence which was chemically synthesized (GenScript) was used in the construct. SV40 promoter was used for ILTV gD. The insertion locus is SORF3-US2 for ILTV gD and IG1 for IBDV VP2 from vVHT13 (FIG. 2). Donor plasmid HVT US2SVgDwtsyn containing SORF3-US2 arms, SV40 promoter (SEQ ID NO:7), gene encoding ILTV wild-type gD (SEQ ID NO:16 encoding SEQ ID NO:17), and synthetic polyA (SEQ ID NO:9) was constructed (see FIG. 22). Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make recombinant vHVT407.

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify vHVT407.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of vHVT407.

Results

The nucleotide and amino acid sequence of the donor plasmid HVT US2SVgDwtsyn are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Dual Immunofluorescent staining was performed using chicken anti-sera (Pab) and a monoclonal antibody (Mab) followed by a FITC labeled anti-chicken IgG and TRITC labeled Alex Fluor donkey anti-mouse. All examined plaques of vHVT407 were found to express IBDV-VP2 and ILTV gD proteins.

PCR Analysis of vHVT407

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the ILTV gD and IBDV-VP2 genes, and the poly A tail. The PCR results demonstrate that recombinant virus vHVT407 carries the intended expression cassette and the virus stock is free from detectable amounts of parental vHVT13 virus.

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT407 is a recombinant virus containing IBDV-VP2 and ILTV gD genes. The newly generated recombinant vHVT407 is free of any detectable parental vHVT13 virus.

Example 1.8 Construction of Recombinant vHVT308 Expressing NDV-F and ILTV-gD in Opposite Directions

35

The objective of the study is to construct an insertion plasmid for the Intergenic region I site that will contain a Synthetic poly A tail, NDV F, SV40 promoter, HHV3gB promoter, ILTV gD, and SV40 poly A tail for homologous recombination into HVT FC126.

The parental virus used in the construct is HVT FC126. A synthetic Newcastle disease virus Fusion Protein (NDV-F) (SEQ ID NO:21 encoding SEQ ID NO:22) corresponding to genotype V sequence was chemically synthesized and codon optimized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence. A synthetic wildtype ILTV glycoprotein D (SEQ ID NO:16 encoding SEQ ID NO:17) was chemically synthesized. Donor plasmid pHVTIG1gDCaFopt containing the HHV3gB promoter (Human Herpesvirus Type 3 glycoprotein B promoter) in the reverse orientation driving ILTV-gD+SV40 poly A tail, and SV40 promoter driving Newcastle fusion protein+synthetic poly A tail was constructed (see FIG. 23). Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make the recombinant vHVT308. Serial passaging was performed to pre-MSV+13.

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify the recombinant vHVT308.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of the recombinant vHVT308.

Results

The nucleotide and amino acid sequence of the donor plasmid pHVTIG1gDCaFopt are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Dual Immunofluorescent staining was performed using chicken anti-sera (Pab) and a monoclonal antibody (Mab) followed by a FITC labeled anti-chicken IgG and TRITC labeled Alex Fluor donkey anti-mouse. All examined plaques of vHVT308 were found to express NDV-F and ILTV-gD proteins.

PCR Analysis of vHVT308

Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoters, the NDV-F and ILTV-gD genes, and the poly A tails. The PCR results demonstrate that recombinant virus vHVT308 carries the intended expression cassette and the virus stock is free from detectable amounts of parental HVT virus (Table 6.1 and FIGS. 24 and 25).

TABLE 6.1

Expected PCR bands using specific primer sets		
Primer set	HVT FC126	vHVT308
MB080 + MB081	323 bp	4697 bp
syntailR + SV40promoterF	—	2196 bp
CAoptF.RP + 404P12	—	2056 bp
HHV3gBF + SV40tailR	—	2043 bp

PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. As shown above, there is no evidence of parental HVT virus in vHVT308 and vHVT308 is stable at pre-MSV+13 passages.

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT308 is a recombinant HVT virus containing an NDV-F gene under the control of an SV40 promoter and an ILTV-gD gene under the control of an HHV3gB promoter. vHVT308 is free of any detectable parental HVT virus.

Example 1.9 Construction of Recombinant
vHVT322 Expressing NDV-F and ILTV-gD

The objective of the study is to construct a recombinant HVT in which an expression cassette containing an mCMV promoter, Newcastle Disease virus fusion protein (NDV-F), internal ribosome entry site (IRES), Infectious Laryngotracheitis glycoprotein D (ILTV-gD), and Simian virus 40 poly A tail (SV40 poly A) will homologously recombine with the flanking arms in the intergenic region 1 (IG1) of vHVT13 (HVT+IBD).

The parental virus used in the construct is vHVT13. A Newcastle disease virus Fusion Protein (NDV-F) corresponding to the wildtype genotype VII^d sequence (SEQ ID NO:4 encoding SEQ ID NO:5) was chemically synthesized (GenScript). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% nucleotide as well as amino acid sequence identity to NDV-F sequence deposited in GenBank (AY337464). A synthetic wildtype ILTV glycoprotein D (SEQ ID NO:16 encoding SEQ ID NO:17) was chemically synthesized. Donor plasmid_pFwaRESgD contained the left flanking arm of IG1, mCMV (mouse CMV IE) promoter, NDV-F, IRES, ILTV-

gD, SV40 poly A, and the right flanking arm of IG1 (see FIG. 26). Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Recombinant Generation

5 The homologous recombination procedure as described in Example 1.1 was followed to make the recombinant vHVT322. Serial passaging was performed to pre-MSV+13. Analysis of Recombinant by PCR

10 The PCR analysis procedure as described in Example 1.1 was performed to verify the recombinant vHVT322.

Expression Analysis

15 The expression analysis described in Example 1.1 was performed to analyze the expression of the recombinant vHVT322.

Results

The nucleotide and amino acid sequence of the donor plasmid pFwtIRESgD are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

20 Dual Immunofluorescent staining was performed using chicken anti-sera (Pab) and a monoclonal antibody (Mab) followed by a FITC labeled anti-chicken IgG and TRITC labeled Alex Fluor donkey anti-mouse. All examined TRITC positive plaques of vHVT322 were found to express NDV-F and ILTV-gD proteins.

PCR Analysis of vHVT322

25 Purity of recombinant virus was verified by PCR using primer pairs that are specific to the HVT flanking arms, the promoter, the NDV-F and ILTV-gD genes, and the poly A tail. The PCR results demonstrate that recombinant virus vHVT322 carries the intended expression cassette and the virus stock is free from detectable amounts of parental vHVT13 (Table 6.2 and FIGS. 27 and 28).

TABLE 6.2

Expected PCR bands using specific primer sets		
Primer set	vHVT13	vHVT322
MB080 + MB081	3350 bp	5804 bp
MB080 + ILTgDwtF	—	1653 bp
MB080 + 312P6	—	2485 bp
mCMVF + SV40PolyA.R1	3021 bp	5105 bp

35 PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. As shown above, there is no evidence of parental vHVT13 virus in vHVT322.

Conclusion

50 Based on PCR testing and immunofluorescence analysis, vHVT322 is a recombinant HVT virus containing an NDV-F and ILTV-gD gene under the control of mCMV promoter. vHVT322 is free of any detectable parental vHVT13 virus.

55 Example 1.10 Construction of Recombinant
vHVT406 Expressing ILT-gDwt

The objective of the study is to construct a recombinant HVT of which the SORF3-US2 site contains the SV40 promoter, Infectious Laryngotracheitis gD, and synthetic poly A tail for homologous recombination into HVT FC126.

The parental virus used in the construct is HVT FC126. A synthetic Infectious Laryngotracheitis Virus (ILTV) wild-type glycoprotein D (gDwt) was chemically synthesized.

60 Donor plasmid pHVTUS2SVgDwtsyn contained the SORF3 and US2 arms of HVT FC126, SV40 promoter, ILTV gDwt (SEQ ID NO:16 encoding SEQ ID NO:17) and

29

synthetic poly A (see FIG. 29). Chicken embryo fibroblast cells (CEF) were used for in vitro recombination.

Recombinant Generation

The homologous recombination procedure as described in Example 1.1 was followed to make the recombinant vHVT406. Serial passaging was performed to pre-MSV+13 (x+12).

Analysis of Recombinant by PCR

The PCR analysis procedure as described in Example 1.1 was performed to verify the recombinant vHVT406.

Expression Analysis

The expression analysis described in Example 1.1 was performed to analyze the expression of the recombinant vHVT406.

Results

The nucleotide and amino acid sequence of the donor plasmid pHVTUS2SVgDwtsyn are assigned SEQ ID NO as shown in FIG. 1.

Recombinant Generation and Expression Analyses

Genomic DNA of HVT virus was co-electroporated with pHVTUS2SVgDwtsyn donor plasmid to generate recombinant HVT using homologous recombination technique. Recombinant virus was separated from parental HVT virus by immunofluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant HVT virus expressing the ILTV-gD protein was designated vHVT406.

Recombinant vHVT406 viral plaques were visualized using both the TRITC and FITC filters for the dual staining. The FITC showed the ILTV-gDwt expression and the TRITC showed the HVT expression. Because of the small wells of the 96 well plates, each well was recorded with the plaques first counted with the TRITC filter and then recounted with the FITC filter. A combined 600+ plaques were counted between the pre-MSV and pre-MSV+13 passage. All the plaques were positive for both the FITC and TRITC for both passages.

PCR Analysis of vHVT406

PCR analysis of vHVT406 was performed using the PCR primers listed in Table 6.3 (see FIG. 30). As shown in FIG. 31, the sizes of PCR products after gel electrophoresis correspond well with the expected sizes and the banding patterns. There is no evidence of the parental HVT FC126 virus in vHVT406.

30

TABLE 6.3

Expected PCR bands using specific primer sets				
primer	HVT FC126	pHVTUS2SVgDwtsyn	vHVT406	
SORF3.FP + US2.RP	0.334	2.218	2.218	
SORF3.FP + 404P12	—	0.733	0.733	
SV40promoterF + syntailR	—	1.829	1.829	
MB080 + MB081	0.323	—	0.323	
SB-1		pHVTUS2SVgDwtsyn	vHVT406	
SB1SORF4 + SB1US2R	0.989	—	—	

Conclusion

Based on PCR testing and immunofluorescence analysis, vHVT406 is a recombinant HVT virus containing an SV40 promoter, ILTV-gDwt gene, and synthetic poly A tail in the SORf3-US2 site. vHVT406 is free of any detectable parental HVT virus.

Example 1.11 In Vitro Stability Study of the HVT Vectors

The HVT vectors constructed above were tested for genomic/expression stability after multiple in vitro passages in Chicken embryo fibroblast cells (CEF). The HVT vectors expressing two genes were stable after multiple passages. Contrary to the common knowledge that HVT with multiple inserts are less stable, the results demonstrated surprisingly that the HVT vectors of the present invention are stable and express two genes efficiently.

Example 2 Newcastle Disease (ND) Efficacy Induced at D28 by vHVT306, vHVT309, vHVT310 & vHVT311 in SPF Chicks

The aim of the study was to assess the efficacy of four HVT recombinant constructs (vHVT306, vHVT309, vHVT310 & vHVT311) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against Newcastle disease challenges (Texas GB strain) performed on D28.

The characteristics of these vaccine candidates are described in Table 7 below.

TABLE 7

Characteristics of the vectors used in the challenge study					
Name	Parental virus	Promoter/gene	Promoter/linker	Poly-A	Locus
vHVT306*	vHVT13**	IBDV VP2	mCMV IE	SV40 Poly A	IG1
		NDV F	SV40	Synthetic PolyA	SORF3-US2
vHVT309	vHVT13	IBDV VP2	mCMV IE	SV40 poly A	IG1
		NDV F	SV40	Synthetic PolyA	IG1
vHVT310	vHVT13	IBDV VP2	mCMV IE	N/A	IG1
		NDV F	IRES	SV40 poly A	IG1
vHVT311	vHVT13	IBDV VP2	mCMV IE	N/A	IG1
		NDV F	P2A	SV40 poly A	IG1

vHVT306*: the vHVT vector expressing IBDV VP2 and NDV F (see U.S. Pat. No. 9,114,108), used as a control.

vHVT13** is the active ingredient of the licensed VAXXITEK HVT-IBD vaccine based on an HVT vector expressing the IBDV VP2 gene (described as vHVT17 in U.S. Pat. No. 5,980,906 and EP 0 719 864).

Ninety five one-day-old specific pathogen free (SPF) chicks were assigned to 5 groups as shown in Table 8. All birds from groups 1 to 4 (20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated (see Table 8). The 15 birds from group 5 were left unvaccinated. Twenty eight (D28) days post-vaccination, the birds in each group were challenged with NDV Texas GB strain by the intramuscular (IM) route ($10^{4.0}$ egg infectious dose 50% (EID50) in 0.1 mL/bird). Birds were observed for clinical signs during 14 days after challenge. Birds that did not show any ND clinical signs (including central nervous, or respiratory signs and/or death) for up to 14 days post-challenge were considered as protected.

Results of protection are shown in Table 8. All control birds of group 5 died after the challenge. Protection in the vaccinated groups reached at least 90%.

TABLE 8

ND efficacy induced by different HVT-IBD + ND double constructs in SPF chicks			
Group	Vaccine	Dose (PFU)	ND protection after D 28 challenge
1	vHVT306*	1580	95% (19/20)
2	vHVT309	1680	90% (18/20)
3	vHVT310	2840	95% (19/20)
4	vHVT311	2980	90% (18/20)
5	—	—	0% (0/15)

vHVT306*: used as a control

Example 3 IBD Efficacy Induced by vHVT309, vHVT310, vHVT311 and vHVT407 Against a Standard IBDV Challenge at D35

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT309, vHVT310 & vHVT311) expressing the IBDV VP2 gene and NDV F gene and one construct (vHVT407) expressing the IBDV VP2 gene and ILTV gD gene administered to one-day-old SPF chickens against standard IBDV challenge performed on D35.

One-day-old specific pathogen free (SPF) chicks were assigned to 4 groups as shown in Table 9. All birds from groups 1 to 4 (20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND or HVT-IBD+ILT constructs at the dose indicated. The 20 birds from group 5 were left unvaccinated. Thirty five days after vaccination (at D35), all birds were challenged with the infectious bursal disease virus (IBDV) classical STC strain by the intraocular (TO) route ($10^{2.0}$ EID50 in 0.03 mL/bird). Four days post-challenge (at D39) all birds were terminated and necropsied to examine for gross bursal lesions.

Results of protection are shown in Table 9. All vaccinated birds (except two vHVT311-vaccinated birds) were protected against IBD, whereas none of the control birds were protected.

TABLE 9

IBD efficacy induced by different HVT-IBD + ND or HVT-IBD + ILT double constructs in SPF chicks after challenge at D 35 with STC IBDV strain			
Group	Vaccine	Dose (PFU)	IBD STC protection after D 35 challenge
1	vHVT309	2180	100% (20/20)
2	vHVT310	3980	100% (20/20)
3	vHVT311	3180	90% (18/20)
4	vHVT407	1220	100% (20/20)
5	—	—	0% (0/20)

Example 4 IBD Efficacy Induced by vHVT309, vHVT310, vHVT311 and vHVT407 Against a Variant IBDV Challenge at D35

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT309, vHVT310 & vHVT311) expressing the IBDV VP2 gene and NDV F gene and one construct (vHVT407) expressing the IBDV VP2 gene and ILTV gD gene administered to one-day-old SPF chickens against a variant (Delaware E) IBDV challenge performed on D35.

One-day-old specific pathogen free (SPF) chicks were assigned to 6 groups as shown in Table 10. All birds from groups 1 to 4 (19-20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND or HVT-IBD+ILT constructs at the dose indicated. Birds from group 5 (19 birds) and group 6 (18 birds) were left unvaccinated. At D35, all birds from groups 1 to 5 were challenged with the infectious bursal disease virus (IBDV) variant Delaware E strain by the intraocular (TO) route ($10^{3.0}$ EID50 in 0.03 mL/bird). Birds from group 6 were left unchallenged. At D46, body weight and bursal weight of all birds were measured. The B/B wt. ratios (bursa weight/body weight ratio $\times 100$) were calculated for all groups.

Results of protection are shown in Table 10. Vaccinated birds from groups 1 and 2 had a mean B/B wt. ratio similar as that of non-vaccinated non-challenged controls (group 6) and greater than those of non-vaccinated challenged controls (group 5). Birds of group 3 were not protected and birds of group 4 were partially protected. Surprisingly, vHVT310 which contains IRES provided better protection than vHVT311 which contains P2A.

TABLE 10

IBD efficacy induced by different HVT-IBD + ND or HVT-IBD + ILT double constructs in SPF chicks after challenge at D 35 with variant E IBDV strain					
Group	Vaccine	Dose (PFU)	Number of birds	IBDV challenge at D 35	Mean B/B wt. ratio
1	vHVT309	2180	20	Yes	0.43
2	vHVT310	3980	20	Yes	0.50
3	vHVT311	3180	20	Yes	0.18
4	vHVT407	1220	19	Yes	0.32
5	—	—	19	Yes	0.13
6	—	—	18	No	0.45

Example 5 IBD Efficacy Induced by vHVT306, vHVT309 & vHVT310 Against a vvIBDV Challenge at D28 in Broilers

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 &

vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old broiler chickens against vvIBDV challenge performed on D28.

Seventy one-day-old broiler chicks (Hubbard JA957 line) were assigned to 5 groups as shown in Table 11. All birds from groups 2 to 5 (about 15 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. Ten birds from group 1 were left unvaccinated. Twenty eight days after vaccination (at D28), all birds were challenged with the very virulent IBDV (vvIBDV) 91-168 strain by the intraocular (TO) route ($10^{4.3}$ EID50 in 0.05 mL/bird). Ten days post-challenge (at D38) all birds were terminated and necropsied to examine for gross bursal lesions. Bursal and body were weighted and histopathology was performed on the bursa. Histological lesions of the bursa were scored from 0 to 5 according to the following scale: 0—No lesion, normal bursa; 1—1% to 25% of the follicles show lymphoid depletion (i.e., less than 50% of depletion in 1 affected follicle), influx of heterophils in lesions; 2—26% to 50% of the follicles show nearly complete lymphoid depletion (i.e., with more than 75% of depletion in 1 affected follicle), the affected follicles show necrosis lesions and severe influx of heterophils may be detected; 3—51% to 75% of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected; 4—76% to 100% of the follicles show nearly complete lymphoid depletion; hyperplasia and cyst structures are detected; affected follicles show necrosis lesions and severe influx of heterophils is detected; and 5—100% of the follicles show nearly complete lymphoid depletion; complete loss of follicular structure; thickened and folded epithelium; fibrosis of bursal tissue. Birds were considered as protected if they did not show clinical signs post-challenge and if their histology score was ≤ 2 .

There were some early mortalities in the first week in this batch of broilers likely due to colibacillosis. The dose of the tested vaccines was lower than expected (2000 PFU). Results of protection are shown in Table 11. Partial protection was induced by vaccination which shows vHVT310 being higher than vHVT306 and vHVT309.

TABLE 11

IBD efficacy induced by different HVT-IBD + ND double constructs in broiler chicks after challenge at D 28 with vvIBDV strain				
Group	Vaccine	Dose (PFU)	Mean Bursal/body weight ratio (*1000)	Protection based on histopathology score
1	—	—	0.75	0%
2	vHVT306	955	1.07	20%
3	vHVT309	741	0.89	20%
4	vHVT310	708	1.38	53%
5	vHVT13*	2000	1.99	80%

vHVT13*: used as a control.

Example 6 ND Efficacy Induced by vHVT306, vHVT309 & vHVT310 Against a Velogenic NDV Challenge at D42 in Broilers

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old broiler chickens against velogenic NDV challenge performed on D42.

One-day-old broiler chicks (Hubbard JA957 line) were assigned to 4 groups as shown in Table 12. All birds from groups 2 to 4 (16-20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. Twelve birds from group 1 were left unvaccinated. Forty two days after vaccination (at D42), all birds were challenged with the velogenic NDV Herts 33 strain by the intramuscular (IM) route ($10^{5.0}$ EID50 in 0.2 mL/bird). All birds were observed for clinical signs during 14 days post-challenge. Birds were considered as protected if they did not die or show ND clinical signs.

There were some early mortalities in the first week in this batch of broilers likely due to colibacillosis. The dose of the tested vaccines was lower than expected (2000 PFU). Results of protection are shown in Table 12. Best protections were induced by vaccination with vHVT309 & vHVT310, followed by vHVT306.

TABLE 12

ND efficacy induced by different HVT-IBD + ND double constructs in broiler chicks after challenge at D 42 with velogenic NDV strain				
Group	Vaccine	Dose (PFU)	Protection against mortality	Protection against mortality & morbidity
1	—	—	8.3%	0%
2	vHVT306	955	68.8%	62.5%
3	vHVT309	741	85%	85%
4	vHVT310	708	85%	80%

Example 7 ND Efficacy Induced by vHVT306, vHVT309 & vHVT310 Against a Velogenic NDV Challenge at D42 in Broilers

The aim of the study was to re-assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old broiler chickens against velogenic NDV challenge performed on D42.

One-day-old broiler chicks (Hubbard JA957 line) were assigned to 4 groups as shown in Table 13. All birds from groups 2 to 4 (16-20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at 2000 PFU. Nineteen birds from group 1 were left unvaccinated. Forty two days after vaccination (at D42), all birds were challenged with the velogenic NDV Herts 33 strain by the intramuscular (IM) route ($10^{5.0}$ EID50 in 0.2 mL/bird). All birds were observed for clinical signs during 14 days post-challenge. Birds were considered as protected if they did not die or show ND clinical signs.

Results of protection are shown in Table 13. Overall, the levels of protection were higher than the previous study (see example 6), but they follow the same trend: best protections were induced by vaccination with vHVT309 & vHVT310, followed by vHVT306.

The results showed that vHVT309 is more efficacious than vHVT306 against ND challenges in SPF as well as broilers (Tables 12 & 13), suggesting that inserting heterologous polynucleotides in one locus have less negative impact on the overall fitness of the virus than inserting in multiple loci.

TABLE 13

ND efficacy induced by different HVT-IBD + ND double constructs in broiler chicks after challenge at D 42 with velogenic NDV strain

Group	Vaccine	Dose (PFU)	Protection against mortality	Protection against mortality & morbidity
1	—	—	0%	0%
2	vHVT306	955	75%	75%
3	vHVT309	741	94%	89%
4	vHVT310	708	94%	94%

Example 8 IBD Efficacy Induced by vHVT306, vHVT309 & vHVT310 Against a Standard IBDV Challenge at D14 in SPF Chicks

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against standard IBDV challenge performed at D14.

One-day-old specific pathogen free (SPF) chicks were assigned to 4 groups as shown in Table 14. All birds from groups 1 to 3 (21-22 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. The 22 birds from group 4 were left unvaccinated. Fourteen days after vaccination (at D14), all birds were challenged with the infectious bursal disease virus (IBDV) classical STC strain by the intraocular (TO) route ($10^{1.4}$ EID50 in 0.03 mL/bird). Four days post-challenge (at D18) all birds were terminated and necropsied to examine for gross bursal lesions.

Results of protection are shown in Table 14 Similar levels of IBD protection were induced by the 3 experimental vaccines, whereas all but one control birds was infected.

TABLE 14

IBD efficacy induced by different HVT-IBD + ND double constructs in SPF chicks after challenge at D 14 with STC IBDV strain

Group	Vaccine	Dose (PFU)	IBD STC protection after D 14 challenge (infected/total)
1	vHVT306	2061	68.2% (7/22)
2	vHVT309	1476	76.2% (5/21)
3	vHVT310	1970	68.2% (7/22)
4	—	—	4.5% (1/22)

Example 9 IBD Efficacy Induced by vHVT306, vHVT309 & vHVT310 in SPF Chicks after Variant IBD Challenge at D14

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against variant IBDV challenge performed at D14.

One-day-old specific pathogen free (SPF) chicks were assigned to 5 groups as shown in Table 15. All birds from groups 1 to 3 (20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. Birds from group 4 and group 5 (19-20 birds/group) were left unvaccinated. At D14, all birds from groups 1 to 4 were challenged with the infectious bursal disease virus (IBDV) variant Delaware E strain by the intraocular (TO) route ($10^{2.2}$ EID50 in 0.03

mL/bird). Birds from group 5 were left unchallenged. At D25, body weight and bursal weight of all birds were measured. The B/B wt. ratios (bursa weight/body weight ratio $\times 100$) were calculated for all groups.

Results of protection are shown in Table 15. Partial protection was induced at D14 by the 3 vaccines, protection being higher for vHVT309 and vHVT310.

Recombinant vHVT306 and vHVT309 have two independent expression cassettes (two mRNAs). The constructs expressing two genes through an IRES or P2A (for example, vHVT310, vHVT317, vHVT311, vHVT316, vHVT322) are not only in one insertion site, but also the genes are expressed from a single mRNA. Comparing all the data presented in Tables 11 to 19, it shows that one insertion site recombinants vHVT309 and vHVT310 are more efficacious than two insertion site recombinant vHVT306, indicating that HVT recombinants carrying more than one heterologous polynucleotides in one insertion locus are biologically more fit than HVT recombinants carrying heterologous polynucleotides in multiple insertion loci. Furthermore, surprisingly, expressing more than one heterologous polynucleotides from a single mRNA expressed through an IRES has less negative impact on IBD efficacy, particularly in broilers (see results on Table 11).

TABLE 15

IBD efficacy induced by different HVT-IBD + ND double constructs in SPF chicks after challenge at D 14 with variant E IBDV strain

Group	Vaccine	Dose (PFU)	Number of birds	IBDV challenge at D 14	Mean B/B wt. ratio
1	vHVT306	2061	20	Yes	0.18
2	vHVT309	1476	20	Yes	0.33
3	vHVT310	1970	20	Yes	0.27
4	—	—	19	Yes	0.13
5	—	—	20	No	0.64

Example 10 IBD Efficacy Induced by vHVT306, vHVT309 & vHVT310 Against a Standard IBDV Challenge at D28 in SPF Chicks

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against standard IBDV challenge performed at D28.

One-day-old specific pathogen free (SPF) chicks were assigned to 4 groups as shown in Table 16. All birds from groups 1 to 3 (20-22 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. The 22 birds from group 4 were left unvaccinated. Twenty eight days after vaccination (at D28), all birds were challenged with the infectious bursal disease virus (IBDV) classical STC strain by the intraocular (TO) route ($10^{2.0}$ EID50 in 0.03 mL/bird). Four days post-challenge (at D32) all birds were terminated and necropsied to examine for gross bursal lesions.

Results of protection are shown in Table 16. Full protection was induced by vHVT310 whereas only a few birds were not protected for the other vaccine candidates.

TABLE 16

IBD efficacy induced by different HVT-IBD + ND double constructs in SPF chicks after challenge at D 28 with STC IBDV strain			
Group	Vaccine	Dose (PFU)	IBD STC protection after D 28 challenge (infected/total)
1	vHVT306	2061	86.4% (3/22)
2	vHVT309	1476	95.0% (1/20)
3	vHVT310	1970	100% (0/22)
4	—	—	4.5% (21/22)

Example 11 IBD Efficacy Induced by vHVT306, vHVT309 & vHVT310 in SPF Chicks after Variant IBD Challenge at D28

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT306, vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against variant IBDV challenge performed at D28.

One-day-old specific pathogen free (SPF) chicks were assigned to 5 groups as shown in Table 17. All birds from groups 1 to 3 (20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. Birds from group 4 and group 5 (18-19 birds/group) were left unvaccinated. At D28, all birds from groups 1 to 4 were challenged with the infectious bursal disease virus (IBDV) variant Delaware E strain by the intraocular (TO) route ($10^{2.2}$ EID50 in 0.03 mL/bird). Birds from group 5 were left unchallenged. At D39, body weight and bursal weight of all birds were measured. The B/B wt. ratios (bursa weight/body weight ratio $\times 100$) were calculated for all groups.

Results of protection are shown in Table 17. The B/B wt ratio for group 5 (unchallenged group) could not be obtained since this group was unexpectedly infected with the STC IBDV strain. Protection induced by vHVT310 was higher than that induced by vHVT306 and vHVT309.

TABLE 17

IBD efficacy induced by different HVT-IBD + ND double constructs in SPF chicks after challenge at D 28 with variant E IBDV strain					
Group	Vaccine	Dose (PFU)	Number of birds	IBDV challenge at D 28	Mean B/B wt. ratio
1	vHVT306	2061	20	Yes	0.21
2	vHVT309	1476	20	Yes	0.26
3	vHVT310	1970	20	Yes	0.37
4	—	—	19	Yes	0.11
5	—	—	20	No	ND*

*Not done due to standard IBDV exposure in this group

Example 12 Newcastle Disease (ND) Efficacy Induced at D21 and D28 by vHVT306, vHVT309 & vHVT310 in SPF Chicks

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT309, vHVT310 & vHVT311) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against Newcastle disease challenges (Texas GB strain) performed on D21 and D28.

One-day-old specific pathogen free (SPF) chicks were assigned to 4 groups as shown in Table 18. All birds from groups 1 to 3 (50 birds/group) were vaccinated by the

subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. The 30 birds from group 4 were left unvaccinated. Twenty one (D21) days post-vaccination, 20 birds from groups 1-3 and 15 birds from group 4 were challenged with NDV Texas GB strain by the intramuscular (IM) route ($10^{4.2}$ egg infectious dose 50% (EID50) in 0.1 mL/bird). Twenty eight (D28) days post-vaccination, 30 birds from groups 1-3 and 15 birds from group 4 were challenged with NDV Texas GB strain by the intramuscular (IM) route ($10^{4.3}$ egg infectious dose 50% (EID50) in 0.1 mL/bird). Birds were observed for clinical signs during 14 days after challenge. Birds that did not show any ND clinical signs (including central nervous, or respiratory signs and/or death) for up to 14 days post-challenge were considered as protected.

Results of protection are shown in Table 18. All control birds of group 4 died after the challenge. Protection induced by vHVT310 was the best followed by vHVT306 and vHVT309.

TABLE 18

ND efficacy at D 21 and D 28 induced by different HVT-IBD + ND double constructs in SPF chicks						
Group	Vaccine	Dose (PFU)	ND protection after D 21 challenge (protected/total)		ND protection after D 28 challenge (protected/total)	
			ND protection after D 21 challenge (protected/total)	ND protection after D 28 challenge (protected/total)		
1	vHVT306*	2248	80% (16/20)	90% (27/30)		
2	vHVT309	1765	60% (12/20)	86.2% (25/29)		
3	vHVT310	2106	85% (17/20)	100% (29/29)		
4	—	—	0% (0/15)	0% (0/15)		

vHVT306*: used as a control

Example 13 Marek's Disease (MD) Efficacy Induced by vHVT306, vHVT309 & vHVT310 in SPF Chicks

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT309, vHVT310 & vHVT311) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against Marek's disease challenges (GA strain, 2 batches & 2 dilutions).

One-day-old specific pathogen free (SPF) chicks were assigned to 4 groups as shown in Table 19. All birds from groups 1 to 3 (20 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. The 20 birds from group 4 were left unvaccinated. Four days post-vaccination (D4), 18-20 birds from groups 1-4 were challenged with two dilutions (1:5 and 1:640) of two different batches (#1 and #2) of the vMDV GA22 strain by the SC route. Birds were observed for clinical signs attributable to Marek's disease during 46-50 days post-hatch. At D46-D50, all remaining birds were necropsied and checked for Marek's disease lesions. Birds that did not show any MD clinical signs or lesions were considered as protected.

Results of protection are shown in Table 19. Infectivity in control birds of group 4 varied between 75-90%. Overall, protection induced by vHVT310 was the best followed closely by vHVT306 and then vHVT309.

TABLE 19

MD efficacy induced by different HVT-IBD + ND double constructs in SPF chicks against 2 different lots of GA22 challenge either diluted 1:5 or 1:640						
Group	Vaccine	Dose (PFU)	MD protect. GA22 lot #1 1:5 dil.	MD protect. GA22 lot #1 1:640 dil.	MD protect. GA22 lot #2 1:5 dil.	MD protect. GA22 lot #2 1:640 dil.
1	vHVT306*	2420	75% (15/20)	85% (17/20)	26.3% (5/19)	70% (14/20)
2	vHVT309	1893	50% (10/20)	72.2% (13/18)	55% (11/20)	70% (14/20)
3	vHVT310	2127	80% (16/20)	84.2% (16/19)	40% (8/20)	90% (18/20)
4	—	—	25% (5/20)	10% (2/20)	10% (2/20)	20% (4/20)

vHVT306*: used as a control

Example 14 IBD Efficacy Induced by vHVT306
and vHVT407 Against a Classical IBDV Challenge
at D21 in SPF Chicks

The aim of the study was to assess the efficacy of two HVT recombinant constructs, one (vHVT306) expressing the IBDV VP2 gene and NDV F gene and the other (vHVT407) expressing the IBDV VP2 gene and ILTV gD gene administered to one-day-old SPF chickens against a classical IBDV challenge performed on D21.

Forty one-day-old SPF chicks (white Leghorn) were assigned to 3 groups as shown in Table 20. All birds from groups 2 & 3 (about 15 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT306 or vHVT407 construct at the dose indicated. Ten birds from group 1 were left unvaccinated. Twenty one days after vaccination (at D21), all birds were challenged with the classical 52/70 Faragher IBDV strain by the intraocular (TO) route ($10^{2.0}$ EID50 in 0.05 mL/bird). Eleven days post-challenge (at D32) all birds were terminated and necropsied to examine for gross bursal lesions. Bursal and body were weighted to calculate the bursal on body weight ratio. Birds were considered as protected if they did not show clinical signs or bursal lesion post-challenge.

Results of protection are shown in Table 20. Complete IBD protection was induced by vaccination with vHVT306 or vHVT407.

TABLE 20

IBD efficacy induced by two HVT constructs expressing two genes in SPF chicks after challenge at D 21 with Faragher IBDV strain						
Group	Vaccine	Dose (log10 PFU)	Clinical signs #dead/#sick/total	Mean Bursal/body weight ratio (*1000)	% with gross bursal lesion	Clinical Protection
1	—	—	3/4/10	1.6 ± 0.7**	100%	
2	vHVT306*	3.1	0/0/15	6.1 ± 1.1	0%	
3	vHVT407	3.1	0/0/15	6.3 ± 1.1	0%	

vHVT306*: used as a control.

**mean ± standard deviation

Example 15 ILT Efficacy Induced by vHVT407
Against an ILTV Challenge at D21 in SPF Chicks

The aim of the study was to assess the efficacy of two vHVT407 recombinant construct expressing the IBDV VP2 gene and the ILTV gD gene administered to one-day-old SPF chickens against an ILTV challenge performed on D21.

15 Twenty four one-day-old SPF chicks (white Leghorn) were assigned to 2 groups as shown in Table 21. All birds (about 12 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT13 (used as a negative control) or vHVT407 construct at the dose indicated. Twenty 20 one days after vaccination (at D21), all birds were challenged with the ILT-96-3 ILTV strain by the intratracheal (IT) route ($10^{3.6}$ EID50 in 0.5 mL/bird). The birds were observed for clinical signs for 11 days post-challenge. On 25 Study Days 25-29 and 32 all the birds were observed for clinical signs including breathing pattern, conjunctivitis, depression and mortality. On Study Day 32, all the remaining birds were terminated. Birds were considered as protected if they did not show ILT clinical signs such as respiratory distress associated with coughing, sneezing, rales, depression, gasping and/or bloody mucous exudates, including mortality.

30 Results of protection are shown in Table 21. Significant 35 ILT protection was induced by vaccination with vHVT407 in these challenge conditions.

TABLE 21

ILT efficacy induced by vHVT407 construct in SPF chicks after challenge at D 21 with ILT-96-3 ILTV strain				
Group	Vaccine	Dose (PFU)	Clinical signs #dead/#sick/total	Clinical Protection
1	vHVT13*	3420	6/2/11	27%
2	vHVT407	2880	2/0/12	83%

vHVT13*: used as a negative control.

50 Example 16 ILT Efficacy Induced by vHVT407, a Commercial HVT-ILT and a Commercial Chicken Embryo Origin (CEO) Vaccine Against an ILTV Challenge at D21 in Broiler Chicks

55 The aim of the study was to assess the efficacy of vHVT407 recombinant construct expressing the IBDV VP2 gene and the ILTV gD gene administered to one-day-old broiler chickens compared to a commercial HVT-ILT vaccine (INNOVAX® ILT) against an ILTV challenge performed on D21.

60 Forty eight one-day-old commercial broiler chicks were assigned to 3 groups as shown in Table 22. All birds (about 12 birds/group) of groups 1-3 were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT13 (used as a negative control), vHVT407 or INNOVAX® ILT (used as a positive control) constructs at the dose indicated. Twenty

US 12,385,068 B2

41

one days after vaccination (at D21), all birds were challenged with the ILT-96-3 ILTV strain by the intratracheal (IT) route ($10^{4.2}$ EID50 in 0.5 mL/bird). The birds were observed for clinical signs for 12 days post-challenge. On Study Days 25-29 and 32-33 all the birds were observed and scored for clinical signs including breathing pattern, conjunctivitis, depression and mortality. On Study Day 34, all the remaining birds were terminated. Birds were considered as protected if they did not show ILT clinical signs such as respiratory distress associated with coughing, sneezing, rales, depression, gasping and/or bloody mucous exudates, including mortality.

Results of protection are shown in Table 22. ILT protection was induced by vaccination with vHVT407, which was higher than that induced by INNOVAX ILT.

TABLE 22

ILT efficacy induced by vHVT407 and INNOVAX ILT constructs in broiler chicks after challenge at D 21 with ILT-96-3 ILTV strain				
Group	Vaccine	Dose	Clinical signs #dead/#sick/total	Clinical Protection
1	vHVT13*	2200 PFU	5/7/12	0%
2	vHVT407	1860 PFU	1/4/11	55%
3	INNOVAX ILT**	2240 PFU	0/10/12	17%

vHVT13*: used as a negative control.

**INNOVAX ® ILT used as a positive control

42

Example 17 Newcastle Disease (ND) Efficacy Induced at D14, D21 and D32 by vHVT310 & vHVT316 in SPF Chicks

The aim of the study was to compare the onset of ND immunity of two HVT recombinant constructs (vHVT310 & vHVT316) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against Newcastle disease challenges (Texas GB strain) performed on D14, D21 and D32.

One-day-old specific pathogen free (SPF) chicks were assigned to 3 groups as shown in Table 23. All birds from groups 1 to 2 (59-70 birds/group; see table) were vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT-IBD+ND constructs at the dose indicated. The 45 birds from group 3 were left unvaccinated. At D14, D21 and D32, 15-30 birds (see table) from groups 1-3 were challenged with NDV Texas GB strain by the intramuscular (IM) route ($10^{4.0}$ EID50/bird) in 0.1 mL/bird). Birds were observed for clinical signs during 14 days after challenge. Birds that did not show any ND clinical signs (including central nervous, or respiratory signs and/or death) for up to 14 days post-challenge were considered as protected.

Results of protection are shown in Table 23. All control birds of group 3 died after the challenge. Protection levels induced by both vHVT310 and vHVT316 were similar, with a possible earlier onset of immunity induced by vHVT316.

TABLE 23

ND efficacy at D 14, D 21 and D 32 induced by different HVT-IBD + ND double constructs in SPF chicks						
Group	Vaccine	Dose (PFU)	ND protection after D 14 challenge		ND protection after D 21 challenge	
			(protected/total)	(protected/total)	(protected/total)	(protected/total)
1	vHVT310	2473	30% (6/20)	80% (16/20)	97% (29/30)	
2	vHVT316	2367	45% (9/20)	80% (16/20)	100% (19/19)	
3	—	—	0% (0/15)	0% (0/15)	0% (0/15)	

43

Example 18 ILTV Efficacy Induced by HVT Vectors Expressing ILTV gD and IBDV VP2 or Expressing ILTV gD and NDV F

The aim of the study is to assess the efficacy of the HVT recombinant constructs expressing ILTV gD and IBDV VP2 (such as vHVT317 and vHVT407) or expressing ILTV gD and NDV F genes (such as vHVT308 and vHVT322) administered to chickens against ILTV challenges.

Chickens are assigned to different groups. Birds are vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT constructs. The birds from one group are left unvaccinated. Birds are challenged with ILTV by the intra-tracheal (IT) or the infraorbital sinus route. Birds are observed for clinical signs during 11-14 days after challenge. Birds that do not show any ILTV clinical signs (including respiratory distress associated with coughing, sneezing, rales, depression, gasping and/or bloody mucous exudates and/or death) for up to 14 days post-challenge are considered as protected.

The results show that the HVT vectors provide protection against ILTV infection.

Example 19 IBD Efficacy Induced by HVT Vectors Expressing ILTV gD and IBDV VP2

The aim of the study is to assess the efficacy of the HVT recombinant constructs expressing ILTV gD and IBDV VP2 (such as vHVT317 and vHVT407) administered to chickens against IBD challenges.

Chickens are assigned to different groups. Birds are vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT constructs. The birds from one group are left unvaccinated. Birds are challenged with IBD by the intraocular (TO) route. Birds are observed for clinical signs during 4 to 10 days after challenge. Birds that do not show any IBD clinical signs (including depression and/or death) and that do not show bursal lesions and/or atrophy for up to 10 days post-challenge are considered as protected.

The results show that the HVT vectors provide protection against IBD infection.

Example 20 NDV Efficacy Induced by HVT Vectors Expressing ILTV gD and NDV F

The aim of the study is to assess the efficacy of the HVT recombinant constructs expressing ILTV gD and NDV F genes (such as vHVT308 and vHVT322) administered to chickens against NDV challenges.

Chickens are assigned to different groups. Birds are vaccinated by the subcutaneous (SC) route with 0.2 mL of different HVT constructs. The birds from one group are left unvaccinated. Birds are challenged with NDV by the intramuscular (IM) route. Birds are observed for clinical signs during 14 days after challenge. Birds that do not show any NDV clinical signs (including central nervous, or respiratory signs and/or death) for up to 14 days post-challenge are considered as protected.

The results show that the HVT vectors provide protection against NDV infection.

Example 21 IBD Efficacy Induced by vHVT316 & vHVT317 Against a Standard IBDV Challenge at D28 in SPF Chicks

The aim of the study was to assess the efficacy of two HVT recombinant constructs (vHVT316 & vHVT317)

44

expressing either the IBDV VP2 gene and NDV F gene (vHVT316) or the IBDV VP2 gene and ILTV gD gene (vHVT317) administered to one-day-old SPF chickens against standard IBDV challenge performed at D28.

One-day-old specific pathogen free (SPF) chicks were assigned to 3 groups as shown in Table 24. All birds from groups 1 & 2 (15 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT316 & vHVT317 at the dose indicated. The 15 birds from group 3 were left unvaccinated. Twenty eight days after vaccination (at D28), all birds were challenged with the infectious bursal disease virus (IBDV) classical STC strain by the intraocular (TO) route ($10^{2.0}$ EID50 in 0.03 mL/bird). Four days post-challenge (at D32), all birds were terminated and necropsied to examine for gross bursal lesions.

Results of protection are shown in Table 24. 100% and 80% protection were induced by vHVT316 and vHVT317, respectively; however, the dose administered of vHVT317 was nearly 3 times lower than that of vHVT316.

TABLE 24

IBD efficacy induced by HVT-IBD + ND (vHVT316) and HVT-IBD + ILT (vHVT317) double constructs in SPF chicks after challenge at D 28 with STC IBDV strain			
Group	Vaccine	Dose (PFU)	IBD STC protection after D 28 challenge (infected/total)
1	vHVT316	2910	100% (0/15)
2	vHVT317	1030	80.0% (3/15)
3	—	—	6.7% (14/15)

Example 22 IBD Efficacy Induced by vHVT310, vHVT316 & vHVT317 in SPF Chicks after Variant IBD Challenge at D28

The aim of the study was to assess the efficacy of three HVT recombinant constructs (vHVT310, vHVT316 & vHVT317) expressing either the IBDV VP2 gene and NDV F gene (vHVT310 & vHVT316) or the IBDV VP2 gene and ILTV gD gene (vHVT317) administered to one-day-old SPF chickens against variant IBDV challenge performed at D28.

One-day-old specific pathogen free (SPF) chicks were assigned to 5 groups as shown in Table 25. All birds from groups 1 to 3 (15 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT310, vHVT316 & vHVT317 at the dose indicated. Birds from group 4 and group 5 (15 birds/group) were left unvaccinated. At D28, all birds from groups 1 to 4 were challenged with the infectious bursal disease virus (IBDV) variant Delaware E strain by the intraocular (TO) route ($10^{3.0}$ EID50 in 0.03 mL/bird). Birds from group 5 were left unchallenged. At D39, body weight and bursal weight of all birds were measured. The B/B wt. ratios (bursa weight/body weight ratio $\times 100$) were calculated for all groups.

Results of protection are shown in Table 25. Protection was observed in all vaccinated groups. Protection with vHVT317 was slightly higher than that induced by vHVT310 and vHVT316 despite its lower dose.

TABLE 25

IBD efficacy induced by different HVT constructs with double inserts in SPF chicks after challenge at D 28 with variant E IBDV strain					
Group	Vaccine	Dose (PFU)	Number of birds	IBDV challenge at D 28	Mean B/B wt. ratio
1	vHVT310	2260	15	Yes	0.34
2	vHVT316	2910	15	Yes	0.33
3	vHVT317	1030	15	Yes	0.40
4	—	—	15	Yes	0.12
5	—	—	15	No	0.43

Example 23 ILT Efficacy Induced by vHVT317
Against a ILTV Challenge at D28 in SPF Chicks

The aim of the study was to assess the efficacy of the vHVT317 recombinant construct expressing the IBDV VP2 gene and the ILTV gD gene administered to one-day-old SPF chickens against an ILTV challenge performed on D28.

Thirty six one-day-old SPF chicks (white Leghorn) were assigned to 2 groups as shown in Table 26. All birds (about 18 birds/group) were either vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT317 or left unvaccinated. Twenty eight days after vaccination (at D28), all birds were challenged with the ILT-96-3 ILTV strain by the intratracheal (IT) route ($10^{3.0}$ EID50 in 0.2 mL/bird). The birds were observed for clinical signs and mortality at D32, D36 & D39. Clinical signs included breathing pattern, conjunctivitis, depression and mortality. On Study Day 32, all the remaining birds were terminated. Evaluation of protection was used using 3 different criteria: (1) Any bird exhibiting any clinical signs for three consecutive days or that died after challenge is considered as ILT positive; (2) Any bird exhibiting any moderate or severe clinical signs in any category for any day or that died after challenge is considered as ILT positive; and (3) Any bird exhibiting any moderate or severe clinical signs in any category for two consecutive days or that died after challenge is considered as ILT positive.

Results of protection based on the 3 different criteria are shown in Table 26. The ILT challenge was severe since it killed (or birds were euthanized when they show very severe clinical signs for ethical reason) 86.7% of non-vaccinated birds. High levels of ILT protection were induced by vaccination with vHVT317 in these challenge conditions.

TABLE 26

ILT efficacy induced by vHVT317 construct in SPF chicks after challenge at D 28 with ILT-96-3 ILTV strain					
Group	Vaccine	Dose (PFU)	Number of birds	% Mortality	% Protection based on criteria 1/2/3
1	vHVT317	1030	15	0%	100%/86.7%/100%
2	—	—	15	86.7%	6.7%/6.7%/6.7%

Example 24 ILT Efficacy Induced by vHVT317, a Commercial HVT-ILT and a Commercial Chicken Embryo Origin (CEO) Vaccine Against an ILTV Challenge at D21 in Broiler Chicks

The aim of the study was to assess the efficacy of vHVT317 recombinant construct expressing the IBDV VP2 gene and the ILTV gD gene administered to one-day-old broiler chickens compared to a commercial HVT-ILT vaccine (INNOVAX® ILT, Merck Animal Health) against an ILTV challenge performed on D28.

Fifty one one-day-old commercial broiler chicks were assigned to 3 groups as shown in Table 27. All birds (17 birds/group) were either vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT317 or INNOVAX® ILT (used as a positive control) at the dose indicated or left unvaccinated. At D26, the number of birds per group was reduced to 15 and each bird was weighed. Twenty eight days after vaccination (at D28), all birds were challenged with the 63140 ILTV strain by the infraorbital route ($10^{4.3}$ EID50 in 0.2 mL/bird). On Study Days 31 to 35, and Study Day 38, all birds were individually observed for clinical signs. On Study Day 38, all the remaining birds were individually weighed and terminated. Evaluation of protection was performed using 3 different criteria: (1) Any bird exhibiting any clinical signs for three consecutive days or that died after challenge is considered as ILT positive; (2) Any bird exhibiting any moderate or severe clinical signs in any category for any day or that died after challenge is considered as ILT positive; and (3) Any bird exhibiting any moderate or severe clinical signs in any category for two consecutive days or that died after challenge is considered as ILT positive. The body weight was also compared at D26 and D38.

Results of protection using the 3 criteria are shown in Table 27. All controls were considered non-protected for the 3 criteria. Both tested vaccines induced high and similar ILT protection. There were no significant difference between body weight at D26 (before challenge); however, after challenge, body weights of vaccinated birds were significantly ($p<0.0001$) higher than those of non-vaccinated birds indicating protection against weight loss.

TABLE 27

ILT efficacy induced by vHVT317 and INNOVAX ILT (positive control) constructs in broiler chicks after challenge at D 28 with 63140 ILTV strain						
Group	Vaccine	Dose (PFU)	Number of birds	% Protection based on criteria 1/2/3		
				Body weight at D 26*	Body weight at D 38*	
1	vHVT317	3820	15	86.7%/86.7%/86.7%	1544 ± 61	2931 ± 63
1	INNOVAX	3700	15	100%/93.3%/93.3%	1491 ± 61	2839 ± 61
2	—	—	15	0%/0%/0%	1461 ± 61	2433 ± 63

*mean ± standard deviation in g

Example 25 IBD Efficacy Induced by the in Ovo Administration of vHVT317 after Variant IBD Challenge at 28 Day-of-Age in SPF Chicks

The aim of the study was to assess the efficacy of vHVT317 expressing the IBDV VP2 gene and ILTV gD gene administered in ovo to 18-19 day-old embryos from SPF chickens against variant IBDV challenge performed at 28 day-of-age (31 days post-vaccination).

18-19 day-old embryos from specific pathogen free (SPF) chickens were assigned to 3 groups as shown in Table 28. All birds from groups 1 & 2 (about 30 eggs/group) were vaccinated by the in ovo (SC) route with 0.05 mL of vHVT317 at the dose indicated. Embryonated eggs from group 3 were sham-inoculated with 0.05 mL of Marek's vaccine diluent. At hatch, 22 chicks per group were kept and, before challenge, all 3 groups were reduced to 20 birds. Thirty one days after vaccination (at 28 day-of-age), birds from all 3 groups were challenged with the infectious bursal disease virus (IBDV) variant Delaware E strain by the intraocular (TO) route (target dose of $10^{3.0}$ EID50 in 0.03 mL/bird). Birds from group 5 were sham challenged with TPB (tryptose phosphate broth, 0.03 mL/bird). Eleven days post-challenge, body weight and bursal weight of all birds were measured. The B/B wt. ratios (bursa weight/body weight ratio $\times 100$) were calculated for all groups.

Results of protection are shown in Table 28. A clear bursal atrophy was observed in all non-vaccinated challenged birds. Protection was observed in vHVT317-vaccinated groups at the 2 tested doses.

TABLE 28

IBD efficacy induced by vHVT317 administered in ovo after challenge at 28 day-of-age with variant E IBDV strain in SPF chicks				
Group	Vaccine	Dose (PFU)	Number of birds	IBDV challenge
1	vHVT317	2250	20	Yes
2	vHVT317	3225	20	Yes
3	—	—	20	Yes
4	—	—	20	No

Example 26 ILT Efficacy Induced by vHVT317 Administered by the in Ovo Route Against a ILTV Challenge at D28 in SPF Chicks

The aim of the study was to assess the efficacy of the vHVT317 recombinant construct expressing the IBDV VP2 gene and the ILTV gD gene administered by the in ovo route to 18-19 day-old embryos against an ILTV challenge performed on D28 (at 25 day-of-age) in SPF chickens.

18-19 day-old embryos from specific pathogen free (SPF) chickens were assigned to 2 groups as shown in Table 29. All birds from groups 1 (about 30 eggs/group) were vaccinated by the in ovo (SC) route with 0.05 mL of vHVT317 at the dose indicated. Embryonated eggs from group 2 were sham-inoculated with 0.05 mL of Marek's vaccine diluent. At hatch, 22 chicks per group were kept and, one day before challenge, both groups were reduced to 20 birds. Twenty five days after vaccination (at D28), birds from both groups were challenged with the 63140 ILTV strain administered in the infraorbital sinus ($10^{4.7}$ EID50 in 0.2 mL/bird). The birds were observed for clinical signs and mortality on D28 to D38. On Study Day 38, all the remaining birds were terminated. Efficacy against ILT challenge was determined by the absence of typical ILT clinical signs such as: depression, respiratory distress associated with coughing, sneez-

ing, rales, gasping with extended neck, with or without bloody and/or mucous discharge; dyspnea and mouth breathing; infra-orbital sinuses swelling, with or without drainage; and/or swollen conjunctiva with partial or complete closure of the eyes. Any mortality post-challenge, except due to trauma, or any clear condition that excludes the bird from the study, were considered positive for ILT.

Results of ILT protection are shown in Table 29. The results showed that most vHVT317 vaccinated birds were protected.

TABLE 29

ILT efficacy induced by vHVT317 administered by the in ovo route after infraorbital sinus challenge at D 28 with 63140 ILTV strain in SPF chicks				
Group	Vaccine	Dose (PFU)	Number of birds	% Protection (number protected/total)
1	vHVT317	2300	20	85% (17/20)
2	—	—	20	5% (1/20)

Example 29 ND Efficacy Induced by vHVT309 & vHVT310 Against a Velogenic NDV Challenge at D21 in SPF Chickens

The aim of the study was to assess the efficacy of two HVT recombinant constructs (vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against velogenic NDV challenge performed on D21.

One-day-old SPF chicks (white leghorn) were assigned to 3 groups of birds as shown in Table 30. All birds from groups 2 and 3 were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT309 (14 birds; group 2) or vHVT310 (15 birds; group 3) at a target dose of 2000 PFU. Birds from group 1 (5 birds) were left unvaccinated. Two birds of group 2 died on D5 for unknown reason. Twenty one days after 35 vaccination (at D21), the blood of 10 birds from group 3 was collected for serology; then, all birds from all 3 groups were challenged with the velogenic NDV Herts 33 strain by the intramuscular (IM) route ($10^{5.0}$ EID50 in 0.2 mL/bird). All 40 birds were observed for clinical signs during 14 days post-challenge. Birds were considered as protected if they did not die or show ND clinical signs.

Results of protection are summarized in Table 30. All 45 non-vaccinated birds of group 1 died after challenge; all vaccinated birds were protected. The vHVT310 construct induced significant anti-NDV (mean of 3.7 ± 0.3 (standard deviation) log 10 by ELISA (ID Screen Newcastle Disease Indirect kit from ID-VET) and mean of 3.9 ± 0.7 log 2 by HI test) and anti-IBDV (mean of $3.7 \log 10 \pm 0.2 \log 10$ by 50 ELISA (ProFLOK IBD Plus ELISA kit from Zoetis) antibodies in all the 10 G3-bird sera sampled on D21.

TABLE 30

ND efficacy induced by different HVT-IBD + ND double constructs in broiler chicks after challenge at D 21 with velogenic NDV strain					
Group	Vaccine	Dose (PFU)	Number of birds	Number of Dead & sick birds	Protection
1	—	—	5	5 & 0	0%
2	vHVT309	2000	12	0 & 0	100%
3	vHVT310	2000	15	0 & 0	100%

Example 28 IBD Efficacy Induced by vHVT309 and vHVT310 Against a Classical IBDV Challenge at D21 in SPF Chicks

The aim of the study was to assess the efficacy of two HVT recombinant constructs (vHVT309 & vHVT310) expressing the IBDV VP2 gene and NDV F gene administered to one-day-old SPF chickens against a classical IBDV challenge performed on D21.

One-day-old SPF chicks (white Leghorn) were assigned to 3 groups as shown in Table 31. All birds from groups 2 & 3 (about 15 birds/group) were vaccinated by the subcutaneous (SC) route with 0.2 mL of vHVT309 (group 2) or vHVT310 (group 3) construct at a target dose of 2000 PFU. Ten birds from group 1 were left unvaccinated. Two unspecific early deaths were recorded in group 2. Twenty one days after vaccination (at D21), all birds were challenged with the classical 52/70 Faragher IBDV strain by the intraocular (TO) route ($10^{2.0}$ EID50 in 0.05 mL/bird). Eleven days post-challenge (at D32) all birds were terminated and necropsied to examine for gross bursal lesions. Bursal and body were weighted to calculate the bursal on body weight ratio. The bursa was then stored in formaldehyde for histology. Histological lesions of the bursa were scored according to the scale presented in Table 32. The severity of the challenge was validated if (1) at least 50% of the challenge controls died or showed characteristic signs of the disease, especially apathy/ruffled feathers during more than 2 days or prostration, and (2) 100% of the surviving challenge controls showed histology scores of the Bursa of Fabricius ≥ 3 . The efficacy of the vaccine candidates was demonstrated if at least 90% of the chickens were protected. The chickens were considered protected if (1) they survived and did not show notable clinical signs of the disease, especially no apathy/ruffled feathers during more than 2 days or absence of prostration, and (2) they showed a histology score of the Bursa of Fabricius < 3 .

Results of protection are shown in Table 31. All controls were positive for IBD infection. Complete IBD protection was induced by vaccination with vHVT309 or vHVT310.

TABLE 31

IBD efficacy induced by two HVT constructs expressing two genes in SPF chicks after challenge at D 21 with Faragher IBDV strain

Group	Vaccine	Dose (log ₁₀ PFU)	Clinical signs #dead/#sick/total	Mean Bursal/body weight ratio (*1000)	Protection
1	—	—	4/1/10	1.7 ± 0.6**	0%
2	vHVT309	3.3	0/0/14	5.4 ± 1.2	100%
3	vHVT310	3.3	0/0/15	5.5 ± 0.7	100%

**mean ± standard deviation

TABLE 32

Scoring scale of histological lesions of the bursa of Fabricius*

Score Histology observation/lesions

- 0 No lesion, normal bursa
- 1 1% to 25% of the follicles show lymphoid depletion (i.e. less than 50% of depletion in 1 affected follicle), influx of heterophils in lesions
- 2 26% to 50% of the follicles show nearly complete lymphoid depletion (i.e. more than 75% of depletion in 1 affected

TABLE 32-continued

Score	Histology observation/lesions
5	follicle), affected follicles show necrosis and severe influx of heterophils may be detected
3	51% to 75% of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected
4	76% to 100% of the follicles show nearly complete lymphoid depletion; hyperplasia and cyst structures are detected; affected follicles show necrosis and severe influx of heterophils is detected
5	100% of the follicles show nearly complete lymphoid depletion; complete loss of follicular structure, thickened and folded epithelium, fibrosis of bursal tissue

*sourced from Monograph No. 04/2013: 0587 of European Pharmacopoeia "Avian Infectious Bursal Disease vaccine (live)"

Example 29 Impact of in Ovo Administration of vHVT317 on Hatchability of SPF Chicks

The aim of the study was to assess the safety of vHVT317 on hatchability when administered by the in ovo route.

The results are a compilation of data from several studies including those described in examples 23, 24, 25, and 26. Embryonated eggs at 18-19 days of incubation were inoculated either with vHVT317 at a target dose of 2000 or 3000 PFU or with Marek's disease vaccine diluent. The percentage of hatchability was evaluated for each group. Results are summarized in Table 33 and showed excellent levels of hatchability in vaccinated eggs.

TABLE 33

Hatchability after in ovo administration of vHVT317					
Group	Vaccine	Target Dose (PFU)	Number of vaccinated eggs	Number of eggs hatched	% hatchability
1	Diluent	—	150	149	99.3%
2	vHVT317	2000	139	135	97.1%
3	vHVT317	3000	80	78	97.5%

Example 30 ILT Efficacy Induced by vHVT406 Against ILTV Challenges

Example 30.1 ILT Efficacy Induced by vHVT406 Against an ILTV Challenge at D28

The aim of the study is to assess and compare the efficacy of vHVT406 recombinant construct expressing the ILTV gD gene and a commercial HVT-ILT vectored vaccine against ILT challenge.

Twelve (12) one-day-old SPF birds were assigned to each group. The birds in Groups 1-2 were vaccinated SQ with 0.2 mL per bird. After vaccination, all birds were placed into their respective units. On Day 28, all birds were challenged via the intratracheal (IT) route with Infectious Laryngotracheitis Virus (ILT), ILT-93-3 EP2. All birds were observed for 11 days post-challenge for clinical signs due to the challenge. On Day 32, tracheal and conjunctival swabs were collected from all remaining birds. Swabs were processed for q-PCR analysis. On Day 39, all remaining birds were terminated.

Results are shown in Table 34 below. The results showed that all vHVT406 vaccinated birds were protected. Surprisingly, the results also showed that good protection (100% protection) was achieved in vHVT406 group when lower dose (6,960 pfu/0.2 mL) was used when compared to the higher dose (10,340 pfu/0.2 mL) used for the commercial product Innovax HVT-ILT.

TABLE 34

Number of Birds Positive for ILT and Percent Positive by Group ¹						
Group	Vaccine	Dose/SQ ²	# Birds	# Positive/ Total # Birds	% Protection (% Infection)	% Found Dead
1	vHVT406	6,960 pfu/ 0.2 ml HVT	11 ³	0/11	100	0
2	Innovax HVT-ILT ⁴	10,340 pfu/ 0.2 ml HVT	12	0/12	100	0

¹Birds were considered positive if they showed clinical signs for three consecutive days, including mortality or mortality after swabbing.

²Plaque forming units (pfu)-Subcutaneous administration (SQ); 0.20 ml per dose.

³One bird in vHVT406 group was excluded from the study due to paralysis.

⁴Commercial product of MSD Animal Health

Example 30.2 ILT Efficacy Induced by vHVT406 Against an ILTV Challenge at D21

The goal of the study is to assess and compare the efficacy of the vHVT406 and two commercial HVT-ILT vectored vaccines against ILT challenge.

Twelve (12) one-day-old SPF birds were assigned to each group. The randomization also assigned the isolation units where the birds were placed (12 birds per unit, one unit per group). Birds in Groups 1-3 were vaccinated SQ with 0.2 ml per bird. On Day 21, all birds in Groups 1-2 were challenged via the intratracheal (IT) route with Infectious Laryngotracheitis Virus (ILT), ILT-96-3 EP2. The birds were observed for 11 days post-challenge for clinical signs due to the challenge. On Day 25, tracheal and conjunctival swabs were

collected on all remaining birds. Swab samples were processed for q-PCR. On Day 32, all remaining birds were terminated.

Results are shown in Table 35 below. The results showed that all but one vHVT406 vaccinated birds were protected. Surprisingly, the results also showed that good protection (91.7% protection) was achieved in vHVT406 group when lower dose (810 pfu/0.2 ml) was used when compared to the higher dose (1590 pfu/0.2 ml) used for the commercial product Innovax HVT-ILT to achieve the same protection level (91.7%). Further, vHVT406 provided better protection (91.7%) when used at a lower dose than the commercial product Vectormune HVT-ILT which only provided 75% protection.

TABLE 35

Number of Birds Positive for ILT and Percent Positive by Group ¹						
Group	Vaccine	Dose/SQ ²	# Birds	Total # Birds	% Protection (% Infection)	% Found Dead
1	vHVT406	810 pfu/ 0.2 ml	12	1/12	91.7	0
2	Innovax HVT-ILT	1590 pfu/ 0.2 ml	12	1/12	91.7	0
3	Vectormune HVT-ILT ³	39,000 pfu/ 0.2 ml	12	3/12	75	25

¹Birds were considered positive if they showed clinical signs for three consecutive days, including mortality or mortality after swabbing.

²Plaque forming units (pfu)-Subcutaneous administration (SQ); 0.20 ml per dose.

³Commercial product of Ceva

Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above examples is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

All documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.

SEQUENCE LISTING

```

Sequence total quantity: 27
SEQ ID NO: 1      moltype = DNA  length = 1359
FEATURE          Location/Qualifiers
source           1..1359
                  mol_type = other DNA
                  organism = synthetic construct
                  note = DNA encoding IBDV VP2

SEQUENCE: 1
atgacaaaac tgcaagatca aacccaaacag attgtccgt tcatacggag ccttctgtat 60
ccaacaaccg gaccggcgtc cattccggac gacaccctgg agaaggcacac tctcagggtca 120
gagacccatcgca ctttcaattt gactgtgggg gacacccgggt cagggttaat tgcgtttttc 180
cctggatccc ttggctcaat tggtgggtgtc cactacacac tgcagagcaa tgggaactac 240
aatgttcgatc agatgttcct gactgtcccg aaccttacccg ccagctacaa ctatgcaga 300
ctagtggatc tggtgttcac agtgagggtca agcacactcc ctgggtgggt ttatgcacta 360
aacggccacca taaaacccgtc gaccctccaa ggaaggcctgtc gtgaaactgac agatgttagc 420
tacaatgggt tgatgttcgc aacacccaaat atcaacgcaca aaattggggaa tgcgttgcgtat 480
ggggaaaggggg tcaactgtccct cagccctaccc acatcatatg atcttgggtt tgcgtgggtt 540
ggtgacccca ttcccgttat agggcttgc ccaaaaaatgg tagctacatg cgacagcagt 600
gacaggccca gaggcttacac cataactgcg gcccgtatg accaaatccc atcacagttac 660
caaccagggtt gggttaacaat cacaactgtt ctagcccaaca ttgatgttat cacaagcctc 720
agcattgggg gagagtcgtt gtttcaaca aacgttccaaag gccttgcact gggcgccacc 780
atctaccta taggtttgtt tggggactgcg gtaatcacca gagctgttagc cgcagataat 840
gggctgtacgg ccggcacccca caatccatgtt ccattcaatc ttgtcatcc aaccaatgg 900
ataaaccacgc caatcatcata catcaaaactt gatgttgcg cttccaaatgg tgggtgttcag 960
gcaggggatc agatgtcatg gtcggcaatg gggaggttgc tagtgcacat ccatgtgttgc 1020
aactatcccg gggccctccg tcccgatcaca ctatgttgcct acgaaaaggtt ggcacacgga 1080
tccgtgttgc tggcgtctgg ggtggatatac ttccaaatcc tgaacttagca 1140
aagaacactgg ttacagaatcc cggccgatgg gaccaggagg ccataactca cacaatgg 1200
atactgatgtt agaggggaccc tcttggatc aacgggttgc ggcacaaatgg gggttgcact 1260
gattttcgtt agtacttcat ggagggtggcc gacctcaact ctccctgaa gatttgcaggaa 1320
gcattttggct tcaaaagatcat aatccgggtt ataaggagg 1359

SEQ ID NO: 2      moltype = AA  length = 453
FEATURE          Location/Qualifiers
source           1..453
                  mol_type = protein
                  organism = synthetic construct
                  note = IBDV VP2 protein

SEQUENCE: 2
MTNLQDQTQQ IVPPFIRSLLM PTTGPASIPD DTLEKHTLRS ETSTYNLTVG DTGSGLIVFF 60
PGPFGSIVGA HYTLQSNGNY KFDQMLLTAQ NLPAWSYNYCR LVSRSLTTRS STLPGVYAL 120
NGTINAVTFQ GSLSELTDSV YNGLMSATAN INDKIGNVLV GEGVTVLSP TSYDLGVYRL 180
GDPIPAIGLD PKMVATCDSS DRPRVYTITA ADDYQFSSQY QPGGVITILF SANIDAITSL 240
SIGGELVFQT SVQGLVLGAT IYLIGFDGTA VITRAVAADN GLTAGTDNLN PFNLVIPTNE 300
ITQPITSIKL EIVTSKSGQQ AGDQMSWSAS GSLAVTIHGG NYPGALARPVTLVAYERVATG 360
SVVTVAGVSN FELIPMPLEA KNLVTEYGRF DPGAMNYTKL ILSERDRLGI KTVWPTRTET 420
DFREYFMEVA DLNSPLKIAG AFGFKDIIRA IRR 453

SEQ ID NO: 3      moltype = DNA  length = 1659
FEATURE          Location/Qualifiers
source           1..1659
                  mol_type = other DNA
                  organism = synthetic construct
                  note = NDV-Fopt VIId of pFSV40VP2 and pFIRESPV2

SEQUENCE: 3
atggggcagca accccagcac aagaatccca gccccccgtt tgctgtatcac ccgcacatcg 60
ctgtatccgtt ggtgtatcac accccacaagg tccctggatg gacgccccctt ggccgtgtcc 120
ggcatcggtt tgaccggcgca caaggccgtt aacgtgtaca ccagcagccaa gaccggcagc 180
atcatcggtt agtctgtgtcc caacatcgcc agagacaaatgg aggcctgtgc caaggcccc 240
ctggaaaggctt acaacacaaac cctgaccacc ccctggggcga cagcatcaga 300

```

-continued

aagatccagg	gctccgttag	cacaaggcgg	ggaggaaagc	agggcagact	gatccggcgcc	360
gtgtatccgc	gcgtggccct	gggagtggct	acagctgcc	agattaccgc	tgcagccgccc	420
ctgtatccagg	ccaaccagaa	cgcggccaa	atcctgagac	tgaaaagagag	cattgcccggcc	480
accaacgagg	ccgtgcacga	agtgaccgac	ggcctgagcc	agctgtccgt	ggccgtgggc	540
aagatgcgc	agtgtcgaa	cgaggatgtt	aacaacacc	ccagagact	ggactgcata	600
aagatcaccc	agcagggtgg	cgtggagctg	aacctgtacc	tgaccggact	gaccacagtg	660
ttcggcccccc	agatcacaag	cccaggcttg	acacagctga	ccatccaggc	cctgtacac	720
ctggctggcg	gcaacatgga	ctatctgtcg	acaaagctgg	aatcggcaa	caaccagctg	780
tcctagctga	tcggaaaggcg	cctgtatcga	ggcttacccca	tcctgtacga	cagccagaca	840
cagctgtcg	gcatccagg	gaaatgtccc	agcgtggcc	acctgtggca	atcgaaaca	900
acctaactgg	aaaccctgtag	cgtgtccacc	accaagggtt	acggccagcgc	cctgtggccc	960
aagggtgtga	cacagggtgg	cagcgtgatc	gaggaactgg	acaccagcta	ctgcacatcgag	1020
acgcgacttgc	acctgtactg	caccagaat	gtgacacctcc	caatgagccc	cgccatctac	1080
agctgcctga	cgccgaacac	cagcgtctgc	atgtacagca	agaccgaagg	cgcaactgaca	1140
acaccctaca	ttggccctgaa	gggaagctgt	atcgccaa	ctgcacatc	cacccgtcaga	1200
tgccaccgacc	ccccaggcat	catcagccag	aactacggcg	aggccgtgag	cctgtatcgat	1260
cgcattctct	gtaaatcgct	gtccctggaa	ggcatcacac	tgagactgag	cgccgagttc	1320
gatgcacatc	accagaagaa	catcagcatc	ctggacagac	aggtgtatcg	gaccggcaac	1380
cttgacatca	gcaaccgtgt	ggttacacgta	aaaaacacq	tcagcaacgc	cctggacac	1440
ctggccgaga	gcaacagaa	gctggaaaaaa	gtgaacgtgc	gcctgacatc	cacttccgt	1500
ctgatcacct	acategtgt	gaccgtgtc	agccctgggt	tcggccgccc	gagctgtgt	1560
ctggccctgt	acctgtatgt	caacgagaag	gcccggcaga	aaaccctgt	gtggctgggc	1620
aacaacaccc	ttggaccatg	gagaccaccc	accagagcc			1659

SEQ ID NO: 4 moltype = DNA length = 1659
 FEATURE Location/Qualifiers
 source 1..1659
 mol_type = other DNA
 organism = synthetic construct
 note = NDV-F wildtype VIIId of pFP2AVP2

SEQUENCE: 4
 atgggctcca aaccttctac caggatccca gcacccctga tgctgtatc acggattatg 60
 ctgtatttgg gctgttatccg tccgacaago tctcttgacg gcaggccctt tgcagctgca 120
 ggaattttagt taacaggaga taaggcgttcc aatgtatcata cttcgtctca gacagggtca 180
 atcatatgtca agttgtctcc gaatatgtcc agggataagg aggctgtgc aaaagccca 240
 tttagggcat ataacagaac actgactact ttgctcactt ctcttggcga ctccatccgc 300
 aagatccaag ggtctgtgtc cacatctgga ggaggcaagc aaggccgcgt gatagggtct 360
 gttatttggca gtgttagtgc tggtttgc acagccggac agataaacagc agctgcggcc 420
 ctaatacaag ccaaccggaa tgccggccaa atcctccggc ttaaggagag cattgtgtca 480
 accaatatgaa ctgtgtatgtc agtcaccgac ggattatcac aactatcagt ggcagttgg 540
 aagatgcagc agtttgtca tgaccagttt aataatacgg cgccgagaatt ggactgtata 600
 aaataatcac aacagggtgg tgtagaaactc aacctatacc taactgtattt gactacagta 660
 ttccggccac agatcaccc tcctgcatta actcagctga ctatccggc actttataat 720
 tttagctgtgtc gcaatatggta ttacttattt actaaggtagt gtataggaa caatcaactc 780
 agctcgatca ttggtagcgg cctgtatcactt ggttacccta tactgtatga ctcacagact 840
 caactcttgg gcatataatgtt gatatttaccgc tcagtccggaa actttaataaa tatgtgtgc 900
 acattttgg agacccatttc tgtaatgtaca accaaaggat atgcctcagc actttgtcccg 960
 aaagtatgtc cacaatgtcg ttccctgtata gaagagcttg acacccatca ctgtatagag 1020
 tccgatctgg atttatattt tactagaata gtgacattcc ccatgtccccc aggttatttt 1080
 tccctgttgc goggcaacac atcagctgc atgttattcaaa agactgaagg cgccactcact 1140
 acggccgtata tggccctttaa aggctcaggat attggccat aatcatgttgc 1200
 tgtagcacc ctcctgttat catatcgaa aattatggag aagctgtatc cctgtatagat 1260
 agacattctgt gcaatgtctt atcatttagac gggataactc taaggctcg tggggatatt 1320
 gatgcacactt atcaaaagaa catctcaata cttagatttc aactgtatcgat gacaggcaat 1380
 cttgatatatcaactaactgatcgtt gttggaaatgc aacaatttcaatcactgatcgtt 1440
 ttggcggaaa gcaacagaa gctggaaaaaa gtcataatgtca gactaaccgc cacaatctgt 1500
 ctcattatccctt atattgttct aactgtcatt tctcttagttt tcgggtcaact tagtctgtgt 1560
 tttagctgtgtt acctgtatgtt caaacagaag gcacaacaaa agacccctgt atggcttggg 1620
 aataatataccctt tcgatcagat gagaccaccc acaagagac 1659

SEQ ID NO: 5 moltype = AA length = 553
 FEATURE Location/Qualifiers
 source 1..553
 mol_type = protein
 organism = synthetic construct
 note = NDV-F VIIId

SEQUENCE: 5
 MGSKPSTRIP APLMLITRIM LILGCIRPTS SLDGRPLAAA GIVVTGDKAV NVYTSSQTGS 60
 IIVKLLPNMP RDKEACAKAP LEAYNRTLTT LLTPLGDSIR KIQGSVSTSG GGKQQLRLIGA 120
 VIGSVALGVA TAAQITAAAA LIQANQNAAN ILRLKESIAA TNEAVHEVTD GLSQLSVAVG 180
 KMQFVNNDQF NNTARELDI KITQQVGVEL NLYLTELTV FGPQITSPAL TQLTIQALYN 240
 LAGGNMDYLL TKLGIGNNQL SSLIGSGLIT GYPILYDSQT QLLGIQVNLP SVGNLNNMRA 300
 TYLETLSVST TKGYASALVP KVVTQVGSVI EELDTSYCLIE SDLDLYCTRI VTFPMSPGIY 360
 SCLSGNTSAC MYSKTEGALT TPYMALKGSV IANCKITTCR CTDPPGIISQ NYGEAVSLID 420
 RHSCNVLSLD GITLRLSGEF DATYQKNISI LDSQVIVTGN LDISTELGNV NNSISNALDR 480
 LABSNNSKLEK VNVRLTSTSA LITYIVLTVI SLVFGALSLV LACYLMYKQK AQQKTLLWL 540
 NNTLDQMRAT TRA 553

SEQ ID NO: 6 moltype = DNA length = 1391

-continued

FEATURE source	Location/Qualifiers 1..1391 mol_type = other DNA organism = synthetic construct note = mCMV IE promoter
SEQUENCE: 6	
	aactccgcc gttttatgac tagaaccat agttttaat gccaaatgca ctgaaatccc 60 ctaatttgca aagccaaacg ccccttatgt gagtaatacg gggactttt acccaatttc 120 ccaaaggcgaa agccccctaa tacatctata tggcatatgatc atcagcacgg tcatgcactc 180 taatggggc ccataggac ttccacata gggggcgtt accatttccc agcatagggg 240 tggtgactca atggcttta cccaaatgtc ttgggtcaat gggaggtaag ccaatgggtt 300 tttccattt ctggcaagca cactgagtca aatgggactt tccactgggt tttgccaag 360 tacattgggt caatggggg tgagccatg gaaaaaaccc attgtgcaca agtacactga 420 ctcaataggg actttttcaat gggttttcc attttggca agcatataag gtcaatgtgg 480 gtgagtcattt agggacttc catttttgcatttggca agcatataag gtcaatgtgg 540 atcaacagga aagtccattt ggagccaaatg acactgcgtc aataggactt ttccatttgg 600 tttgcaccc tacataaagggt caatggggc tgagtcaatg gaaaaaaccc attggagcca 660 agtacactga ctcaataggg actttttcaat gggttttgcatttggca cagtcataaa ggtcaatagg 720 gggtgactca acaggaaatg cccatggatc ccaatgttca tggatcaatg gggactttcc 780 aatgggtttt gcccaggatca taaggtaat gggaggtaag ccaatgggtt tttccattt 840 ctggcacgtt tactgactt ttggggactt tccatgggtt ttggcccaatg acataagggtc 900 aataggggtt aatcaacagg aaagtccatg tggagccaaatg tacactgatc ttttggggatc 960 tttccattttt gttttggccca tcaatggggt gttatggggt tgagtcaatg gggttttcc 1020 cattattggc acgtacataa ggtcaatagg ggtgagtcatttgggttttcc cagccaaattt 1080 aattaaaacg ccattgtactt tcccaatttgcatttggcttactatggca 1140 cgtgacccctt aaacgggtt tactgactt ttccatgggtt tgatggatccg ttctcgagcc 1200 aatacacgtc aatggggatg gaaaggccatg ccaaaacgttca accccggcccc ggttttcccc 1260 tggaaattcc atattggcac gcatttttgcatttggctgatc ttttgggttttcc 1320 ggcgcgacca ggcgtcgatc cgatcgatc ttccgttgcata cccatggatc acgcagatgt 1380 cctcgatgtca g 1391
SEQ ID NO: 7	moltype = DNA length = 345
FEATURE source	Location/Qualifiers 1..345 mol_type = other DNA organism = synthetic construct note = SV40 Promoter for NDV F
SEQUENCE: 7	
	gctgtggat gtgtgtcagt taggggtggg aaagtccccca ggctccccag caggcagaag 60 tatgcaaaatc atgcatttca attatgtcago aaccagggtt ggaaatgtccc caggctcccc 120 agcaggcaga agtatgtcaaa gcatgtatc caattatgtca gcaaccatag tccccccctt 180 aactccgccccc atcccccctt taatccccc cagttccccc catttccccc cccatggctt 240 actaattttttt ttttttttgcatttgcatttggggatc ttttgggttttcc 300 gtatgtggat ggttttttgcatttggggatc ttttgggttttcc 345
SEQ ID NO: 8	moltype = DNA length = 199
FEATURE source	Location/Qualifiers 1..199 mol_type = other DNA organism = synthetic construct note = SV40 Poly A
SEQUENCE: 8	
	ggggatccag acatgataag atacattgtat gggatggc aaaccacaaat tagaatgcag 60 tggaaaaatg gtttttttttgcatttggggatc ttttgggttttcc 120 agctgtcaataa aacaatgttca caacaacaaat ttttgggttttcc 180 ggttttttttgcatttggggatc ttttgggttttcc 199
SEQ ID NO: 9	moltype = DNA length = 154
FEATURE source	Location/Qualifiers 1..154 mol_type = other DNA organism = synthetic construct note = Synthetic Poly A
SEQUENCE: 9	
	ataaaaaat ttttttttgcatttggggatc ttttgggttttcc 60 cttacatgtca aacaaaatg aaacaaaatc aacttagcaaa ataggctgtc 120 cccaggatgtca gtttttttgcatttggggatc ttttgggttttcc 154
SEQ ID NO: 10	moltype = DNA length = 563
FEATURE source	Location/Qualifiers 1..563 mol_type = other DNA organism = synthetic construct note = IRES of pFIRESPV2
SEQUENCE: 10	
	ccccccccccca taacgttact ggccgaagcc gcttggataa aggccgggtt gcttttgtt 60 atgttttattt ttccaccata ttggccgtttt ttggcaatgtt gggccgggg aaacctggcc 120 ctgttttttgcatttggggatc ttttttttgcatttggggatc ttttgggttttcc 180 tggatgttgcatttggggatc ttttgggttttcc 240

-continued

tagcgaacctt ttgcaggcag cggAACCCCCC caccTGGGGA caggTGCCTC tgcccAAaa 300
 acccacgtgt ataagatac cctgcaaagg cggcacaacc ccagtgcac gttgtgagg 360
 ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag gggctgaagg 420
 atgcccagaa ggtacccat tgtatggat ctgatctggg gcctcggtc acatgctta 480
 catgtgttta gtcgaggtta aaaaacgtct aggccccccg aaccacgggg acgtggttt 540
 ccttgaaaaa acacgatgat aat 563

SEQ ID NO: 11 moltype = DNA length = 66
 FEATURE Location/Qualifiers
 source 1..66
 mol_type = other DNA
 organism = synthetic construct
 note = P2A of pFP2AVP2

SEQUENCE: 11
 gggtccggc ccaccaactt ctccctgctc aaggcaggccg gcgacgtgga ggagaacctt 60
 ggacctt 66

SEQ ID NO: 12 moltype = DNA length = 3807
 FEATURE Location/Qualifiers
 source 1..3807
 mol_type = other DNA
 organism = synthetic construct
 note = pFSV40VP2 for vHVT309
 misc_feature 1..1362
 note = IBDV VP2
 misc_feature 1383..1594
 note = SV40 Poly A
 misc_feature 1624..1968
 note = SV40 Promoter
 misc_feature 1981..3645
 note = NDV-Fopt VIId
 misc_feature 3654..3807
 note = Synthetic Poly A

SEQUENCE: 12
 atgacaaacc tgcaagatca aacccaacag attgtccgt tcatacggag ccttctgatg 60
 caacaacaacc gaccggcgctc cattccggac gacacccctgg agaaggcacac tctcaggta 120
 gagacacctga cttacaattt gactgtgggg gacacagggt cagggtcta tgccttttc 180
 cctggattcc ctggctcaat tgcgtgggtt cactacacac tgcagagcaca tggaaactac 240
 aagttcgtatc agatgtccct gactgcccac aacctaccgg ccgactacaa ctactgcaga 300
 ctatgtgatc ggagtctcac agtgaggtaa agcacactcc ctggtggcgt ttatgcacta 360
 aacggccacca taaacggcgt gaccttccaa ggaagcctga gtgaactgac agatgttagc 420
 tacaatgggt tgcgtctgc aacacccaaatcataacgacaa aaattgggaa tgccttgta 480
 ggggaagggg tcaacttgc cagcttaccac acatcatatg atcttgggtt tgcgggctt 540
 ggtgacccca ttccggctat agggttgcac cccaaatgg tagctacatg cgacagcagt 600
 gacaggccca gagtctacac cataactgca gccgatgatt accaattctc atcacagtag 660
 caaccagggtt gggttacaatc cacaactgtc tcaagccaaatc ttgtatgtat cacaaggctc 720
 agcattgggg gtagatgtcg ttttcaaaaac agcgttccaaatc gcttgcgtact gggcccccacc 780
 atttacccatc taggttttgc tggactcggt gtaatccaaatc gactgttagc cgcagataat 840
 gggctgacgg ccggccaccga caatctttagt ccattcaatc ttgttcatcc aaccaatgag 900
 ataacccacgc caatcataatc catcaactgtt gatgtatgtt cttccaaatgg tgggtgtcag 960
 gcaggggatc agatgtcgat gtcggcgtt gggaggcttgc cagtgacat ccatgggttc 1020
 aactatccag gggccctccg tcccgatcata ctatgtatc acgaaagagt ggcacacagg 1080
 tccgtcgatc cggcgctgg ggtgatgttgc ttgcgtatc ttccaaatcc tgaactagca 1140
 aagaacccatgg ttacagaata cggccggattt gaccctgggg ccattaaactt cacaatattg 1200
 atactgatgtt agaggggaccg tcttggatc aagaggatgtt cggatgttgc gggatcact 1260
 gatgttgcgtt agatcttcatc ggagggttgc gacccatcaatc ttcccttgc gatttgacgg 1320
 gcattttggatc tcaaaagatcat aatccgggtt ataaaggatgtt aagcttgcgtc tagagcggcc 1380
 gcccggatcc agacatgtatc agatcatgtt atgatgttgc acaaaccacca actagaatgc 1440
 agtggaaaaaa atgttttattt tgcgtatgttgc tgcgtatgtt gtaaccatc 1500
 taagctgttcaa taaacaaatgtt aacaacaaca atgttcatc ttttatgtt cagggtcagg 1560
 gggaggtgtt ggagggtttt tccggatcata tagatgttgc gaaatcggcc tcggatcagg 1620
 ttggctgtgg aatgtgttgc agtgggtgtt tggaaagtcc ccaggctccc cagcaggcc 1680
 aagtagatgttca agcatgtatc tccatgttgc agcaaccagg tggtaaaatg ccccgaggctc 1740
 cccagcaggc aagatgtatc aacatgttgc tccatgttgc tcaagccaaatc tagtcccgcc 1800
 cctaactccg cccatcccgcc cccatgttgc gcccaggatcc gcccatttcc cggccatgg 1860
 ctgactaattt ttttttattt atgcagaggtt cggcccttc agtatttca 1920
 gaagtagtgc ggggggtttt ttggagggtt aggtttttgc aaaaaggatgc ggccggccacc 1980
 atggggcagac acggccaggac aagaatccca gccccctgtt tggtatgttgc cccgatcatg 2040
 ctgtatccgg ggttgcgtatc accccacaatc tccctggatc gacggccctt ggccgtcgcc 2100
 ggcgtatgttgc tgaccggcga caaggccgtt aacgtgtaca ccagcaggcc gaccggcc 2160
 atcatgttgc agtgcgttgc caacatgttgc agagacaaatg aggccgttgc caggcccccc 2220
 ctggaaaggctt acaacacaaatc cttgtatgttgc ccctggccgc cagcatcaga 2280
 aagatccagg gtcggatgttgc cacaaggccg ggaggaaaggc agggcaggact gatcggcc 2340
 gtgtatgttgc ggttgcgttgc ggggttgc acagctgtcc agatgttgc tgcggcc 2400
 ctgtatccgg ccaaccaggaa cccggccaaatc atcttgcgttgc tggaaatgtt ctttgcgc 2460
 accaaccaggc cccgttgcacgc agtgcgttgc ggcgttgc cagctgtccgtt ggccgtggcc 2520
 aagatgttgc acgttgcgttgc cggccatgttgc aacaacacccg ccagcaggactt ggactgtatc 2580
 aagatcaccatc acggatgttgc cgttgcgttgc aacctgttgc tgaccggatc gaccacatgttgc 2640
 ttccggccccc agatcacaatc cccaggcccttgc acacatgttgc ccatccaggcc cctgtatc 2700

-continued

ctggctggcg	gcaacatgg	ctatctgtg	acaagctgg	gaatcggcaa	caaccagctg	2760
tccagcctga	tcggaaagg	cctgatccc	ggctacccca	tcctgtacga	cagccagaca	2820
cagctgtgg	gcattcagg	gaacctgccc	agegtggcca	acctgaacaa	catgcgcgccc	2880
acctacctgg	aaaccctgag	cgtgtccacc	accaagggt	acggcagcgc	cctgggtggcc	2940
aagggtggta	cacagggtgg	cagegtactg	gaggaactgg	acccaggact	ctgcatcgag	3000
agcgacactg	acctgtact	caccagaatc	gtgaccccttcc	caatgagccc	cggcatactac	3060
agotgcctga	goggcaacac	cagegcctgc	atgtacacga	agaccgaagg	cgcactgaca	3120
acaccctaca	tgcccctgaa	ggggagctgt	atcgccaact	gcaagatcac	cacctgcaga	3180
tgacccgacc	ccccaggcat	catcagccag	aactacggcg	aggccctgtg	cctgtatcgat	3240
cgccatctgg	gtaacatgtct	gtccctggac	ggcatcacac	tgagactgag	cggcgagttc	3300
gtatgccacct	accagaagaa	catcagcatc	ctggacaccc	aggtgtatcg	gaccggcaac	3360
ctggacatca	gcaccgagct	ggggcaacgtg	aataacacga	tcagcaacgc	cctggacaga	3420
ctggccgaga	gcaacagcaa	gctggaaaaa	gtgaaacgtgc	gctgtacatc	cacttccgct	3480
ctgatccactt	acatgtgtct	gaccgtgtac	agcttgggtg	tcggccctt	gagctgtgt	3540
ctggccctgt	acctgtatgt	caaggcagaag	gcccagaga	aaaccctgt	gtggctgggc	3600
aacaacaccc	tggaccagat	gagagccacc	accagagcc	gtgagcggc	cgcaataaaa	3660
tatcttttat	ttcacatcat	ctgtgtgtg	gttttttgt	tgaatcgata	gtactaacat	3720
acgcctctca	tcaaaacaaa	acggaaacaaa	acaaactagc	aaaataggct	gtccccagtg	3780
caagtgcagg	tgccagaaca	tttcttct				3807

SEQ_ID NO: 13	moltype = DNA	length = 3809
FEATURE	Location/Qualifiers	
source	1..3809	
	mol_type = other DNA	
	organism = synthetic construct	
	note = pFIRESPV2 for vHVT310	
misc_feature	1..1362	
	note = IBDV VP2	
misc_feature	1363..1925	
	note = IRES	
misc_feature	1929..3590	
	note = NDV-Fopt VIIid	
misc_feature	3611..3809	
	note = SV40 Poly A	

SEQUENCE: 13						
atgacaaaacc	tgcaagatca	aacccaaacag	attgttccgt	tcatacggag	ccttctgtat	60
ccaacaaccg	gaccggcg	cattccggac	gacaccctgg	agaagcacac	tctcaggatca	120
gagaccatcga	cctacaattt	gactgtgggg	gacacagggt	cagggtataat	tgtctttttc	180
cctggattcc	tggctcaat	tgtgggtgt	cactacacac	tgcagagcaa	tgggaaactac	240
aagttcgatc	agatgtccct	gactgcccag	aaaccttacgg	ccagctacaa	ctactgcaga	300
ctagtggatc	ggaggctcac	agtgggtca	agcacactcc	ctgggtggct	ttatgcacta	360
aacggcacca	taaaacccgt	gaccttccaa	ggaaacgtgc	gtgaaactgac	agatgttagc	420
tacaatgggt	tgtatgtctc	aacaccaac	atcaacgc	aaatggggaa	tgtccctggta	480
ggggaaagggg	tcaactgtct	cagcttaccc	acatcatatg	atcttgggt	tgtgaggctt	540
gggtgacccca	ttcccgctat	agggttgc	ccaaaaatgg	tagctacatg	cgacagcagt	600
gacaggccca	gagtcatacc	cataactca	gccccatgt	accatcttc	atcacagttc	660
caaccaggatg	gggttaacat	cacactgtt	tcagccaa	ttgatgtat	cacaagcetc	720
agcattttgggg	gagagtcgt	gtttcaaca	agegttccaa	gccttgcact	gggcgcacc	780
atctaccta	taggcttga	ttggactgc	gtaatccac	gagctgtatc	cgccagataat	840
gggctgacgg	ccggcaccac	caatcttgc	ccatccat	tgttcatcc	aaccaatgg	900
ataaaccacgc	caatacatac	catcaaaatc	gagatgtgc	cctccaaatgg	tgggtgcag	960
gcaggggatc	agatgtcatg	gtcgccaat	gggggcctag	cagtgcacat	ccatgtggc	1020
aactatccag	gggcctccg	tccgtcaca	ctagtagcc	acgaaaaggt	ggcaacacga	1080
tccgtcgatc	ccgtcgctgg	gggtgat	ttccggatgc	ttccaaatcc	tgaactagca	1140
aagaacacgg	ttacagaata	cggccgattt	gaccggagg	ccatgcacta	cacaaaattt	1200
atactgatgt	agagggaccc	tcttgcac	aacaccgtct	ggccaacaa	ggagtacact	1260
gattttcg	agtaatccat	gggggtggc	gacctcaatc	cctccctgaa	gattgcagga	1320
gcatttgcgt	tcaaagacat	aatccccgg	ataaggaggt	aacccccccc	ccttaacgtt	1380
ctggccgaag	ccgttggaa	taaggccgg	gtgcgtttgt	ctatatgtt	ttttccacca	1440
tattggcg	ttttggcaat	gtgagggccc	ggaaacccgt	cctgttttc	ttgacgagca	1500
tttccatgggg	tttttccct	ctcgccaa	gaatgcagg	tctgttgc	gtcgtgaagg	1560
aaggcgttcc	tcttgcgttgc	aaacaaacgc	ttgtacgc	cattgcgacc	cttgcaggg	1620
agcggaaaccc	cccacccgtgc	gacagggtcc	tctggggc	aaagccacgt	gtataagata	1680
cacctgc	aaacccat	cccccgtcc	acgttgc	ttggatgtt	gtggaaagg	1740
tcaaattggct	ctcccaacgc	gtattcaaca	aggggtgtaa	ggatgc	ccaggaaaggta	1800
attgtatgg	atctgtatgt	gggcctcggt	gcacatgtt	tacatgttt	tagtcgagg	1860
taaaaaacgt	ctaggcccc	cgaaaccacgg	ggacgttgtt	ttcccttgc	aaacacgtt	1920
ataatattac	gggcacaa	ccccat	ggatccc	ccccctgtat	ctgtatcaccc	1980
gcatcatgt	gtatctggc	tgcac	ccacaacgtc	cctggatgc	cgccccctgg	2040
ccgcgtgcgg	cattgtgg	accggc	gacccgtgaa	cgtgtacacc	agcagccaga	2100
ccggcagcat	cattgtgg	ctgtgc	acatgc	ccacgttgc	ggccat	2160
aggccccccc	ggaagcttac	aacagaaccc	tgaccaccc	gctgacccc	ctggggcaca	2220
gcatcagaaa	gatccagg	tccgtg	caagccgg	aggaaagg	ggcagact	2280
tcggcccg	gatccggc	gtggccct	gtgttgttac	agctgccc	attaccgt	2340
cagccgecc	gatccagg	aacc	ccggcc	acat	tgcgttgc	2400
ttggccggcc	caacgg	gtg	ccggac	tgcgttgc	ccgtgac	2460
cgtggccaa	gatgc	ttcg	acc	caac	ccggc	2520
actgcatcaa	gatc	ttcg	ccgg	tgac	accgg	2580
ccacagt	ttcc	ccgg	acat	caac	ccgg	2640

-continued

```

cttaaaggct cagttattgc caattgtaaa ataacaacat gtatgtac agaccctcct 2640
ggtatcatat cgcaaaatta tggagaagct gtatccctga tagatagaca ttctgtcaat 2700
gtcttatacat tagacgggat aactctaagg ctcaagtggg aatttgatgc aacttataaa 2760
aagaacatct caatactaga ttctcaagtc atcgtgacag gcaatctga tataatcaact 2820
gaacttggaa acgtcaacaa ttcaatcago aatgccttgc atagtttgc agaaaagcaac 2880
agcaagctg aaaaagtcaa tgcactgacta accagcacat ctgcctcat tacctatatt 2940
gttctactt tcatttctt agtttcggt gcaacttgc tggtgttagc gtgttacctg 3000
atgtacaaac agaaggcaca acaaaagacc ttgttatggc ttgggataaa taccctcgat 3060
cagatgagag ccactacaag agcgtatgataa gcttgcataa gggccgcgc ggggatccag 3120
acatgataag atacattgtat gagttggac aaaccacaacaa tagaatgcag tgaaaaaaat 3180
gttcttattt tgaaattttgt gatgttatttgc ctttattttgt aaccattata agctgcaata 3240
aacaagttaa caacaacaat tgcatttcatt ttatgttca ggttcagggg gaggtgtggg 3300
aggtttttt 3309

```

```

SEQ ID NO: 15 moltype = DNA length = 3440
FEATURE Location/Qualifiers
source 1..3440
mol_type = other DNA
organism = synthetic construct
note = pVP2IRESGD for vHVT317
misc_feature 1..1362
note = IBDV VP2
1363..1925
note = IRES
misc_feature 1929..3233
note = ILTV-gD
misc_feature 3242..3440
note = SV40 Poly A
SEQUENCE: 15

```

```

atgacaaacc tgcgaagatca aacccaacag attgttccgt tcatacggag cttttgtatg 60
ccaacaaccg gaccggcgctc cattccggac gacaccctgg agaagcacac tctcagggtca 120
gagacctcga cttacaattt gactgtgggg gacacagggt cagggttaat tgccttttc 180
cctggatccc ctggctcaat tgcgtgggtct cactacacac tgcagagccaa tggaaactac 240
aagtgcatac agatgtcttgc gactgtccca aaccaatccgg ccagctacaa ctactgcaga 300
ctagtgcgttgc ggatgttcac agtgggtca agcacactcc ctgggtgggtt ttatgcacta 360
aacggcacca taaaacggccgt gaccccttcaaa ggaagccgtg gtgaactgac agatgttagc 420
tacaatgggt tgatgtctgc aacagccaaatc acacacgaca aaatttggaa tgccttggta 480
ggggaaaggggg tcaatgtctcc cagccatccccc acatcatatgc atcttgggtt tgtagggctt 540
ggtagccccc ttcccgctat agggttgcacccaaatggtagt tagtcatatgc gcacaggcgt 600
gacaggccca gacttacac cataactgc gccgatgatt accaattctc atcacagtag 660
caaccagggtt gggtaacaat cacactgttc tcagccaaactt ttgtatgtat cacaagctc 720
agcatttgggg gtagatgtctgc gttccaaactt aagegtccaaag gcctgtact gggccgcacc 780
atctacccatc taggttttgc tgggtatgcg ttaatccacca gagatgttagc cgcagataat 840
gggctgacggc cccggcaccga caatcttgcat cccatcaactt ttgtcatatcc aaccaatgg 900
ataacccacgc caatcacatc catcaaaacttgc gagatgttgc cttccaaaatgg tgggtgtc 960
gcaggggatc agatgtcatc gtccggcaactt gggaggttgc cactgtactt ccatgggtgc 1020
aactatccatcg gggcccttcgg tcccgatcactt ctagtgcgttgc acgaaagatg ggcacacagg 1080
tccgtcgatc cgggtcgatgg ggttagtaat ttccggatgttgc ttccaaatcc tgaactagca 1140
aagaacccatgg ttacagaataa cggccgatattt gacccaggaa ccatgaacta cacaatgg 1200
atactgtatgc agaggggaccgc tcttgcgtatc aagggctgttgc ggcacaaacaaatgg 1260
gttttgcgttgc agtacttgcatc ggagggtggc gacccatcttgc gattgtggaa 1320
gcatttgcgttgc taaaagacat aatccgggtt ataaagggtt aacccccccc cctaaacgtt 1380
ctggcccaagggcccttggaa taaggccgtt gtgcgtttgtt ctatatgtt ttttccacca 1440
tatttgcgttgc ttttggcaat gttggggccctt ggaacccatgg ccctgttttc ttgacggca 1500
tttccatgggg ttttggccat ctcggccaaatggc gatgtcaagg ttttggactat gtcgtggaa 1560
aaggcgttcc tcttgcgttgc ttttgcgttgc aaccaacatgc ttttgcgttgc ctttgcgttgc 1620
agcggaaacc cccacccatggc gacagggttgc tcttgcgttgc aacccatggc gtttttttttgc 1680
caccatcgaaatggcccaatggccatcc cccatgttgc acgtttgttgc ttggatgttgc gttggaaatgg 1740
tcaaaatgggttccatcgatcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 1800
attgtatggg atctgtatgc ttttgcgttgc gtttttttttgc gtttttttttgc ttggatgttgc 1860
taaaaaacatggt ttttgcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 1920
ataatccatcgatcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 1980
tgcttacaaa acatccatggat ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2040
cttcttccatcgatcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2100
tggaccggcccaatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2160
ctagccagatcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2220
cgatgtatggatccatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2280
cgatgtatggatccatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2340
aaaaagatggaaatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2400
acgacggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2460
tacaactgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2520
ctagccacccatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2580
tcttgcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2640
cttcttccatcgatcgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2700
aatgtgttgc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2760
cagacaccaatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2820
gtcttacaaaatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2880
tcccgccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 2940
cgatgtatggatccatggccatcc ttttgcgttgc aacccatggc gtttttttttgc ttggatgttgc 3000

```

-continued

```

gagaaaaatcc tgccgcctc cccgaagaacg acgaagtccc cgaggacacc gggcacatg 3060
atccaaactc ggatctgac tattacaatg acatgcccg cgtatcccg gtggaggaga 3120
ctactaaaag ttctaatgcc gtctccatgc ccataatccg ggcgttcgt aatggcccg 3180
tcgcgcctgt ggggctactg gtttggagca tcgtaaaatg cgcgcgtac taagccgg 3240
cggggatcca gacatgataa gatacatgg tgagtttgg caaaccacaa ctgaaatgca 3300
gtgaaaaaaaaa tgctttttt tgatgtatg gtttatttg taaccattat 3360
aagctcaat aaacaacat aacaacaacaa ttgcattcat ttatgttc aggttcagg 3420
ggaggtgtgg gaggttttt 3440

```

SEQ ID NO: 16 moltype = DNA length = 1302

FEATURE Location/Qualifiers
source 1..1302
mol_type = other DNA
organism = synthetic construct
note = Polynucleotide encoding ILTV gD

SEQUENCE: 16

```

atgcacccgtc ctcatcttag acggactcg cgtaatcag cgaaaggaga ggtgttaac 60
aaacacatgg attgcggtgg aaaacgggtgc tgctcaggcg cagctgtatt cacttttc 120
tggacttgcg tcaaggattat ggggagcat atctgcgtt tacgcaacgc tatggaccc 180
catttatttt tgaggaatgc tttttggact atcgtaatgc tttttccctt cgctagccag 240
agcacccgcg cccgtcacgtc cgactacat ttaggccgtc ggcgcgtcga cgcgttaacc 300
ataccggcgg ttggccgtg taacagatac ctaacttaggg tatcaagagg ctgcgcacgtt 360
gtcgagctca accgatcc taacgtggac gatgtatgat ggcgcgccaa agaaaaagag 420
aaggggggcc ctttcgaggc ctccgtcgct tgggttctacg tgattaaggg cgacgcaggc 480
gaggacaatg actgttcaat ctatagaaaaa gactacaggg aatgtggcga cgtacaactg 540
ctatctgaat ggcgcgttca atctgcacat atgtggcag tgactatgt tccctagcacc 600
cttgcgtatgc gaaatggcgc gggactgact atattctccc ccactgtgc gctctctggc 660
caatacttgc tgaccctgaa aatcgggaga tttgcgc当地 cagctctgt aactctagaa 720
gttaacgatc gttttttaaa gategggtcg cagcttaact ttttccgtc gaaatgttgg 780
acaacacgaa agtatccatc tggatccaa ggogaacacc tttatccat cgcacacacc 840
aatacacgac acgcggacga ctatatccg ggatacgaat atattctgc ggcgtggaaat 900
aatttgcgtg gaaaaagaa tcctagcgcg ccagaccctt gtcctagatg cgtccgc当地 960
gaaaatcccg ctgtaaacca gaaagcggaa gggcgc当地 cggacgc当地 aagcagc当地 1020
agaaggccccc tcccccaaga ctccggaggac gacatgc当地 cggaggc当地 tggagaaaaat 1080
ctcggccccc tcccccaaga cgacgatgc cccggaggaca cggacgc当地 tgatccaaac 1140
tcggatcttca actattacaa tgacatggcc gccgtatcc cgggtggagga gactactaaa 1200
agttctaattg cccgtctccat gcccatttc gccgcgttgc tagcctgc当地 ggtcgccgctc 1260
gtggggctac tgggttggag catgtaaaaa tgccgc当地 gc 1302

```

SEQ ID NO: 17 moltype = AA length = 434

FEATURE Location/Qualifiers
source 1..434
mol_type = protein
organism = synthetic construct
note = ILTV gD protein

SEQUENCE: 17

```

MHRPHLRRHS RYYAKGEVNL KHMDCGGKRC CSGAAVFTLF WTCVRIMREH ICFVRNAMDR 60
HLFLRNFATWV IVLLSSFASQ STAATYDI LGRLRALDT IPAVGPYNRV LTRVSRGCDV 120
VELNPISNVD DMISAAKEKE KGGPFEASVV WFYVIKGDDG EDKYCPIYRK EYRECVDVQL 180
LSECAVQSAQ MWAVDYPVPST LVSRNGAGLT IFSPATAALSG QYLLTLKIGR FAQTAALVTLE 240
VNDRCLKIGS QLNFLPSKCW TTEQYOTGFQ GEHYLYPIADT NTRHADDVYR GYEDILQRWN 300
NLLRKKNPSA PDPPRPDSVPQ EIPAVTKKAE GRTPDAESSE KKAPPEDSED DMQABASGEN 360
PAALPEDDEV PEDTEHDDPN SDPDYNYNDMP AVIPVEETK SSNAVSMPIF AAFVACAVAL 420
VGLLVWSIVK CARS 434

```

SEQ ID NO: 18 moltype = DNA length = 3804

FEATURE Location/Qualifiers
source 1..3804
mol_type = other DNA
organism = synthetic construct
note = pFwtSV40VP2 for vHFT313

misc_feature 1..1362
note = VP2
misc_feature 1383..1594
note = SV40 Poly A
misc_feature 1624..1968
note = SV40 Promoter
misc_feature 1981..3642
note = NDV-Fwt VIIId
misc_feature 3651..3804
note = Synthetic Poly A

SEQUENCE: 18

```

atgacaaacc tgcaagatca aacccaacag attgttccgt tcatacggag ctttctgtat 60
ccaaacaacc gaccggcgtc cattccggac gacaccttgg agaaggcacac tctcaggatca 120
gagacctcgatc cttacaattt gactgtgggg gacacagggtt cagggttaat ttttttttc 180
cctggattcc ctggctcaat ttttttttttttgggtgtt cactacacac tgcagaccaa tggaaactac 240
aagttcgatc agatgttccct gactgcccag aaccttccgg ccagctacaa ctactgc当地 300
ctatgtggatc ggatgttccat agtggatgtca agcacttcc ctgggtgggtt tttttttttttt 360
aacggccatcca taaaacggccgt gacccatcca ggaaggcctgatc gtgaacttgc当地 agatgttgc 420

```

-continued

tacaatgggt tgatgtctgc aacagccaa acatacgcaca aaattgggaa tgcctgtta 480
 ggggaagggg tcactgtcct cagcttacc acatcatatg atcttgggta tgcgggttt 540
 ggtgacccca ttcccgctat agggcttgc ccaaaaatgg tagctacatg cgacagcagt 600
 gacagggcca gagttcacac cataactgcg gcccgttatt accaatttc atcacagtt 660
 caaccagggtt gggtaaacat cacatgttc tgcggccaa ttgtatgtat cacaagctc 720
 agcattgggg gagagctgtt gtttcaaaaca agcgtccaa ggcgggtact gggccacc 780
 attcaccta taggtttg tggactcg gtaatcacca gagctgtacg cgccgataat 840
 gggctgacgg ccggcaccga caatctttagt ccattcaatc ttgtcatttc aaccaatgg 900
 ataacccaggc caatcacatc catcaacttg gagatgttg cttccaaag tggttgtcag 960
 gcaggggatc agatgtcatg tgcggcaagt gggggcttagt cagtgacat ccatggggc 1020
 aactatcccg gggccctccg tcccgctaca ctatgtcc acgaaagatg ggcaacaggaa 1080
 tccgtcgtaa gggtcgctgg ggtggatcact ttgcggacta ttccaaatcc tgaactagca 1140
 aagaaccccttgg tacaacataa cggccggattt gaccggggg ccatacacta cacaatatt 1200
 atactgtgtt agaggggccg tttggccatc aagaccgtt ggcggccaaag ggagtact 1260
 gattttcggt agtacttcat ggagggtggc gaccctcaatc ctccctgtaa gattgcaggaa 1320
 gcattttggc tcaaaagacat aatccgggtt ataaggggat aagcttgatc tagagccggcc 1380
 gcggggatcc agacatgtata agatcatgttgg atggatgttgg acaaaccaca actagaatgc 1440
 agtggaaaaaa atgctttattt tgcgtatgtt gtcgttattt gtaaccat 1500
 taagctgaaa taaaacaaatgg aacaacaaca attgcattca ttttatgttt cagggtcagg 1560
 ggggggtgtt ggagggtttt tcggatcctc tagatgtcgcg gaattcgagc tgggtacaggc 1620
 ttggctgtgg aatgtgtcgc agttaggttg tggaaagtcc ccaggctccc cagcaggcc 1680
 aagtatgcgaa agcatgtatc tcaatgttgc acaaccagg tggaaagtcc cccagggtt 1740
 cccaggccg aagaatgtgc aagacatgtca ttcaatgttgc tgcggccaa tagtccggcc 1800
 cctaactccg cccatccgc ccctaacttc gcccgttcc gcccatttc cggccatgg 1860
 ctgactaattt ttttttttt atgcggatc cgaggccgc tcggccctcg agtatttcca 1920
 gaagtagtgcg ggagggtttt ttggggccatc aggctttgc aaaaagctgc ggccggccacc 1980
 atggggctca aaccccttcac caggatccca gcacccctgttgcgtatcac ccggattatg 2040
 ctgtatattgg gctgtatccg tccgacaago tctttgcgcg ggggttgcgc 2100
 ggaatttgcg taacaggaga taaggcgtt aatgtatataa ctccgttca gacagggtca 2160
 atcatatgttca agtgggtccc gaatgtccg aaggataaagg aggctgtgc aaaaaggccca 2220
 tttagggatc ataacacaaatcc actgactact ttgcgttactc ctctggcga ctccatccgc 2280
 aagatccaaatcc ggtctgtgtc cacatctggc gggggccatc aaggccgcct gataggtgt 2340
 gtattttggca gtgttagctt tgggggttgc acagccggc acataaaccgc agctggggcc 2400
 ctaataacaaatcc aacccaggaaatcc acatccggccatc ttaaggagatc cattgtgcgc 2460
 accaaatggc ctgtgtatgc agtccccggcggatc aacttccggc ttaaggagatc cattgtgcgc 2520
 aagatgcggc agtgggttgc tggccatc aataataccg cgccggatc ggactgtata 2580
 aaaatcacac aacagggtgg tggatgttgc aaccctatacc taactgtatc gactacatgt 2640
 ttccggccac agatcacccctt ccctggccatc actccggccatc ccatccggc actttataat 2700
 tttagctgttgc gcaatatgttgc ttaacttgcg aactaaggatg gtatggggaa caatcaactc 2760
 agtctgttgc tttggatgttgc ctgtatccatc ggttaccatc tactgtatgc ctcacagact 2820
 caactcttgg gcatataactt gatgttccatc tcagtcgggaa actttaataat tatgcgtgcc 2880
 acctattttgg agacccatcc tggatgttgc aaccaaaaggat atgcctcgcg acttgcgtcc 2940
 aaagtagtgcg cacaatgttgc ttccgttgc gggataacttcc tggggatgttgc 3000
 tccatccggc atttatattgc ttttttttttactaacttgcg tggatgttgc ccatgtcccg aggttattat 3060
 tccctgtttgc gggccacac atcagcttgc atgtattcaatc agactgtatccg cggccactt 3120
 accccggatcc tggccatccatc aggttgcgtt atggccatcgtt gtaaaaataac aacatgtatca 3180
 tggatgttgc tccctgttgc ttttttttttactaacttgcg aattatggatc aacttgcgttgc 3240
 agacatccgtt gcaatgttgc ttttttttttactaacttgcg aacttgcgttgc tggggatgttgc 3300
 gatgtatccatc atcaaaagaaatcc acatctcaata ctggatgttgc aacttgcgttgc tggggatgttgc 3360
 ctgtatccatc acactgttgc tggggatgttgc aaccaatccatc tggatgttgc tggggatgttgc 3420
 ttggccatccatc gcaacacccatc gtttttttttactaacttgcg gtttttttttactaacttgcg 3480
 ctgtatccatc atatttttttactaacttgcg aacttgcgttgc tggggatgttgc tggggatgttgc 3540
 tttagctgttgc acctgtatgcg ttttttttttactaacttgcg gtttttttttactaacttgcg 3600
 aataatccatc tggatgttgc gggccatccatc acatctcaata ctggatgttgc tggggatgttgc 3660
 cttttttttactaacttgcg ttttttttttactaacttgcg gtttttttttactaacttgcg 3720
 ctctccatca aacccaaatcc acatccggccatc acatctcaata ctggatgttgc tggggatgttgc 3780
 gtgcagggtgc cagaacatccatc ctct 3804

SEQ ID NO: 19 moltype = DNA length = 3797
 FEATURE Location/Qualifiers
 source 1..3797
 mol_type = other DNA
 organism = synthetic construct
 note = pVP2IRESFwt for vHVT316
 misc_feature 1..1362
 note = VP2
 misc_feature 1363..1925
 note = IRES
 misc_feature 1929..3590
 note = NDV-Fwt VIIId
 misc_feature 3599..3797
 note = SV40 Poly A
 SEQUENCE: 19
 atgacaaaccc tgcggatc aacccaaatcc acatctcaata ctggatgttgc tggggatgttgc 60
 ccaacaaatcc gggccatccatc acatctcaata ctggatgttgc tggggatgttgc 120
 gagacccatccatc acatctcaata ctggatgttgc tggggatgttgc 180
 ctggatgttgc tggatgttgc ttttttttttactaacttgcg 240
 aagttccatc acatctcaata ctggatgttgc tggggatgttgc 300
 ctgtatccatc acatctcaata ctggatgttgc tggggatgttgc 360

-continued

```

aacggcacca taaacgccgt gaccttcaa ggaaggctga gtgaactgac agatgttagc 420
tacaatgggt tgatgtctgc aacagccaa atcaacgc aatttggaa tgtctggta 480
ggggaaagggg tcactgtccct cagccctaccc acatcatatg atcttgggtt tgtgaggcgt 540
ggtgacccta ttcccgttat agggttgc cccaaaatgg tagctacatg cgacagcagt 600
gacaggccca gagtcacac cataactgc gccgatgatt accaatcc tcacacgtac 660
caaccagggtt gggttacaat cacaacttc tcagccaaata ttgatgtat cacaagcctc 720
agcattgggg gagagctcggt ttccaaca agegttcaag gccttgact gggcgccacc 780
atctaccta taggcttga tggactgc gtaatcacca gagctgtacg cgccagataat 840
gggctgacgg ccggcaccga caatcttgc cccatcaatc ttgtcatcc aaccaatggag 900
ataaaccacgc caatcacatc catcaactg gagatgtga ccccttccaaag tgggtgtcag 960
gcaggggatc agatgtcatg gtcggcaatg gggagccatc cagtgacatc ccattgggtgc 1020
aactatccatggggccctcg tccgtcaca ctatgtgc acgaaaaggt ggcaacacgga 1080
tccgtcgatggcggatggat tccgtcgatgg tttccaaatcc tgaactagca 1140
aagaacatggg tttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 1200
atactgatgg agaggggacgg tttccaaatcc tttccaaatcc tttccaaatcc 1260
gattttcgatgg agtacttcatggatgg gacactcaact ctccctgtt gatttccaaatcc 1320
gcatttgcgtt cttaaagatcatggatgg gatggatgg aacccccccc ccttaacgtt 1380
ctggcccaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 1440
tattggcgatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 1500
ttccctgggg tttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 1560
aaggcgatgg tttccaaatcc tttccaaatcc tttccaaatcc 1620
aegggaaatccc cccacatggc gacagggttc tttccaaatcc tttccaaatcc 1680
caccgttcaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 1740
tcaaatgggtt cttccaaatcc tttccaaatcc tttccaaatcc 1800
attgtatggg atctgtatgg gggccctcgatgg gacactatgtt tacatgtgtt tagtgcgggt 1860
taaaaaacatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 1920
ataaaccatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 1980
ggatttatgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2040
cagctgcaggatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2100
cagggttcaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2160
aaggccccattt agagggttc gtttccaaatcc tttccaaatcc tttccaaatcc 2220
ccatccggcaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2280
taggtgtcgatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2340
ctggccggccatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2400
tttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 2460
cagtttgcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2520
actgtataaaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2580
ctacagtatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2640
tttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 2700
atcaacttcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2760
cacagactcaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2820
tgctgtccatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 2880
tttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 2940
gtatagatgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3000
gtatatttttcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3060
ctgtttggatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3120
catgttagatgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3180
tgatagatgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3240
ggaaatttttttgcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3300
caggcaatctt gtttccaaatcc tttccaaatcc tttccaaatcc 3360
tggatagatgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3420
catctgtctt gtttccaaatcc tttccaaatcc tttccaaatcc 3480
gtctgtgttttgcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3540
ggcttggggatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3600
ggatccagacatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3660
aaaaaaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3720
ctgcaataaaatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3780
gggtgtggggatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc 3797

```

```

SEQ ID NO: 20 moltype = DNA length = 1834
FEATURE Location/Qualifiers
source 1..1834
mol_type = other DNA
organism = synthetic construct
note = HVT US2SVgDwtsyn for VHVT407
misc_feature 1..345
note = SV40 Promoter
misc_feature 362..1666
note = ILTV gDwt
misc_feature 1681..1834
note = synthetic poly A
SEQUENCE: 20
gtgtgtggatgtgtgtcgt taggggtgtgg aaagtccccca ggctccccag caggcagaag 60
tatgc当地 atgc当地 attgtc当地 aaccaggatgtt ggaaatgtccc caggctccc 120
agcaggcaga agtgc当地 gcatgc当地 caatgtgc当地 gcaaccatag tccccc 180
aactccggccatccccc当地 taactccggcc cagttccggcc cattctccgc cccatggctg 240
actaatttttt当地 tttttt当地 cagaggccga ggccgc当地 ctgc当地 tattccagaa 300
gtgtgtggatggcgtt gtttccaaatcc tttccaaatcc tttccaaatcc tttccaaatcc 360
catgc当地 cccatctca gacggcactc gcgatgtactac gcgaaaggag aggtgtt 420

```

-continued

```

caaacacatg gattgcggtg gaaaacgggtg ctgctcaggc gcagctgtat tcactcttt 480
ctggacttgt gtcaggatta tgccggagca tatctgctt gtacgcaacg ctatggaccg 540
ccatttattt ttgaggaatg cttttggac tatcgtaactg ctttcttcct tcgcttagcca 600
gagcacccgcg ccgcgtcactgt acgactacat tttaggccgt cgccgcgtcg acgcgctaac 660
catacccggcg gtggccgtg ataacagata cctcaactagg gtatcaagag gctggegacgt 720
tgtcgagctc aaccgcgtt ctaacgtggc cgacatgata tcggccgcga aaaaaaaaga 780
gaaggggggc ctttcgagg cctccgtgt ctggttcac gtgattaagg ggcgacgacgg 840
cgaggacaag tactgtccaa tctatagaaa agagtacagg gaatgtggcg acgtacaact 900
gtatatctgaa tgcgcgttc aatctgcaca gatgtgggcga gtggactatg ttccctagcac 960
ccttgtatcg cggaaatggcg cgggactgtac tatattctcc cccactgtg cgctctcg 1020
ccaaatcttctgaaatccggag attatccggatg acagcttcgtg taactctaga 1080
agttAACGAT CGCTGTAAAG AGATCGGGTC GCAGCTTAAC TTTTACCGT CGAAATGCTG 1140
GACAACAGAA CAGTATCAGA CTGGATTCA AGGCAGAACAC CTTTATCCGA TCGCAGACAC 1200
CAATACACAGA CACCGGGACG ACGTATCTG GGGGATACGAA GATATTCTGC AGCGCTGGAA 1260
TAATTTCGTC AGGAAAAGA ATCTTAGCGC GCGGAGACCT CGTCCAGATA CGCTCCCGCA 1320
AGAAATTCCC GCTGTAACCA AGAAAAGCGGA AGGGCGCACCG CGGAGCAGCGA AAAGCAGCGA 1380
AAAGAAGGCC CCTCCAGAAG ACTCGGGAGG CGACATCGAG GCAGAGGGCT CTGGAGAAAA 1440
TCCTGCCGCC CTCCCCGAG ACAGACAGT CCCCAGGAGC ACCCGAGCACG ATGATCCAAA 1500
CTCGGATCCT GACTTACCA ATGACATGCC CGCGGTGATC CGCGTGAGG AGACTACTAA 1560
AAGTTCTAAT GCGCTCTCA TGCCCATATT CGGGCGTTG TAGCCTCGC CGGTGCGCCT 1620
CGTGGGGCTA CTGGTTGGG GCTACGTTAA ATGCGCGCTG AGCTAATCGA GCCTAGAGGC 1680
ATAAAAATAT CTTTATTTT ATTACATCGT TGTGTTGGTT TTGTTGTGA ATCGATAGTA 1740
CTAACACATCG CTCTCCATCA AAACAAAACG AAACAAACAA AACTAGCAAATAGGTGTC 1800
CCCACTGCGA GTGCAGGTGC CAGAACACATT CTCT 1834

```

```

SEQ ID NO: 21 moltype = DNA length = 1659
FEATURE Location/Qualifiers
source 1..1659
mol_type = other DNA
organism = synthetic construct
note = Polynucleotide encoding NDV-F of genotype V,
codon-optimized in pHVTIG1gDCaFopt (vHVT308)

```

```

SEQUENCE: 21
atgggcagca agcccagcac ctggatcago gtgaccctgt tgctgatcac cagaaccatg 60
ctgatcctga gtcgtatctg ccccaacaagg agccctggacgc gcagaccctt ggccgctgcc 120
ggcatctgg tgacccggca caaggccgtg aacatctaca ccagcagcca gaccggcagc 180
atcatcatca agctgtgtcc caacatgccc aaggacaag aggccctgcgc caaggcccc 240
ctggaacgt acaaacagaca cctgtggacc ctgtgtggcc caaggatcaga 300
agaatccagg gcagcggccac cacaacggcgg gggggaaaggc agggcagact ggtggcgct 360
atcatcgggaa ggtgtggccct gggcgctggcc acagctgtcc agattacccg tgccggcc 420
ctgattcagg ccaatcagaa cgccgcacaa atccctgagac tgaaagagag cattggcc 480
accaaacgcg cctgtggccggc agtgcacaaa ggactgtccc agtgggtgt cgctgtccgc 540
aaagatgcgcg agttctgtgg aacaccacccg ccagagactt ggactgtcattc 600
aaagatgcgcc accaggtggg cgtggagctg acactgtacc tgaccggactt gaccacagtg 660
ttcggcccccc agatcacaag ccccgctgtg acccagctga caatccaggg cctgtacaac 720
ctggctggcc gcaacatggaa ctatctgtcg actaagctgg gagggtggccaa caaccagctg 780
tccagctgtgatccggc getgtatcaca ggcacccccc tccctgtacga cagccagaca 840
cagctgtggc gatccatgtt caaccgtcc tccctgtggaa gcctgaaccaa catgagagcc 900
acctacctgg aaaccctgtgg cgtgtccacc accaagggtt tccggccagcc cctgtggccc 960
aaaggtgtgtg cacaagggtgg cagcgtgtac gaggaaacttgg acaccagcta ctgtcatcgag 1020
acggacatcg acctgtactt caccagggtt tgaccccttc caatgtacccc cggcatctac 1080
agotgcgtga goggcaacac cagccgtctgc atgtacgcga agaccgaagg agcactgaca 1140
acacccttaca tggccctgtaa gggaaagctgtg atccgtcaactt gcaagatgtac cacctgtcaga 1200
tgcgcccggacc ccccggtgtatccatgtccatgtt gactacggccggc agggccgttgcg cctgtatcgac 1260
aaacatttcttctgtatgtgtt gtcctgtggat ggcacatcacatc tgagactgg cggcgaggatc 1320
gacggccaccc accaagaagaa catcgtatccatgtt gtcgtatcgatc gaccggcaac 1380
ctggacatca gcaacggatc gggcaacgtt gaaaacacggca tcagcagcac cctggacaag 1440
ctggccggatc ccaacacaaat gtcgtatcgatc acctgtggccg cacaaggcc 1500
ctgtatcgatccatgtt gtcctgtggat gtcgtatcgatc gtcgtatcgatc 1560
ctggccgtgtg acctgtatcgatc gtcgtatcgatc gtcgtatcgatc 1620
ataaacaccccttggaccatgtt gtcgtatcgatc gtcgtatcgatc 1680

```

```

SEQ ID NO: 22 moltype = AA length = 553
FEATURE Location/Qualifiers
source 1..553
mol_type = protein
organism = synthetic construct
note = NDV-F of genotype V (vHVT308)

```

```

SEQUENCE: 22
MGSKPSTWIS VTLMILTRTM LILSCICPTS SLDRPLAALAA GIVVTGDKAV NIYTSSQTGS 60
IIIKLLPNMP KDKEACAKAP LEAYNRTLTT LLTPLGDSIR RIQGSATTSG GGKQGRLVGA 120
IIIGSVALGVA TAAQITAAAAA LIQANQNAAAN ILRLKESIAA TNDAVHEVTN GLSQLAVAVG 180
KMQQFVNQNF NNTARELDCI KIAQQVGVEL NLYLTELTTV FGPQITSPAL TQLTIQALYN 240
LAGGNMDYLL TKLGVGNNQQL SSSLIGSLIT GNPILYDSQT QLLGIQINLP SVGSLNNMRA 300
TYLETLSVST TKGFASALVP KVTVQVGSVI EELDTSYCIE SDIDLYCTRV VTFPMSPGIY 360
SCLSGNTSAT MYSKTEGALT TPYMALKGSV IANCKMTTCR CADPPGIISQ NYGEAVSLID 420
KHSCSVLSDL GITLRLSGEF DATYQKNISI LDSQVIVTGN LDISTELGNV NNSISSTLDK 480
KHAESNNKLNK VNVLNTSTSA LITYIVLAI SLAFGVISLV LACYLMYKQR AQQKTLWLWLG 540
NNTLQMRAT TRT 553

```

```

SEQ ID NO: 23          moltype = DNA length = 476
FEATURE
source
1..476
mol_type = other DNA
organism = synthetic construct
note = HHV3gB promoter (reverse direction)

SEQUENCE: 23
ccgggttat atcttctgat ttgtggttat ctacttgcata actctcaaaa aacgagctt 60
gagagaccga cacaaccgcc gtaacaaca aaaaaataat gcataaaaag cataaccaca 120
cccccgtaac ggatgtttagt aaaaacgcccgg gtccgttggaa tccggagcca gccgtcgat 180
tagggtgtat agaagagaaa aaacgtctga atcgttagatt acgacggtat tctggtcgat 240
ccctgttct ccacttgcata taatggccac aaggggcacat gtttcttcgt acgttaata 300
aatggcgtct aagggtccgt gggacgtgc tataccctta ggttggagac tgaccccg 360
tggatcccta cctagacggta caacgcgaca taaccgcacc tcccccaaat ggaaacacaga 420
gttgaatagt gtgggttgcac acacaagtc cctaataat ttccaggcaa gtctct 476

SEQ ID NO: 24          moltype = DNA length = 476
FEATURE
source
1..476
mol_type = other DNA
organism = synthetic construct
note = HHV3gB promoter

SEQUENCE: 24
agagacttgc ctggaaatat attaggggat ttgtgtttgc aaccacacta ttacacctg 60
ttttccattt tggggaggtg cggttatgtc cggttgcaccc tottaggtaa gatccacgcg 120
gggtgcacgtc tcaacccataa ggtatggca gtcccccacgg acccttagac ggcattttt 180
taacgtacga agaaacatgt ccccttgcgtt ctattattca aagtggagaa acagggtatcg 240
accagaataac cgtcgtatac tacgatttagt acgttttttc tcttctatac accctaata 300
agggggctgcgcc ttccggatca acggacccgg cggtttccata acatccgttac cgggggtgt 360
gtttatgtttt ttatgtcatat ttctttgtt tgttacggcg gtttgcgtt tctctccaa 420
ctcggtttttt gagagtttac aagtagagcc cacacaatca aagatataaa cccggg 476

SEQ ID NO: 25          moltype = DNA length = 4347
FEATURE
source
1..4347
mol_type = other DNA
organism = synthetic construct
note = Plasmid pHVTIG1gDCaFopt for vHVT308
misc_feature
1..1199
note = SV40 Poly A in reverse direction
318..1622
note = ILTgD in reverse direction
1635..2110
note = HHV3gB promoter in reverse direction
2129..2496
note = SV40 promoter
2515..4179
note = NDV-F-CA02
4194..4347
note = Syn Poly A

SEQUENCE: 25
aaaaaaacctc ccacacctcc ccctgaacct gaaacataaaa atgaatgcaat ttgtgttgt 60
taacttgcattt atgcgatccataatgttgcata caaataaaacg aatagcatca caaatttcac 120
aaataaaagca ttttttcacat tgcattctatgttgcata tccaaactca tcaatgtatc 180
ttatcatgtc tggatcccccg cgccctatgc qcttttgcata cgtcccaatg aataggcat 240
ggtagatgtat tccatgtatc ttatattatgc agcgtggggc gtggcatgtt ggaagaaaacc 300
acatcttgcata ggcgttgcata gctacgcgcg cattttgcata tgctccaaac cagtagcccc 360
acgagcgcgca cgcgcgcggc tacgaacgcg cgcataatgg gcatggggac ggcattagaa 420
cttttagtagat tccctccacat cggatcgcg cggggcatgtt cattgtataa gtcaggatcc 480
gagttttgtat catgtgttc ggtgtccatcg gggacttgcgt cgttttcggg gagggcggca 540
ggattttcgc cagaacgcgc tgcgtgcgtc tegtcctccgc agtcttcgttgg agggggccccc 600
ttttcgtgcgc ttctcgtgcgc cgggggtgcgc ccttccgcgtt tcttgcgttac agcggggatt 660
ttttcggggca cgcgtatctgg acgggggtatc ggcgcgtatgc gattttttt cctcgcataaa 720
ttatccacgc gtcgcagaat atcttcgtat ccccgatataa cgtcgtccgc gtcgtgttgc 780
tttgcgttgcgc gatcgatccatc aagggtttgcgc ctttgcataatc cagttctgtata 840
gttcacgcattt tccgcgttgcgc aagggtttgcgc ctttgcataatc cagttctgtata 900
acttcgtatccatc ttcgcgttgcgc aatctccgcgc ttttgcgttgcgc cagcaatgtat 960
tggcccgacggc ggcgcgtatgc gggggggat atagtcgtatgc cccgcgcatt tcgcgtatgc 1020
agggtgtatgc gacatgtatgc cactgcgcac atcttcgtatgc atggaaacggc gcatcgtat 1080
agcagttgtatgc ttcgcgtatgc tcttttgcataatc agatggacatc gtacttgc 1140
tcggccgtatgc cgcgcgtatgc cagtcgtatgc cagacgcacggc aggccctccggaa agggggccccc 1200
ttcttcgtatgc ttttgcgtatgc cgcgtatgc ttcgcgtatgc tggaaatccgc gtttgcgtatgc 1260
acaaacgtgcgc acgcgtatgc tccatgtatgc aggtatgtatgc tatacggggcc aaccggccgtt 1320
atgggttagcgc ttcgcgtatgc ggcgcgtatgc aaaaatgtatgc cgtacgtatgc ggcggccgtt 1380
cttcgtatgc cgcgtatgc aagggtatgc atgttccaaat aagcatttcgtatgc caaaaataaa 1440
tggccgtatgc ttcgcgtatgc tacaatccgc atatgtatgc gtcgtatgc gacacaatgc 1500
cagaaaatccgc ttcgcgtatgc ttcgcgtatgc cgcgtatgc atccatgtatgc 1560
tttgcgtatgc ctcgtatgc ttcgcgtatgc cgcgtatgc gtcgtatgc aggacggcgtt 1620

```

-continued

atgggtggcg	ccggccccggg	ttatatcttc	tgattgtgtg	ggctctactt	gtaaactctc	1680
aaaaaacag	cttggagaga	ccgacacaac	cgcgtaaaca	aacaaagaaa	atatgcataa	1740
aaagcataac	cacacccccc	taacggatgt	tatgaaaacg	ccgggtccgt	tgaatccgga	1800
gccagccgc	gcattagggt	gtatagaaga	aaaaaaacgt	ctgaategta	gattacgacg	1860
gtattctgt	cgatccctgt	ttctccactt	tgaataatag	ccacaagggg	acatgtttct	1920
tcgtacgtt	aataaatggc	gtctaaagggt	ccgtggaa	tgcataaacc	tttaggttga	1980
gacgtgacc	ccgcgtgatc	cttacatgta	cgggtcaacgc	gacataaccc	cacccccc	2040
caatggaaa	cagagggtgaa	tagtgtgggt	gcaaaacacaa	gtccctaata	atattccag	2100
gcaagtctt	gaattaattc	cctcgaccatc	attcgagctt	ggtacagctt	ggctgtggaa	2160
tgtgtgtcg	ttaggggtgt	gaaagttcccc	aggctccccc	gcagggaa	gtatgcaaaag	2220
catgcattc	atttagtca	caaccagggt	ttggaaaggcc	ccaggctccc	cagcaggcc	2280
aagtatgc	agcatgcata	tcaatttagtc	agoaaccata	gtcccgcccc	taactccgc	2340
catccgcoc	ctaaatccgc	ccatgtccgc	ccatctccgc	cccacatgg	gactaatttt	2400
ttttatatt	cgagaggccg	aggccgcgc	ggcctctgg	stattccaga	agtatgtagg	2460
aggctttttt	ggaggccctag	gtctttgc	aaagctcccg	gggcggccgc	caccatggc	2520
agcaagecc	gcacctggat	cagegtgacc	ctgatgctga	tcaccagaac	catgtgtatc	2580
ctgagctgc	tctggcccc	aaggccgcgc	gacggcajac	ccctggccgc	tgccggatc	2640
gtgtgtggcc	gogacaaggc	cgtgaacatc	tacaccaggc	gcggacccgg	cagecatc	2700
atcaagtc	tgcccaacat	gccaaggac	aaagaggcc	ggcccaaggc	ccccctggaa	2760
gcctacaaca	gaaccctgac	caccctgt	accccccgg	gegacagcat	cagaagaatc	2820
caagggcag	ccaccacaag	cggcgaggga	aagcaggcc	gactgtggg	cgctatcatc	2880
ggggagcgtg	ccctgggggt	ggccacagat	ggccaggat	cgcgtcagc	cccccgtatt	2940
caggccaa	taaagccgc	caacatctg	agactaaag	agacatggc	cgccaccaac	3000
gacggcgtgc	acgaagtgc	aaacggactg	tcccagctgg	ctgtcgctgt	cgccaaggat	3060
cagcagtctc	tgaacaacaa	gttcaacaa	accggccagag	agctggactg	catcaagatc	3120
gcccagcagg	ttgggggtgt	gcttcaaccc	tttttttttgc	tacctgtgg	agtgatgtgg	3180
cccccatca	caagccccgc	tctgtaccc	ctgtacatcc	aggccctgt	caacccgtgt	3240
ggggccaaca	tggactatct	gctgtactag	ctgggggtgg	gcaacaacca	gctgtccage	3300
ctgtatcggt	ccgggggtgt	cacaggcaat	ccatctctgt	acgacaccc	gacacagctg	3360
ctggggatcc	agatacaacat	gcccattcg	ggaaaggctgt	acaacatgt	agccacccatc	3420
ctggaaacc	tggacgtgt	caccacaa	ggcttcgcca	ggccctgtgt	gccccagggt	3480
gtgtacacagg	ttggggcgtgt	gatcgaggaa	ctgtgaccatc	gctactgtat	cgagagcgac	3540
atcgaccatgt	actgcaccag	agtgtgttgc	ttttttatgt	gccccggat	ctacagctgc	3600
ctgagcggcc	acaccaggcgc	ctgtatgtac	agcaagaggc	aaaggagact	gacaacaccc	3660
tacatggccc	tgaaggggaa	tgtatgcgc	aactgtca	tgtaccatgt	cagatgcgc	3720
gaccccccac	gcatcatc	ccagaactac	ggggaggcc	tgagctgtat	cgacaaacat	3780
tcctgttagc	tgctgtccct	ggatggatc	acactgtgg	tgagcggcga	tttcgacgccc	3840
accttacc	agaacatc	catccgttgc	agccagggt	ttgtgtgg	caacccgtgc	3900
atcagcaggc	agctggccaa	cgtgaacaa	agcatcgtca	gcaccctgt	caagctggcc	3960
gagtccaa	acaagctgaa	caaaatgt	gttgaacctg	ccagcacaa	cccccgtatc	4020
acctatcg	tgctggccat	cgtgtccctg	gccttccgg	tgatcgtgt	gggtgtggcc	4080
tgtatcgta	tgtataa	ggggccggcc	cagaaaaacc	ttgtgtgg	ggcaataa	4140
accctggacc	agatggggc	caccatgat	ttttttttgt	ccggccg	atcaataaa	4200
tatctttt	tccattacat	ctgtgtgt	ttttttgtgt	tgaatcgtat	gtactaata	4260
acgctctca	tcaaaaacaaa	acgaaacacaa	acaaactatc	aaaatagggt	gtccccagt	4320
caagtgcagg	tgccagaaca	tttctct				4347

SEQ ID NO: 26 moltype = DNA length = 5149
 FEATURE Location/Qualifiers
 source 1..5149
 mol_type = other DNA
 organism = synthetic construct
 note = Plasmid pFwtIRESgD for vHVT322
 misc_feature 1..1391
 note = mCMV promoter
 misc_feature 1400..3061
 note = NDV-Fwt VIIId
 misc_feature 3072..3634
 note = IRES
 misc_feature 3638..4942
 note = ILTgD
 misc_feature 4951..5149
 note = SV40 Poly A

SEQUENCE: 26
 aactccggcc gttttatgac tagaaccat agttttatc gccaaatgca ctgaaatccc 60
 ctaatttgc aagccaaacg ccccttatgt gagtaatacg gggactttt acccaattt 120
 ccacgcggaa agcccccata tacatctca tggcatatgtc atcggccatgg tcatgcactc 180
 taatggccgc ccataggatc ttcccacata gggggcgatc accatctccc agcatagggg 240
 ttggtgactca atggccatca cccaaatgtc ttgggtcaat gggaggatgtt ccaatgggtt 300
 tttccatca ctggcaagca cactgtgtc aatgggactt ttccactgtggg tttggccaa 360
 tacatgggtt caatggggg tgagccatg gggaaaaccc attgtgtccca agtacactgt 420
 cttcaatagggtt cttttttccatc ttgtgtgtca agcatatgt gtcaatgtgg 480
 gtgtatcgat agggactttc cattgttattc tgcccagttc ataaagggttcaat taggggttga 540
 atcaacaggat aagtccatgtt ccggccaaatg acactgtgcgtc aatagggttccatcgtt 600
 ttttgccatca tacataagggtt caatggggat tgagtcaatg gggaaaaccc attggggca 660
 agtacactgtca ctcaatagggtt actttccatc gggttttgc cagttacataa ggtcaatagg 720
 gggtgactgtca acaggaaaatgttccatcgtt ccggccaaatg tgagtcaatg gggactttcc 780
 aatgggtttt gcccactaca taagggttcaat gggaggatgtt caatgggtt tttccatca 840
 ctggcacgtt tactgtgtca ttggggactt ccataatgggtt tttggccatc acataaagggt 900

-continued

aatagggtg aatcaacagg aaagtcccat tggagccaag tacactgagt caataggac 960
 ttccatgg gtttgccta gtacaaaagg tcaatagggg tgagtcattt gggttttcc 1020
 cattatggc acgtacataa ggtcaatagg ggtgagtcatt tgggttttc cagccaattt 1080
 aattaaaaacg ccatgtactt tcccaccatt gacgtcaatg ggctattgaa actaatgca 1140
 ctgtgacccctt aaacggtaact tccccatgg tgatataatgg gaaagtaccc ttctcgagcc 1200
 aatacacgtc aatgggaagt gaaagggcag cccaaacgtc acaccgcccc gggtttcccc 1260
 tggaaattcc atatggcac gcattctatt ggtgagtcgt cggttacgt gggataaga 1320
 ggccgcgacca gctgcggta cgtcgacgtc ttccgtctga ccacgtaga acgcagagct 1380
 ctcgcgtca ggccgcgcga tgggtcaca accttctacc aggtacccag cacctctgtat 1440
 ctgtatccccc cggatatgtc tgatattggg ctgtatccgtt cccgacaaatgttccgtacgg 1500
 caggccctt gcaatgtcag gaaatggtagt aacaggagat aaggcgtca atgtataac 1560
 ttctgtctcg acagggtaaa tcatagtcaa gttgtcccg aatatgccc gggataagga 1620
 ggccgtgtca aaagccccat tagaggcata taacagaacca ctgactactt tgctcactcc 1680
 ttttggcgtccatccatggccaa agatccaaagg gtttggcgtccatccatggccaa 1740
 aggccgcgtt atagggtctg ttatggcgt tgtagtctt ggggttgcacaa cagccgcaca 1800
 gataacagca gctgcggccc taatacaago caaccagaat gccgcaaca tcctccggct 1860
 taaggagacg atgtcgacaa ccaatgtca gttgtcatgaa gtcacccgacg gattatcaca 1920
 actatcgatg ccaatggggaa agatgtcag gtttggcgtccatccatggccaa 1980
 gcaatggatgg gactgtataa aaatcacaca acaggttggt gtagaaactca acctataacct 2040
 aactgaattt actacgtat tcggggcaca gatcacccctt cctgcattaa ctcagctgac 2100
 catccaggca cttaaattt tagctgtgg caatatggat tacttattaa ctaagtttagg 2160
 tataggggac aatcaatctca gctcgatcatt tggtacccgg ctgtatccgtt gttaccctat 2220
 actgtatgac tcacacactt aactttggg catacaatgg aattttacccctt cagtcgggaa 2280
 cttaaataat atgcgtgcca cctatttggaa gacccatccatccatggccaa 2340
 tgcctcagca ttgtcccgaa aagtatgtac acaatgtcgtt tccgtatccatggccaa 2400
 caccttcatac ttttatggatccatccatggaa 2460
 catgtcccca ggttattttt ccctttgttag cggcaacaca tcacgttca ttttccatggccaa 2520
 gactgaaggc gcaactcaactt ccgggtatata gggccatccatggccaa 2580
 taaaataaca acatgtatggat gtcacggccatccatggccaa 2640
 agtgtatccatccatggccaa 2700
 aaggctcgtt gggggatttt atgcgtatccatggccaa 2760
 agtcgtatccatggccaa 2820
 cagcaatgcc ttggataggt tggcggatccatggccaa 2880
 actaacccgc acatctgtcc tcattttggatccatggccaa 2940
 ccgtgcgttccatggccaa 2990
 aacttgcgttccatggccaa 3000
 gacccgttccatggccaa 3060
 agccggccccc cccccccttccatggccaa 3120
 tgggttgcgtccatggccaa 3180
 gaaacacgttccatggccaa 3240
 aatgcgtatccatggccaa 3300
 aacaacgttccatggccaa 3360
 ctgcggcccaaa aacccgttccatggccaa 3420
 cgttgcgttccatggccaa 3480
 ggggttgcgtccatggccaa 3540
 cacatgtttt acatgtttt ccgttgcgttccatggccaa 3600
 gacgtgtttt ccgttgcgttccatggccaa 3660
 geactcgtccatggccaa 3720
 acgggtgtccatggccaa 3780
 ggagcatatccatggccaa 3840
 ttgtgtatccatggccaa 3900
 ctacatccatggccaa 3960
 cagatccatccatggccaa 4020
 cgttgcgttccatggccaa 4080
 cgttgcgttccatggccaa 4140
 tagaaaaagatccatggccaa 4200
 tgcacacatccatggccaa 4260
 actgactata ttctccccc ttttttttttccatggccaa 4320
 cggggatggccatccatggccaa 4380
 cgggttgcgttccatggccaa 4440
 atttcaaggccatccatggccaa 4500
 atatcggttccatggccaa 4560
 tagcgtatccatggccaa 4620
 agccggccatccatggccaa 4680
 ggaggccgttccatggccaa 4740
 cggccatccatggccaa 4800
 catgccccccgttccatggccaa 4860
 catatccgttccatggccaa 4920
 cgttgcgttccatggccaa 4980
 gagtttggatccatggccaa 5040
 gatgttccatggccaa 5100
 tgcatttcatttccatggccaa 5149

SEQ ID NO: 27 moltype = DNA length = 1857
 FEATURE Location/Qualifiers
 source 1..1857
 mol_type = other DNA
 organism = synthetic construct
 note = plasmid pHVTUS2SvDwtsyn for vHVT406
 misc_feature 1..362

-continued

misc_feature	note = SV40 promoter 379..1683
misc_feature	note = ILTV gD 1695..1857
SEQUENCE: 27	
gagctcggtt cagttggct	gtggaatgtg tgcgttagt ggtgtggaaa gtcccccaggc 60
tccccagcac gcaagaatgtat	gcaaaagcatg catctcaattt agtcagcaac cagggtgttgg 120
aagtccccccg gtcgttccaaat	aggcagaatgt atgcaaaagca tcgcattttttt ttatgtcagca 180
accatagtcg cggcccttaac	tcggccatccat ccggcccttactt ccggcccttactt 240
tctccggcccc atgggttgcgt	atattttttt atttatgttggaggc ggcggccggc 300
tctgagatcat tccagaagta	gtgaggaggtt tttttttttt ggcctaggctt ttgcaaaaaaag 360
ctgcccgggg cccggccatct	cacatcgacat cggccacttgcgtt ttactacgcgt 420
aaaggagagg tgcgttccaaat	acacatggat tgccgttgaaa aacgggtgttgcgtt 480
gtctgttccat ctcttttctg	gactttgttc aggattatgc gggagcatat ctgttttgta 540
cgcaacgcata tggaccgcca	tttattttttt aggaatgttctt ttggactat cgtactgtt 600
tttcccttcg ctatgcagag	cacccggccgcgtt acacatgtt ttggactat cggccgtcgc 660
gctgtcgacg ctgttccaaat	acccggcggtt ggcctgttata acagataact cactagggtt 720
tcaaggaggctt gctgttccaaat	ccggattttcaat acgttggacgtt catgatated 780
gcccccaaaag aaaaagagaa	ggggggccctt ttcgaggccctt ccgtcgctgtt gttctacgt 840
attaaggccg acggccgcga	ggacaatgtt tgcgttccat ataaaaaaaat gtcaggaa 900
tgtggccagc tacaactgtt	atctgttgcgtt ggcgttcaat ctgcacatgtt gtggccatgt 960
gactatgttcc ctatgcaccc	tttgcgttggggaaaatggccggcgtt gactgttactt atttcccccc 1020
actgtctggc tctctggcca	atacttgcgtt accctgaaaaat ttcggggatgtt tgcgttccaaaca 1080
gtctctgttccat ctcttgcgtt	taacgtatgcgtt tttttttttt ttcgggttgcgtt gcttaactttt 1140
tttaccgttgcgaaatgttccat	aacacacacatgcgtt tttttttttt ttcgggttgcgtt gcttaactttt 1200
tatccgtatcg cagacaccaa	tatccgtatcg gtcgttccat ccggccgttccat tttttttttt 1260
atttctgcacgt gcttgcataaa	ttttgttggggaaaatggccggcgtt gactgttactt atttcccccc 1320
ccagatgcgt tccgcgttccaaat	aatttttttttccat gtaaccaaga aagcggaaagg ggcgttccat 1380
gacgcgaaaa gcaatgcgttccaaat	ggggccctt ccggaaatgtt ccggggccctt ccggaaatgtt ccggggccctt 1440
gaggcccttcg gatggccatccat	ttccggccctt ccggaaatgtt ccggggccctt ccggaaatgtt ccggggccctt 1500
gaggccatccatccat	ttccggccctt ccggaaatgtt ccggggccctt ccggaaatgtt ccggggccctt 1560
gttggaggaga ctactaaaat	tttgcgttccat ccggccgttccat tttttttttt ttcgggttgcgtt gctgttccat 1620
gctgtcgccgtt ttcggccgttccat	tttttttttccat gtttttttttccat ttttttttttccat ttttttttttccat 1680
taatcgacccatccat	tttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1740
tgtgtgaatctt gatgtactat	acatatgttccat ttttttttttccat ttttttttttccat ttttttttttccat 1800
tagaaaataa ggtgttccat	tttttttttccat ttttttttttccat ttttttttttccat ttttttttttccat 1857

What we claim is:

1. A vaccine comprising a recombinant herpesvirus of turkeys (HVT) vector, wherein the HVT vector comprises a first heterologous polynucleotide coding for and expressing an Infectious Bursal Disease Virus (IBDV) viral protein 2 (VP2) antigen and a second heterologous polynucleotide coding for and expressing a Newcastle Disease Virus Fusion Protein (NDV-F) antigen,

wherein the IBDV VP2 antigen has at least 85% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, and wherein the NDV-F antigen has at least 85% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5;

50 wherein the two heterologous polynucleotides are inserted into one locus in a non-essential region of the HVT genome selected from the group consisting of intergenic region 1 locus, intergenic region 2 locus, intergenic region 3 locus, UL43 locus, US10 locus, US2 locus, and SORF3/US2 locus;

wherein the two heterologous polynucleotides are linked by internal ribosome entry site (IRES); and wherein the expression of the two heterologous poly- 55 nucleotides is driven by a mouse cytomegalovirus (mCMV) immediate early (IE) promoter or human cytomegalovirus (hCMV) IE promoter.

2. The vaccine of claim 1, wherein the first heterologous polynucleotide is operably linked to mCMV IE promoter at the 5' end, and the IRES at the 3' end.

3. The vaccine of claim 1, wherein the non-essential region is the IG1 locus of the HVT genome.

4. The vaccine of claim 1, wherein the IBDV VP2 antigen has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2.

35 5. The vaccine of claim 1, wherein the IBDV VP2 antigen has the polypeptide sequence as set forth in SEQ ID NO: 2.

6. The vaccine of claim 1, wherein the first heterologous polynucleotide encoding the IBDV VP2 antigen has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1.

40 7. The vaccine of claim 1, wherein the first heterologous polynucleotide encoding the IBDV VP2 antigen has the sequence as set forth in SEQ ID NO: 1.

8. The vaccines of claim 1, wherein the NDV-F antigen has at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:5.

9. The vaccines of claim 1, wherein the NDV-F antigen has the polypeptide sequence as set forth in SEQ ID NO: 5.

10. The vaccine of claim 1, wherein the second heterologous polynucleotide encoding the NDV-F antigen has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:3.

11. The vaccine of claim 1, wherein the second heterologous polynucleotide encoding the NDV-F antigen has the sequence as set forth in SEQ ID NO: 3.

12. The vaccines of claim 1, wherein the expression of the NDV-F antigen is regulated by the Simian virus 40 (SV40) poly A signal having the sequence as set forth in SEQ ID NO: 8.

13. The vaccine of claim 1, wherein the IRES has the sequence as set forth in SEQ ID NO: 10.

14. The vaccine of claim 1, wherein the first heterologous polynucleotide has the sequence as set forth in SEQ ID NO:

1, and wherein the second heterologous polynucleotide has
the sequence as set forth in SEQ ID NO: 3;
wherein the non-essential region is the IG1 locus of the
HVT genome;
wherein the first heterologous polynucleotide is operably 5
linked to a mCMV IE promoter at the 5' end, and the
IRES at the 3' end, and wherein the IRES has the
sequence as set forth in SEQ ID NO: 10; and
wherein the expression of the NDV-F antigen is regulated
by the SV40 poly A signal having the sequence as set 10
forth in SEQ ID NO: 8.

15. The vaccine of claim 1, further comprising a pharmaceutically or veterinarianly acceptable carrier, excipient, vehicle or adjuvant.

16. A method of inducing an immunological response in 15
an animal against one or more antigens or a protective
response in an animal against one or more avian pathogens,
comprising inoculating the animal at least once with the
vaccine of claim **15**.

17. The method of claim **16**, wherein the animal is an 20
avian.

18. The method of claim **16**, wherein the avian pathogen
is selected from the group consisting of Newcastle Disease
Virus (NDV) and Infectious Bursal Disease Virus (IBDV).

19. The method of claim **16**, wherein the vaccine is 25
administered to one-day old chicks subcutaneously or intra-
muscularly.

20. The method of claim **16**, wherein the vaccine is
administered to an avian in ovo in 17-19 day-old embryos.